var title_f22_18_22816="Sunburn back PI";
var content_f22_18_22816=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F71537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F71537&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Sunburn",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 432px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This person has a sunburn on the back. The skin that was not covered by clothes has turned red.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22816=[""].join("\n");
var outline_f22_18_22816=null;
var title_f22_18_22817="Catch-up immunization schedule age 4 months through 6 years";
var content_f22_18_22817=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58271%7EPEDS%2F72079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58271%7EPEDS%2F72079&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Catch-up immunization schedule for persons aged 4 months through 6 years who start late or who are more than 1 month behind - United States, 2013",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"6\" width=\"16%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Minimum age for dose 1",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Minimum interval between doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Dose 1 to dose 2",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose 2 to dose 3",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose 3 to dose 4",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose 4 to dose 5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hepatitis B*",
"       </td>",
"       <td>",
"        Birth",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        8 weeks (and at least 16 weeks after first dose; minimum age for the final dose is 24 weeks)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Rotavirus",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Diphtheria, tetanus, pertussis",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        6 months",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        <em>",
"         Haemophilus influenzae",
"        </em>",
"        type b",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks if first dose administered at younger than age 12 months",
"       </td>",
"       <td>",
"        4 weeks",
"        <sup>",
"         &loz;",
"        </sup>",
"        if current age is younger than 12 months",
"       </td>",
"       <td rowspan=\"3\">",
"        8 weeks (as final dose). This dose only necessary for children aged 12 months through 59 months who received 3 doses before age 12 months.",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8 weeks (as final dose) if first dose administered at age 12 to 14 months",
"       </td>",
"       <td>",
"        8 weeks (as final dose",
"        <sup>",
"         &loz;",
"        </sup>",
"        ) if current age is 12 months or older and first dose administered at younger than age 12 months and second dose administered at younger than 15 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No further doses needed if first dose administered at age 15 months or older",
"       </td>",
"       <td>",
"        No further doses needed if previous dose administered at age 15 months or older",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"3\">",
"        Pneumococcal",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td rowspan=\"3\">",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks if first dose administered at younger than age 12 months",
"       </td>",
"       <td>",
"        4 weeks if current age is younger than 12 months",
"       </td>",
"       <td rowspan=\"3\">",
"        8 weeks (as final dose). This dose only necessary for children aged 12 months through 59 months who received 3 doses before age 12 months or for high-risk children who received 3 doses at any age.",
"       </td>",
"       <td rowspan=\"3\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8 weeks (as final dose for healthy children) if first dose administered at age 12 months or older or current age 24 through 59 months",
"       </td>",
"       <td>",
"        8 weeks (as final dose for healthy children) if current age is 12 months or older",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        No further doses needed for healthy children if first dose administered at age 24 months or older",
"       </td>",
"       <td>",
"        No further doses needed for healthy children if previous dose administered at age 24 months or older",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Inactivated poliovirus",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        6 months",
"        <sup>",
"         &yen;",
"        </sup>",
"        (minimum age 4 years for final dose)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Meningococcal",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        8 weeks",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        See footnote (������)",
"       </td>",
"       <td>",
"        See footnote (������)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Measles, mumps, rubella",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Varicella**",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        3 months",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hepatitis A",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The above table provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use this table in conjunction with its footnotes and the table of the schedule of recommended childhood immunizations for children 0 through 6 years of age in the United States.",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      Hepatitis B (HepB) vaccine:",
"     </strong>",
"     Unvaccinated persons should complete a 3-dose series.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      <strong>",
"       Rotavirus (RV) vaccines:",
"      </strong>",
"      The maximum age for the first dose in the series is 14 weeks, 6 days. Vaccination should not be initiated for infants aged 15 weeks 0 days or older. The maximum age for the final dose in the series is 8 months, 0 days. If RV1 (Rotarix) is administered for the first and second doses, a third dose is not indicated.",
"      <br>",
"       &Delta;",
"       <strong>",
"        Diphtheria and tetanus toxoids and acellular pertussis (DTaP) vaccine:",
"       </strong>",
"       The fifth (booster) dose of DTaP vaccine is not necessary if the fourth dose was administered at age 4 years or older.",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        <strong>",
"         <em>",
"          Haemophilus influenzae",
"         </em>",
"         type b (Hib) conjugate vaccine:",
"        </strong>",
"        If dose 1 was administered at ages 12 to 14 months, administer booster (as final dose) at least 8 weeks after dose 1. If the first 2 doses were PRP-OMP (PedvaxHIB or Comvax), and were administered at age 11 months or younger, the third (and final) dose should be administered at age 12 through 15 months and at least 8 weeks after the second dose. If the first dose was administered at age 7 through 11 months, administer the second dose at least 4 weeks later and a final dose at age 12 through 15 months, regardless of Hib vaccine (PRP-T [Hiberix] or PRP-OMP) used for first dose. For unvaccinated children aged 15 months or older, administer only 1 dose; however if the combination Hib-meningococcal conjugate vaccine (Menhibrix [HibMenCY]) is used, two doses, eight weeks apart, should be administered.",
"        <strong>",
"         Vaccination of persons with high-risk conditions:",
"        </strong>",
"        Hib vaccine is not routinely recommended for patients older than 5 years of age. However one dose of Hib vaccine should be administered to unvaccinated or partially vaccinated persons aged 5 years or older who have leukemia, malignant neoplasms, anatomic or functional asplenia (including sickle cell disease), human immunodeficiency virus (HIV) infection, or other immunocompromising conditions.",
"        <br>",
"         &sect;",
"         <strong>",
"          Pneumococcal vaccines:",
"         </strong>",
"         <em>",
"          (Minimum age: 6 weeks for pneumococcal conjugate vaccine [PCV]; 2 years for pneumococcal polysaccharide vaccine [PPSV23]).",
"         </em>",
"         Administer 1 dose of PCV13 to all healthy children aged 24 through 59 months who are not completely vaccinated for their age.",
"         <strong>",
"          Vaccination of persons with high-risk conditions:",
"         </strong>",
"         For children aged 24 through 71 months with high-risk conditions (listed below) administer 1 dose of PCV13 if 3 doses of PCV were received previously, or administer 2 doses of PCV13 at least 8 weeks apart if fewer than 3 doses of PCV were received previously. Administer PPSV23 at least 8 weeks after the last dose of PCV to children aged 2 years or older with high-risk conditions (listed below). A single revaccination with PPSV23 should be administered after 5 years to children with anatomic or functional asplenia (including sickle cell disease) or an immunocompromising condition. A single dose of PCV13 may be administered to previously unvaccinated children aged 6 through 18 years who have anatomic or functional asplenia (including sickle cell disease), HIV infection or an immunocompromising condition, cochlear implant or cerebrospinal fluid leak. See MMWR 2010; 59 (No. RR-11), available at",
"         <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5911.pdf\" target=\"_blank\">",
"          www.cdc.gov/mmwr/pdf/rr/rr5911.pdf",
"         </a>",
"         .",
"         <strong>",
"          High-risk conditions for pneumococcal vaccines:",
"         </strong>",
"         1) Immunocompetent children with chronic heart disease (particularly cyanotic congenital heart disease and cardiac failure); chronic lung disease (including asthma if treated with high-dose oral corticosteroid therapy), diabetes mellitus; cerebrospinal fluid leaks; or cochlear implant. 2) Children with anatomic or functional asplenia (including sickle cell disease and other hemoglobinopathies, congenital or acquired asplenia, or splenic dysfunction). 3) Children with immunocompromising conditions: HIV infection, chronic renal failure and nephrotic syndrome, diseases associated with treatment with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas and Hodgkin disease; or solid organ transplantation, congenital immunodeficiency.",
"         <br>",
"          &yen;",
"          <strong>",
"           Inactivated poliovirus (IPV) vaccine:",
"          </strong>",
"          In the first 6 months of life, minimum age and minimum intervals are only recommended if the person is at risk for imminent exposure to circulating poliovirus (ie, travel to a polio-endemic region or during an outbreak). If 4 or more doses are administered before age 4 years, an additional dose should be administered at age 4 through 6 years. A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose. If both oral poliovirus vaccine (OPV) and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age.",
"          <br>",
"           &Dagger;",
"           <strong>",
"            Meningococcal conjugate vaccines (MCV):",
"           </strong>",
"           <em>",
"            (Minimum age: 6 weeks for Menhibrix [HibMenCY], 9 months for Menactra [MCV4-D]; 2 years for Menveo [MCV4-CRM]).",
"           </em>",
"           <strong>",
"            Vaccination of persons with high-risk conditions:",
"           </strong>",
"           MCV vaccine is not routinely recommended for healthy children. For children younger than 19 months of age with anatomic or functional asplenia (including sickle cell disease), administer an infant series of HibMenCY at 2, 4, 6, and 12-15 months. For children aged 2 through 18 months with persistent complement component deficiency, administer either an infant series of HibMenCY at 2, 4, 6, and 12 through 15 months or a 2-dose primary series of MCV4-D starting at 9 months, with at least 8 weeks between doses. For children aged 19 through 23 months with persistent complement component deficiency who have not received a complete series of HibMenCY or MCV4-D, administer 2 primary doses of MCV4-D at least 8 weeks apart. For children aged 24 months and older with persistent complement component deficiency or anatomic or functional asplenia (including sickle cell disease), who have not received a complete series of HibMenCY or MCV4-D, administer 2 primary doses of either MCV4-D or MCV4-CRM. MCV4-D (Menactra) should not be administered to a child with asplenia (including sickle cell disease) until 2 years of age and at least 4 weeks after the completion of all PCV13 doses. See MMWR 2011; 60:1391, available at",
"           <a href=\"file://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf\" target=\"_blank\">",
"            www.cdc.gov/mmwr/pdf/wk/mm6040.pdf",
"           </a>",
"           . For children aged 9 months and older who are residents of or travelers to countries in the African meningitis belt or to the Hajj, administer an age-appropriate formulation and series of MCV4 for protection against serogroups A and W-135. Prior receipt of HibMenCY is not sufficient for children traveling to the meningitis belt or the Hajj. See MMWR 2011; 60:1391,",
"           <br>",
"            available at",
"            <a href=\"file://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf\" target=\"_blank\">",
"             www.cdc.gov/mmwr/pdf/wk/mm6040.pdf",
"            </a>",
"            . For children who are present during outbreaks caused by a vaccine serogroup, administer or complete an age- and formulation-appropriate series of HibMenCY or MCV4. For booster doses among persons with high-risk conditions refer to",
"            <a href=\"file://www.cdc.gov/vaccines/pubs/acip-list.htm#mening\" target=\"_blank\">",
"             www.cdc.gov/vaccines/pubs/acip-list.htm#mening",
"            </a>",
"            .",
"            <br>",
"             &dagger;",
"             <strong>",
"              Measles, mumps, and rubella (MMR) vaccine:",
"             </strong>",
"             Ensure that all school-aged children and adolescents have had 2 doses of MMR vaccine; the minimum interval between the 2 doses is 4 weeks.",
"             <br>",
"              **",
"              <strong>",
"               Varicella (VAR) vaccine:",
"              </strong>",
"              The minimum interval between doses is 3 months.",
"              <br>",
"               <font class=\"double_bullet\">",
"                &bull;&bull;",
"               </font>",
"               <strong>",
"                Hepatitis A (Hep A) vaccine:",
"               </strong>",
"               The minimum interval between the two doses is 6 months.",
"               <strong>",
"                Special populations:",
"               </strong>",
"               Administer 2 doses of HepA vaccine at least 6 months apart to previously unvaccinated persons who live in areas where vaccination programs target older children, or who are at increased risk for infection.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from:",
"     <br>",
"      1. Akinsanya-Beysolow I, Jenkins R, Meissner HC, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Persons Aged 0 Through 18 Years - United States, 2013. MMWR Surveill Summ 2013; 62:2. Available at:",
"      <a href=\"file://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf\" target=\"_blank\">",
"       www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf",
"      </a>",
"      (Accessed on February 3, 2013).",
"      <br>",
"       2. Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC. Prevention and control of meningococcal disease. MMWR Recomm Rep 2013; 62:1. Available at:",
"       <a href=\"file:///\" style=\"FONT-STYLE: italic\">",
"        file://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm",
"       </a>",
"       (Accessed on April 1, 2013).",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Catch-up immunization schedule for persons aged 7 through 18 years who start late or who are more than 1 month behind - United States, 2013",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Vaccine",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Minimum age for dose 1",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"3\">",
"        Minimum interval between doses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Dose 1 to dose 2",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose 2 to dose 3",
"       </td>",
"       <td class=\"subtitle2\">",
"        Dose 3 to dose 4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Tetanus, diphtheria/tetanus, diphtheria, pertussis*",
"       </td>",
"       <td rowspan=\"2\">",
"        7 years*",
"       </td>",
"       <td rowspan=\"2\">",
"        4 weeks",
"       </td>",
"       <td>",
"        4 weeks if first dose administered at younger than age 12 months",
"       </td>",
"       <td rowspan=\"2\">",
"        6 months if first dose administered at younger than age 12 months",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6 months if first dose administered at 12 months or older",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Human papillomavirus",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        9 years",
"       </td>",
"       <td colspan=\"3\">",
"        Routine dosing intervals are recommended",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hepatitis A",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        6 months",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Hepatitis B",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Birth",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        8 weeks (and at least 16 weeks after first dose)",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Inactivated poliovirus",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        4 weeks",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        6 months",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Meningococcal",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        6 weeks",
"       </td>",
"       <td>",
"        8 weeks",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Measles, mumps, rubella",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td>",
"        12 months",
"       </td>",
"       <td>",
"        4 weeks",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Varicella",
"        <sup>",
"         ������",
"        </sup>",
"       </td>",
"       <td rowspan=\"2\">",
"        12 months",
"       </td>",
"       <td>",
"        3 months if person is younger than age 13 years",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"       <td rowspan=\"2\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4 weeks if person is aged 13 years or older",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    The above table provides catch-up schedules and minimum intervals between doses for children whose vaccinations have been delayed. A vaccine series does not need to be restarted, regardless of the time that has elapsed between doses. Use this table in conjunction with its footnotes and the table of the schedule of recommended childhood immunizations for children 7 through 18 years of age in the United States.",
"    <div class=\"footnotes\">",
"     *",
"     <strong>",
"      Tetanus and diphtheria toxoids and acellular pertussis (Tdap) vaccine:",
"     </strong>",
"     Persons aged 7 through 10 years who are not fully immunized with the childhood diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) vaccine series, should receive Tdap vaccine as the first dose in the catch-up series; if additional doses are needed, use tetanus and diphtheria toxoids (Td) vaccine. For these children, an adolescent Tdap vaccine should not be given. Persons aged 11 through 18 years who have not received Tdap vaccine should receive a dose followed by Td booster doses every 10 years thereafter. An inadvertent dose of DTaP vaccine administered to children aged 7 through 10 years can count as part of the catch-up series. This dose can count as the adolescent Tdap dose, or the child can later receive a Tdap booster dose at age 11&ndash;12 years.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     <strong>",
"      Human papillomavirus (HPV) vaccines (HPV4 [Gardasil] and HPV2 [Cervarix]):",
"     </strong>",
"     Administer the vaccine series to females (either HPV2 or HPV4) and males (HPV4) at age 13 through 18 years if not previously vaccinated. Administer the second dose 1 to 2 months after the first dose and the third dose 6 months after the first dose (at least 24 weeks after the first dose).",
"     <br/>",
"     &Delta;",
"     <strong>",
"      Hepatitis A (HepA) vaccine:",
"     </strong>",
"     The minimum interval between the 2 doses is 6 months.",
"     <strong>",
"      Special populations:",
"     </strong>",
"     Administer 2 doses of HepA vaccine at least 6 months apart to previously unvaccinated persons who live in areas where vaccination programs target older children, or who are at increased risk for infection.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     <strong>",
"      Hepatitis B (HepB) vaccine:",
"     </strong>",
"     Unvaccinated persons should complete a 3-dose series. A 2-dose series (doses separated by at least 4 months) of adult formulation Recombivax HB is licensed for use in children aged 11 through 15 years.",
"     <br/>",
"     &sect;",
"     <strong>",
"      Inactivated poliovirus (IPV) vaccine:",
"     </strong>",
"     A fourth dose is not necessary if the third dose was administered at age 4 years or older and at least 6 months after the previous dose. If both OPV and IPV were administered as part of a series, a total of 4 doses should be administered, regardless of the child's current age. IPV is not routinely recommended for US residents aged 18 years or older.",
"     <br/>",
"     &yen;",
"     <strong>",
"      Meningococcal conjugate vaccines (MCV):",
"     </strong>",
"     Administer MCV4 vaccine at age 13 through 18 years if not previously vaccinated. If the first dose is administered at age 13 through 15 years, a booster dose should be administered at age 16 through 18 years with a minimum interval of at least 8 weeks between doses. If the first dose is administered at age 16 years or older, a booster dose is not needed.",
"     <strong>",
"      Vaccination of persons with high-risk conditions:",
"     </strong>",
"     MCV vaccine is not routinely recommended for healthy children. For children aged 24 months and older with persistent complement component deficiency or anatomic or functional asplenia (including sickle cell disease), who have not received a complete series of Menhibrix (HibMenCY) or Menactra (MCV4-D), administer 2 primary doses of either MCV4-D or Menveo (MCV4-CRM). MCV4-D should not be administered to a child with asplenia (including sickle cell disease) until 2 years of age and at least 4 weeks after the completion of all PCV13 doses. See MMWR 2011; 60:1391, available at",
"     <a href=\"file://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf\" target=\"_blank\">",
"      www.cdc.gov/mmwr/pdf/wk/mm6040.pdf",
"     </a>",
"     . For children aged 9 months and older who are residents of or travelers to countries in the African meningitis belt or to the Hajj, administer an age-appropriate formulation and series of MCV4 for protection against serogroups A and W-135. Prior receipt of HibMenCY is not sufficient for children traveling to the meningitis belt or the Hajj. See MMWR 2011; 60:1391, available at",
"     <a href=\"file://www.cdc.gov/mmwr/pdf/wk/mm6040.pdf\" target=\"_blank\">",
"      www.cdc.gov/mmwr/pdf/wk/mm6040.pdf",
"     </a>",
"     . For children who are present during outbreaks caused by a vaccine serogroup, administer or complete an age and formulation-appropriate series of HibMenCY or MCV4. For booster doses among persons with high-risk conditions refer to",
"     <a href=\"file://www.cdc.gov/vaccines/pubs/acip-list.htm#mening\" target=\"_blank\">",
"      www.cdc.gov/vaccines/pubs/acip-list.htm#mening",
"     </a>",
"     .",
"     <br/>",
"     &Dagger;",
"     <strong>",
"      Measles, mumps, and rubella (MMR) vaccine:",
"     </strong>",
"     Ensure that all school-aged children and adolescents have had 2 doses of MMR vaccine; the minimum interval between the 2 doses is 4 weeks.",
"     <br/>",
"     &dagger;",
"     <strong>",
"      Varicella (VAR) vaccine:",
"     </strong>",
"     Ensure that all persons aged 7 through 18 years without evidence of immunity (see MMWR 2007; 56 [No. RR-4], available at",
"     <a href=\"file://www.cdc.gov/mmwr/pdf/rr/rr5604.pdf\" target=\"_blank\">",
"      www.cdc.gov/mmwr/pdf/rr/rr5604.pdf",
"     </a>",
"     ) have 2 doses of varicella vaccine. For children aged 7 through 12 years the recommended minimum interval between doses is 3 months (if the second dose was administered at least 4 weeks after the first dose, it can be accepted as valid); for persons aged 13 years and older, the minimum interval between doses is 4 weeks.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Akinsanya-Beysolow I, Jenkins R, Meissner HC, Immunization Services Division, National Center for Immunization and Respiratory Diseases, CDC. Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Persons Aged 0 Through 18 Years - United States, 2013. MMWR Surveill Summ 2013; 62:2. Available at:",
"     <a href=\"file://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf\" target=\"_blank\">",
"      www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-schedule.pdf",
"     </a>",
"     (Accessed on February 3, 2013).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22817=[""].join("\n");
var outline_f22_18_22817=null;
var title_f22_18_22818="Econazole: Pediatric drug information";
var content_f22_18_22818=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Econazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?4/56/4995?source=see_link\">",
"    see \"Econazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?30/30/31203?source=see_link\">",
"    see \"Econazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1047166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Topical",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1047162\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/56/4995?source=see_link\">",
"      see \"Econazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children and Adults: Topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tinea cruris, corporis, pedis, and tinea versicolor: Apply once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cutaneous candidiasis: Apply twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F164047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical, as nitrate: 1% (15 g, 30 g, 85 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F164035\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1047169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical: Apply a sufficient amount of cream to cover affected areas; do not apply to the eye or intravaginally",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1047168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical treatment of tinea pedis, tinea cruris, tinea corporis, tinea versicolor, and cutaneous candidiasis",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F164109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Burning, erythema, itching, stinging",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Pruritic rash",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1047172\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to econazole or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1047161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Discontinue the drug if sensitivity or chemical irritation occurs; cross-sensitization may occur with other imidazole derivatives (ie, clotrimazole, miconazole)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1047160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not for ophthalmic or intravaginal use",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F164099\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2E1 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F164043\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F164044\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F164053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetotoxic and embryotoxic events were observed in animal reproduction studies following oral administration.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1047159\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Alters fungal cell wall membrane permeability; may interfere with RNA and protein synthesis, and lipid metabolism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1047171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Following topical administration, &lt;10% is percutaneously absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver to &gt;20 metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: &lt;1% of an applied dose recovered in urine or feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1047165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/30/31203?source=see_link\">",
"      see \"Econazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only. Notify physician if condition worsens or persists, or if irritation occurs.",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1047173\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Candidal infections and tinea cruris, versicolor, and corporis should be treated for 2 weeks and tinea pedis for 1 month; occasionally, longer treatment periods may be required",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13263 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-E64CDCC3B7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22818=[""].join("\n");
var outline_f22_18_22818=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047166\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047162\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164047\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164035\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047169\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047168\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164109\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047172\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047161\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047160\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164099\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164043\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164044\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F164053\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047159\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047171\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047165\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1047173\">",
"      Additional Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13263\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13263|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/56/4995?source=related_link\">",
"      Econazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/30/31203?source=related_link\">",
"      Econazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_18_22819="Penicillin G benzathine and penicillin G procaine: Patient drug information";
var content_f22_18_22819=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Penicillin G benzathine and penicillin G procaine: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/38/25188?source=see_link\">",
"     see \"Penicillin G benzathine and penicillin G procaine: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F207718\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Bicillin&reg; C-R;",
"     </li>",
"     <li>",
"      Bicillin&reg; C-R 900/300",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10015630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10015629\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702702",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to penicillin, benzathine, procaine, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10015634\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10015635\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       For women, vaginal yeast infection. Report itching or discharge.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10015637\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10015632\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a muscle.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10015639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11246 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22819=[""].join("\n");
var outline_f22_18_22819=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F207718\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015630\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015629\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015634\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015635\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015637\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015632\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10015639\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/38/25188?source=related_link\">",
"      Penicillin G benzathine and penicillin G procaine: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_18_22820="Abnormal uterine bleeding";
var content_f22_18_22820=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Abnormal uterine bleeding (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/18/22820/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22820/contributors\" id=\"au5093\">",
"       Howard A Zacur, MD, PhD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/18/22820/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22820/contributors\" id=\"se4464\">",
"       Robert L Barbieri, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?22/18/22820/contributors\">",
"       Deputy Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22820/contributors\" id=\"de1930\">",
"       Sandy J Falk, MD",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?22/18/22820?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      INTRODUCTION",
"     </span>",
"    </p>",
"    <p>",
"     The inside of the uterus has two layers. The thin inner layer is called the endometrium. The thick outer layer is the myometrium (myo = muscle) (",
"     <a class=\"graphic graphic_figure graphicRef80271 \" href=\"UTD.htm?14/52/15171\">",
"      figure 1",
"     </a>",
"     ). In women who menstruate, the endometrium thickens every month in preparation for pregnancy. If the woman does not become pregnant, the endometrial lining is shed during the menstrual period. After menopause, the lining normally stops growing and shedding.",
"    </p>",
"    <p>",
"     Under normal circumstances, a woman's uterus sheds a limited amount of blood during each menstrual period (less than 5 tablespoons or 80 mL). Bleeding that occurs between menstrual periods or excessive menstrual bleeding is considered to be abnormal uterine bleeding. Once a woman who is not taking hormone therapy enters menopause and the menstrual cycles have ended, any uterine bleeding is considered abnormal.",
"    </p>",
"    <p>",
"     Abnormal uterine bleeding can be caused by many different conditions. This topic review discusses the possible causes of abnormal bleeding, how it is evaluated, and various treatment strategies that may be recommended.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      CAUSES OF ABNORMAL UTERINE BLEEDING",
"     </span>",
"    </p>",
"    <p>",
"     Most conditions that cause abnormal uterine bleeding can occur at any age, but some are more likely to occur at a particular time in a woman's life.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H3\">",
"     <span class=\"h2\">",
"      Abnormal uterine bleeding in young girls",
"     </span>",
"     &nbsp;&mdash;&nbsp;Bleeding before menarche (the first period in a girl's life) is always abnormal. It may be caused by trauma, a foreign body (such as toys, coins, or toilet tissue), irritation of the genital area (due to bubble bath, soaps, lotions, or infection), or urinary tract problems. Bleeding can also occur as a result of sexual abuse.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      Adolescents",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many girls have episodes of irregular bleeding during the first few months after their first menstrual period. This usually resolves without treatment when the girl's hormonal cycle and ovulation normalizes. If bleeding persists beyond this time, or if the bleeding is heavy, further evaluation is needed.",
"    </p>",
"    <p>",
"     Abnormal bleeding in this age group can also be caused by any of the conditions that cause bleeding in all premenopausal women, including: pregnancy, infection, and bleeding disorder or other medical illnesses. These and other causes are discussed in the next section.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      Premenopausal women",
"     </span>",
"     &nbsp;&mdash;&nbsp;Many different conditions can cause abnormal bleeding in women between adolescence and menopause. Abrupt changes in hormone levels at the time of ovulation can cause vaginal spotting, or small amounts of bleeding. Breakthrough bleeding can also occur in premenopausal women who use hormonal birth control methods.",
"    </p>",
"    <p>",
"     Some women do not ovulate regularly and may experience intermittent light or heavy vaginal bleeding. Although anovulation is most common when periods first begin and during perimenopause, it can occur at any time during the reproductive years. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      \"Patient information: Absent or irregular periods (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Some women who ovulate normally experience excessive blood loss during their periods or bleed between periods. The most common causes of such bleeding are uterine fibroids or polyps. These irregular growths and benign tumors are composed of uterine tissue that distort the structure of the uterus and lead to abnormal uterine bleeding. Fibroids and polyps can also occur in anovulatory women. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"      \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"     </a>",
"     and",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"      \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other causes of abnormal uterine bleeding in premenopausal women include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Pregnancy",
"      </li>",
"      <li>",
"       Cancer or precancer of the cervix or the endometrium (lining of the uterus) (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"        \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Infection or inflammation of the cervix or endometrium",
"      </li>",
"      <li>",
"       Clotting disorders such as von Willebrand disease, platelet abnormalities, or problems with clotting factors",
"      </li>",
"      <li>",
"       Medical illnesses such as hypothyroidism, liver disease, or chronic renal disease",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4836698\">",
"     <span class=\"h3\">",
"      Hormonal birth control",
"     </span>",
"     &nbsp;&mdash;&nbsp;Girls and women who use hormonal birth control (eg, pills, ring, shot, patch) may experience \"breakthrough\" bleeding between periods. If this occurs during the first few months, it may be due to changes in the lining of the uterus. If it persists for more than a few months, evaluation may be needed",
"     <span class=\"nowrap\">",
"      and/or",
"     </span>",
"     a different birth control pill may be recommended. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      \"Patient information: Hormonal methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Breakthrough bleeding can also happen if a hormonal birth control method is forgotten or taken late. In this situation, there is a risk that the woman could become pregnant if she has sex. Another form of birth control (eg, condoms) is recommended if the",
"     <span class=\"nowrap\">",
"      pill/patch/shot",
"     </span>",
"     is not taken on time.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Women in the menopausal transition",
"     </span>",
"     &nbsp;&mdash;&nbsp;Before the menstrual periods end, a woman passes through a period called the menopausal transition. During the menopausal transition, normal hormonal cycling begins to change and ovulation may be inconsistent. While estrogen secretion continues, progesterone secretion declines. These hormonal changes can cause the endometrium to grow and produce excess tissue, increasing the chances that polyps or endometrial hyperplasia (thickened lining of the uterus) will develop and potentially cause abnormal bleeding.",
"    </p>",
"    <p>",
"     Women in the menopausal transition are also at risk for other conditions that cause abnormal bleeding, including cancer, infection, and bodywide illnesses. Further evaluation is needed in women with persistent irregular menstrual cycles or an episode of profuse bleeding.",
"    </p>",
"    <p>",
"     Women in the menopausal transition still ovulate some of the time and can become pregnant; pregnancy can cause abnormal bleeding. In addition, women in perimenopause may use hormonal birth control medications, which can cause breakthrough bleeding.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Menopausal women",
"     </span>",
"     &nbsp;&mdash;&nbsp;A number of conditions can cause abnormal bleeding during the menopause. Women who take hormone replacement therapy may experience cyclical bleeding. Any other bleeding that occurs during menopause is abnormal and should be investigated. Causes of abnormal bleeding during menopause include:",
"    </p>",
"    <p>",
"     <ul class=\"bulletCompact-block\">",
"      <li>",
"       Atrophy (excessive thinning) of the tissue lining the vagina and uterus",
"      </li>",
"      <li>",
"       Cancer of the uterine lining (endometrium) (see",
"       <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"        \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       Polyps or fibroids",
"      </li>",
"      <li>",
"       Endometrial hyperplasia",
"      </li>",
"      <li>",
"       Infection of the uterus",
"      </li>",
"      <li>",
"       Use of blood thinners or anticoagulants",
"      </li>",
"      <li>",
"       Side effects of radiation therapy",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      ABNORMAL UTERINE BLEEDING EVALUATION",
"     </span>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Initial assessment",
"     </span>",
"     &nbsp;&mdash;&nbsp;While taking a woman's medical history, a clinician will review the duration and amount of bleeding; factors that seem to bring the bleeding on; symptoms that occur along with the bleeding such as pain, fever, or vaginal odor; if bleeding occurs after sexual intercourse; whether there is a personal or family history of bleeding disorders; the woman's medical history and medications she is taking; recent weight changes, stress, a new exercise program, or underlying medical problems.",
"    </p>",
"    <p>",
"     The clinician will perform a physical examination to evaluate the woman's overall health, and a pelvic examination to confirm that the bleeding is from the uterus and not from another site (eg, the external genitals or rectum). During the pelvic exam, the clinician will look for any obvious lesions (cuts, sores, or tumors) and will examine the size and shape of the uterus. He or she will examine the cervix to look for signs of cervical bleeding, and a Pap smear may be obtained to examine the cells of the cervix (the lower end of the uterus, where it opens to the vagina). (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      \"Patient information: Cervical cancer screening (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Lab tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;In premenopausal women, a pregnancy test is performed. If there is any abnormal vaginal discharge, a cervical culture may be performed. Blood tests may also be done to determine if there are problems with blood clotting or other bodywide conditions, such as thyroid disease, liver disease, or kidney problems.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Tests to determine ovulatory status",
"     </span>",
"     &nbsp;&mdash;&nbsp;Because hormonal irregularities can contribute to abnormal uterine bleeding, testing may be recommended to determine if the woman ovulates (produce an egg) during each monthly cycle.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Endometrial assessment",
"     </span>",
"     &nbsp;&mdash;&nbsp;Tests that assess the endometrium (lining of the uterus) may be performed to rule out endometrial cancer and structural abnormalities such as uterine fibroids or polyps. Such tests include:",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h3\">",
"      Endometrial biopsy",
"     </span>",
"     &nbsp;&mdash;&nbsp;An endometrial biopsy is often performed in women over age 35 to rule out endometrial cancer or abnormal endometrial growths. A biopsy may also be performed in women younger than 35 if they have risk factors for endometrial cancer. Risks include obesity, chronic anovulation, history of breast cancer, tamoxifen use or a family history of breast cancer or colon cancer. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"      \"Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     During the biopsy, a thin instrument is inserted through the vagina into the uterus to obtain a small sample of endometrial tissue. The biopsy can be performed in a healthcare provider's office without anesthesia. Because only a small portion of the endometrium is sampled, the biopsy may miss some causes of bleeding and other tests are sometimes necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H15\">",
"     <span class=\"h3\">",
"      Transvaginal ultrasound",
"     </span>",
"     &nbsp;&mdash;&nbsp;An ultrasound uses sound waves to measure an organ's shape and structure. In a transvaginal ultrasound, a small ultrasound probe is inserted into the vagina so that it is closer to the uterus and can provide a clear image of the uterus. The lining of the uterus is evaluated and measured; postmenopausal women normally have a very thin endometrial lining (usually less than 4 or 5 mm). Ultrasound cannot distinguish between different types of abnormalities (eg, polyp versus cancer) and further testing may be necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H16\">",
"     <span class=\"h3\">",
"      Saline infusion sonography ( sonohysterography)",
"     </span>",
"     &nbsp;&mdash;&nbsp;In this test, a transvaginal ultrasound is performed after sterile saline is instilled into the uterus. This procedure gives a better picture of the inside of the uterus, and small lesions can be more easily detected. However, because tissue samples cannot be obtained during the procedure, a final diagnosis is not always possible and additional evaluation, usually including hysteroscopy with dilation and curettage (D&amp;C) may be necessary.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H17\">",
"     <span class=\"h3\">",
"      Imaging tests",
"     </span>",
"     &nbsp;&mdash;&nbsp;A magnetic resonance image (MRI) is a non-invasive test that is sometimes used to determine if fibroids or other structural abnormalities of the uterus are present.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H18\">",
"     <span class=\"h3\">",
"      Hysteroscopy",
"     </span>",
"     &nbsp;&mdash;&nbsp;During hysteroscopy, a small scope is inserted through the cervix and into the uterus. Air or fluid is injected to expand the uterus and to allow the physician to see the inside of the uterus. Tissue samples may be taken. Anesthesia is used to minimize discomfort during the procedure. In most cases, hysteroscopy is performed along with a D&amp;C.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H19\">",
"     <span class=\"h3\">",
"      Dilation and curettage (D&amp;C)",
"     </span>",
"     &nbsp;&mdash;&nbsp;In a D&amp;C, the cervix or opening of the uterus is dilated and instruments are inserted and used to remove endometrial or uterine tissue. A D&amp;C usually requires anesthesia. It can sometimes be used as a treatment for prolonged or excessive bleeding that is due to hormonal changes and that is unresponsive to other treatments. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=see_link\">",
"      \"Patient information: Dilation and curettage (D and C) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H20\">",
"     <span class=\"h1\">",
"      ABNORMAL UTERINE BLEEDING TREATMENT",
"     </span>",
"    </p>",
"    <p>",
"     The treatment of abnormal bleeding is based upon the underlying cause.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H21\">",
"     <span class=\"h2\">",
"      Birth control pills",
"     </span>",
"     &nbsp;&mdash;&nbsp;Birth control pills are often used to treat uterine bleeding that is due to hormonal changes or hormonal irregularities. Birth control pills may be used in women who do not ovulate regularly to establish regular bleeding cycles and prevent excessive growth of the endometrium. In women who do ovulate, they may be used to treat excessive menstrual bleeding. Nonsteroidal anti-inflammatory drugs (NSAIDS, eg ibuprofen, naproxen sodium) may also be helpful in reducing blood loss and cramping in these women.",
"    </p>",
"    <p>",
"     During the menopausal transition, birth control pills or other hormonal therapy may be used to regulate the menstrual cycle and prevent excessive growth of the endometrium. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"      \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H22\">",
"     <span class=\"h2\">",
"      Progesterone",
"     </span>",
"     &nbsp;&mdash;&nbsp;Progesterone is a hormone made by the ovary that is effective in preventing excessive bleeding in women who do not ovulate regularly. A synthetic form of progesterone, called progestin, may be recommended to treat abnormal bleeding. Progestins are usually given as pills (eg, medroxyprogesterone acetate, norethindrone), and are taken once a day for 10 to 12 days each month or two. Progestins can be taken for longer periods if there has been overgrowth of the uterine lining. Vaginal bleeding will begin before the seventh day of progestin treatment if the uterine lining is overgrown; otherwise, it may not be seen until several days after the last progestin tablet is taken. In some cases, the progestin is given on a regular basis (eg, every few months) to prevent excessive growth of the uterine lining and heavy menstrual bleeding. If no bleeding is seen after progestin treatment, the possibility of an unintended pregnancy should be explored.",
"    </p>",
"    <p>",
"     Progestins may also be given in other ways, such as in an injection, an implant, or an intrauterine device. These treatments are discussed in detail in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"      \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H23\">",
"     <span class=\"h2\">",
"      Intrauterine device",
"     </span>",
"     &nbsp;&mdash;&nbsp;An intrauterine contraceptive device (IUD) that secretes progestin (eg, Mirena) may be recommended for women who do not ovulate regularly. IUDs are inserted by a healthcare provider through the vagina and cervix into the uterus. Most are made of molded plastic and include an attached plastic string that projects through the cervix, enabling the woman to check that the device remains in place (",
"     <a class=\"graphic graphic_picture graphicRef74378 \" href=\"UTD.htm?19/5/19550\">",
"      picture 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Progestin-releasing IUDs decrease menstrual blood loss by 40 to 50 percent and decrease pain associated with periods. Some women completely stop having menstrual bleeding as a result of the IUD, which is reversible when the IUD is removed. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      \"Patient information: Long-term methods of birth control (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H24\">",
"     <span class=\"h2\">",
"      Surgery",
"     </span>",
"     &nbsp;&mdash;&nbsp;Surgery may be necessary to remove abnormal uterine structures (eg, fibroids, polyps). Women who have completed childbearing and have heavy menstrual bleeding can consider a surgical procedure such as endometrial ablation. This procedure is done while the woman is under general or regional anesthesia, and uses heat, cold, or a laser to destroy the lining of the uterus. More information about endometrial ablation is available in a separate topic review. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"      \"Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Women with fibroids can have surgical treatment of their fibroids, either by removing the fibroid(s) (eg, myomectomy) or by reducing the blood supply of the fibroids (eg, uterine artery embolization). More information about these treatments is available separately. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"      \"Patient information: Uterine fibroids (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H25\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1818958475\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1201850\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/12/23747?source=see_link\">",
"      Patient information: Uterine cancer (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?28/33/29202?source=see_link\">",
"      Patient information: Dilation and curettage (D and C) (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/8/143?source=see_link\">",
"      Patient information: Endometrial ablation (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H1201876\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?21/32/22021?source=see_link\">",
"      Patient information: Hormonal methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/12/29891?source=see_link\">",
"      Patient information: Absent or irregular periods (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?20/20/20804?source=see_link\">",
"      Patient information: Uterine fibroids (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?22/35/23094?source=see_link\">",
"      Patient information: Menorrhagia (excessive menstrual bleeding) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?18/55/19314?source=see_link\">",
"      Patient information: Endometrial cancer diagnosis and staging (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?24/14/24802?source=see_link\">",
"      Patient information: Chlamydia (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?1/44/1730?source=see_link\">",
"      Patient information: Gonorrhea (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?7/53/8019?source=see_link\">",
"      Patient information: Cervical cancer screening (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/24/8578?source=see_link\">",
"      Patient information: Dilation and curettage (D and C) (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?4/16/4355?source=see_link\">",
"      Patient information: Long-term methods of birth control (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H26\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/7/31866?source=see_link\">",
"      An overview of endometrial ablation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/41/20122?source=see_link\">",
"      Chronic menorrhagia or anovulatory uterine bleeding",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/13/39130?source=see_link\">",
"      Clinical features and diagnosis of polycystic ovary syndrome in adolescents",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/41/35480?source=see_link\">",
"      Dilation and curettage",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/53/38744?source=see_link\">",
"      Evaluation of the endometrium for malignant or premalignant disease",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/25/20887?source=see_link\">",
"      Initial approach to the premenopausal woman with abnormal uterine bleeding",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/18/35113?source=see_link\">",
"      Overview of causes of genital tract bleeding in women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/24/23944?source=see_link\">",
"      Terminology and evaluation of abnormal uterine bleeding in premenopausal women",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/41/2711?source=see_link\">",
"      Postmenopausal uterine bleeding",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"        www.nlm.nih.gov/medlineplus/healthtopics.html",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The American College of Obstetricians and Gynecologists",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.acog.org/\">",
"        file://www.acog.org/",
"       </a>",
"       )",
"      </li>",
"      <li>",
"       The Nemours Foundation",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.kidshealth.org/\">",
"        www.kidshealth.org",
"       </a>",
"       , search for menstrual)",
"      </li>",
"      <li>",
"       The Hormone Foundation",
"       <br/>",
"       <br/>",
"       (",
"       <a class=\"external\" href=\"file://www.hormone.org/\">",
"        www.hormone.org",
"       </a>",
"       )",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?22/18/22820/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?22/18/22820?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22820/abstract/1\">",
"      Fraser IS, Critchley HO, Munro MG, et al. A process designed to lead to international agreement on terminologies and definitions used to describe abnormalities of menstrual bleeding. Fertil Steril 2007; 87:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22820/abstract/2\">",
"      Mohan S, Page LM, Higham JM. Diagnosis of abnormal uterine bleeding. Best Pract Res Clin Obstet Gynaecol 2007; 21:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22820/abstract/3\">",
"      van Dongen H, de Kroon CD, Jacobi CE, et al. Diagnostic hysteroscopy in abnormal uterine bleeding: a systematic review and meta-analysis. BJOG 2007; 114:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22820/abstract/4\">",
"      Gray SH, Emans SJ. Abnormal vaginal bleeding in adolescents. Pediatr Rev 2007; 28:175.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f22_18_22820=[""].join("\n");
var outline_f22_18_22820=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           INTRODUCTION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           CAUSES OF ABNORMAL UTERINE BLEEDING",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           ABNORMAL UTERINE BLEEDING EVALUATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H20\">",
"           ABNORMAL UTERINE BLEEDING TREATMENT",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H25\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/52/15171\" title=\"figure 1\">",
"           Female anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          PICTURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/5/19550\" title=\"picture 1\">",
"           Mirena IUD PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f22_18_22821="Cilazapril and hydrochlorothiazide: Patient drug information";
var content_f22_18_22821=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Cilazapril and hydrochlorothiazide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/60/6088?source=see_link\">",
"     see \"Cilazapril and hydrochlorothiazide: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F5928248\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Cilazapril&reg;/Hctz;",
"     </li>",
"     <li>",
"      Inhibace&reg; Plus;",
"     </li>",
"     <li>",
"      Novo-Cilazapril/HCTZ",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10021763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10021765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691888",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat high blood pressure.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10021764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701805",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to cilazapril, hydrochlorothiazide, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701385",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a sulfa (sulfonamide) allergy, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are not able to pass urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701080",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are pregnant or may be pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10021769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are having surgery, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697207",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), this drug may sometimes raise blood sugar. Talk with your doctor about how to fine tune this.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood pressure checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697100",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a salt substitute that has potassium, potassium-sparing diuretics, or potassium, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696833",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take antacids within 2 hours of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697627",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using OTC products that may raise blood pressure. These include cough or cold drugs, diet pills, stimulants, ibuprofen or like products, and some natural products or aids.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696701",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Be careful in hot weather. Drink lots of fluids to stop fluid loss.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697794",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may get sunburned more easily. Avoid sun, sunlamps, bright indoor lights, and tanning beds. Wear clothing and eyewear that protects you from the sun. Sunscreens will not protect you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697779",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Watch for gout attacks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697740",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use birth control that you can trust to stop pregnancy while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10021770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10021772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698650",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you have too much sweat, fluid loss, throwing up, or loose stools. This may lead to low blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough that does not go away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10021767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695872",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause you to pass urine more often. To keep from having sleep problems, try to take before 6 pm.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10021768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10021773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10021774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12001 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-213.131.41.98-64F77B4D5B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22821=[""].join("\n");
var outline_f22_18_22821=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5928248\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021763\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021765\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021764\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021769\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021770\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021772\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021767\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021768\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021773\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10021774\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?5/60/6088?source=related_link\">",
"      Cilazapril and hydrochlorothiazide: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_18_22822="US 2011 trauma field triage algorithm";
var content_f22_18_22822=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F81002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F81002&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 653px\">",
"   <div class=\"ttl\">",
"    US 2011 trauma field triage algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 633px; height: 863px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     EMS: emergency medical services.",
"     <br>",
"      * The upper limit of respiratory rate in infants is &gt;29 breaths per minute to maintain a higher level of overtriage for infants.",
"      <br>",
"       &Delta; Trauma centers are designated Level I-IV. A Level I center has the greatest amount of resources and personnel for care of the injured patient and provides regional leadership in education, research, and prevention programs. A Level II facility offers similar resources to a Level I facility, possibly differing only in continuous availability of certain subspecialties or sufficient prevention, education, and research activities for Level I designation; Level II facilities are not required to be resident or fellow education centers. A Level III center is capable of assessment, resuscitation, and emergency surgery, with severely injured patients being transferred to a Level I or II facility. A Level IV trauma center is capable of providing 24-hour physician coverage, resuscitation, and stabilization to injured patients before transfer to a facility that provides a higher level of trauma care.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        Any injury noted in Step two or mechanism identified in Step three triggers a \"yes\" response.",
"        <br>",
"         &sect; Age &lt;15 years.",
"         <br>",
"          &yen; Intrusion refers to interior compartment intrusion, as opposed to deformation which refers to exterior damage.",
"          <br>",
"           ������ Includes pedestrians or bicyclists thrown or run over by a motor vehicle or those with estimated impact &gt;20 mph with a motor vehicle.",
"           <br>",
"            ������ Local or regional protocols should be used to determine the most appropriate level of trauma center within the defined trauma system; need not be the highest-level trauma center.",
"            <br>",
"             ** Age &gt;55 years.",
"             <br>",
"              &Delta;&Delta; Patients with both burns and concomitant trauma for whom the burn injury poses the greatest risk for morbidity and mortality should be transferred to a burn center. If the nonburn trauma presents a greater immediate risk, the patient may be stabilized in a trauma center and then transferred to a burn center.",
"              <br>",
"               <span class=\"double_lozenge\">",
"                &loz;&loz;",
"               </span>",
"               Patients who do not meet any of the triage criteria in Steps one through four should be transported to the most appropriate medical facility as outlined in local EMS protocols.",
"              </br>",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Sasser SM, Hunt RC, Faul M, et al. Guidelines for field triage of injured patients: Recommendations of the National Expert Panel on Field Triage, 2011. MMWR 2012; 61:1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22822=[""].join("\n");
var outline_f22_18_22822=null;
var title_f22_18_22823="Glossary of common biostatistical and epidemiological terms";
var content_f22_18_22823=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"0\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Glossary of common biostatistical and epidemiological terms",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22823/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22823/contributors\">",
"     Peter A L Bonis, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22823/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22823/contributors\">",
"     Suzanne W Fletcher, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22823/contributors\">",
"     Robert H Fletcher, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22823/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22823/contributors\">",
"     Fenny H Lin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/18/22823/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;This topic review will provide a catalog of common biostatistical and epidemiological terms encountered in the medical literature. A list of textbooks that are geared toward health professionals interested in these topics is provided in the references [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22823/abstract/1-8\">",
"     1-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STATISTICS THAT DESCRIBE HOW DATA ARE DISTRIBUTED",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Measures of central tendency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three measures of central tendency are most frequently used to describe data:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mean equals the sum of observations divided by the number of observations.",
"     </li>",
"     <li>",
"      Median equals the observation in the middle when all observations are ordered from smallest to largest; when there are an even number of observations the median is defined as the mean of the middle two data points.",
"     </li>",
"     <li>",
"      Mode equals the observation that occurs most frequently.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Measures of dispersion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dispersion refers to the degree to which data are scattered around a specific value (such as the mean). The most commonly used measures of dispersion are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Range &mdash; The range equals the difference between the largest and smallest observation.",
"     </li>",
"     <li>",
"      Standard deviation &mdash; The standard deviation measures the variability of data around the mean. It provides information on how much variability can be expected among individuals within a population. In samples that follow a \"normal\" distribution (ie, Gaussian), 68 and 95 percent of values fall within one and two standard deviations of the mean, respectively.",
"     </li>",
"     <li>",
"      Standard error of the mean &mdash; Standard deviation of the mean (for a sample population) should be distinguished from the standard error of the mean, which describes how much variability can be expected when measuring the mean from several different samples.",
"     </li>",
"     <li>",
"      Percentile &mdash; The percentile equals the percentage of a distribution that is below a specific value. As an example, a child is in 90th percentile for weight if only 10 percent of children the same age weigh more than she does.",
"     </li>",
"     <li>",
"      Interquartile range &mdash; The interquartile range refers to the upper and lower values defining the central 50 percent of observations. The boundaries are equal to the observations representing the 25th and 75th percentiles. The interquartile range is depicted in a box and whiskers plot (",
"      <a class=\"graphic graphic_figure graphicRef57798 \" href=\"UTD.htm?40/32/41484\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     TERMS USED TO DESCRIBE THE FREQUENCY OF AN EVENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incidence and prevalence are the two main terms used to describe the frequency of an event.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Incidence represents the number of new events that have occurred in a specific time interval divided by the population at risk at the beginning of the time interval. The result gives the likelihood of developing an event in that time interval.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevalence refers to the number of individuals with a given disease at a given point in time divided by the population at risk at that point in time. Prevalence has been further defined as being \"point\" or \"period.\" Point prevalence refers to the proportion of individuals with a condition at a specified point in time, while period prevalence refers to the proportion of individuals with a condition during a specified interval (eg, a year).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Person-years",
"    </span>",
"    &nbsp;&mdash;&nbsp;Person years refers to the total number of years that each member of a study population has been under observation or treatment. It is obtained by multiplying the number of years times the number of members of a sample population who have had a certain condition or undergone a particular treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TERMS USED TO DESCRIBE THE MAGNITUDE OF AN EFFECT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The types of descriptors used to define the relationship among variables of interest in a data set and the effect of one variable on another depend upon the type of data. Important examples are the relative risk and odds ratio, which are commonly encountered expressions describing the relationship between nominal characteristics (ie, variables that are grouped as unique categories) (",
"    <a class=\"graphic graphic_figure graphicRef71957 \" href=\"UTD.htm?35/38/36462\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Relative risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative risk (or risk ratio) equals the incidence in exposed individuals divided by the incidence in unexposed individuals. The relative risk can be calculated from studies in which the proportion of patients exposed and unexposed to a risk is known, such as a cohort study. (See",
"    <a class=\"local\" href=\"#H33\">",
"     'Cohort study'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Odds ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;The odds ratio equals the odds that an individual with a specific condition has been exposed to a risk factor divided by the odds that a control has been exposed. The odds ratio is used in case-control studies and is often generated in multivariate analyses as well. (See",
"    <a class=\"local\" href=\"#H34\">",
"     'Case-control study'",
"    </a>",
"    below.) The odds ratio provides a reasonable estimate of the relative risk for uncommon conditions (",
"    <a class=\"graphic graphic_figure graphicRef71957 \" href=\"UTD.htm?35/38/36462\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The relative risk and odds ratio are interpreted relative to the number one. An odds ratio of 0.6, for example, suggests that patients exposed to a variable of interest were 40 percent less likely to develop a specific outcome compared to the control group. Similarly, an odds ratio of 1.5 suggests that the risk was increased by 50 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Absolute risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;The relative risk and odds ratio provide an understanding of the magnitude of risk compared with a standard. However, it is more often desirable to know information about the absolute risk. As an example, a 40 percent increase in mortality due to a particular exposure does not provide direct insight into the likelihood that exposure in an individual patient will lead to mortality.",
"   </p>",
"   <p>",
"    The \"attributable risk\" represents the difference in the rate of a disease in an exposed, compared with a non-exposed, population. It reflects the additional incidence of disease related to an exposure taking into account the background rate of the disease. The attributable risk is calculated by subtracting the incidence of a disease in nonexposed persons from the incidence of disease in exposed persons.",
"   </p>",
"   <p>",
"    A related term, the \"population attributable risk\" is used to describe the contribution that an exposure has on the incidence of a specific disease in a population. It is calculated by multiplying the attributable risk by the prevalence of exposure to a risk factor in a population. The population attributable risk is particularly important when considering public health measures and the allocation of resources intended to reduce the incidence of a disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Number needed to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of an intervention can be expressed by the \"number needed to treat\" (NNT). NNT is the reciprocal of the absolute risk reduction (the absolute adverse event rate for placebo minus the absolute adverse event rate for treated patients). Its interpretation can be illustrated by the following sentence: \"This study suggests that I would have to treat five patients with a drug to prevent one death.\"",
"   </p>",
"   <p>",
"    As an example, consider a placebo-controlled trial involving 100 patients. Thirty patients died during the study period (10 receiving active drug and 20 receiving placebo) giving a mortality rate of 20 percent with active drug (10 divided by (10 +40)) versus 40 percent (20 divided by (20 + 30)) with placebo as shown in the left panel of the figure (",
"    <a class=\"graphic graphic_figure graphicRef53580 \" href=\"UTD.htm?33/44/34508\">",
"     figure 3",
"    </a>",
"    ). The difference between these two rates, the \"risk difference\", is used to calculate NNT.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      40 percent minus 20 percent = 20 percent = 0.2",
"     </li>",
"     <li>",
"      1 divided by 0.2 = 5",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, this study suggests that only five patients need to be treated with the drug (compared with placebo) to prevent one death.",
"   </p>",
"   <p>",
"    Because it is intuitive, the NNT has become an increasingly popular expression of absolute benefit or risk, potentially allowing for comparison of the relative benefit (or harm) of different interventions. However, the NNT can be misleading:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It implies that the option is to treat or not to treat rather than to treat or switch to another more effective treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22823/abstract/9\">",
"       9",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There are variations on how NNT is determined; NNTs from different studies cannot be compared unless the methods used to determine them are identical [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22823/abstract/10\">",
"       10",
"      </a>",
"      ]. This may be a particular consideration when NNTs are calculated for treatment of chronic diseases in which outcomes (such as mortality) do not cluster in time.",
"     </li>",
"     <li>",
"      Calculation of the NNT depends upon the control rate (ie, the rate of events in the control arm). The control rate can be variable (particularly in small controlled trials, which are more vulnerable to random effects). As a result, the NNT may not accurately reflect the benefit of an intervention if events occurred in the control arm more or less than would be expected based upon the biology of the disease. This effect can be particularly problematic when comparing the NNTs among placebo controlled trials (",
"      <a class=\"graphic graphic_figure graphicRef53580 \" href=\"UTD.htm?33/44/34508\">",
"       figure 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22823/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When the outcome is a harm rather than a benefit, a number needed to harm (NNH) can be calculated similarly. As an example, if statin therapy causes myalgias in 5 percent of patients, then treating 20 patients with statins would be expected to cause one case of myalgia, for an NNH of 20. Other variations that sometimes appear in the medical literature include number needed to prevent and number needed to diagnose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     TERMS USED TO DESCRIBE THE QUALITY OF MEASUREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most commonly used measures to describe the quality of an observation are reliability and validity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Reliability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reliability refers to the extent to which repeated measurements of a relatively stable phenomenon fall closely to each other. Several different types of reliability can be measured, such as inter- and intraobserver reliability and test-retest reliability.",
"   </p>",
"   <p>",
"    As an example, the kappa statistic is a measure of the agreement between two observers and can range from -1.0 to +1.0. If there is perfect agreement, the value is 1.0, whereas if the observed agreement is what would be expected by chance alone, the value is zero. If the degree of agreement is worse than what would be expected by chance, the kappa value will be negative, with complete disagreement resulting in a value of -1.0. Kappa statistics are often interpreted as:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Excellent agreement &mdash; 0.8 to 1.0",
"     </li>",
"     <li>",
"      Good agreement &mdash; 0.6 to 0.8",
"     </li>",
"     <li>",
"      Moderate agreement &mdash; 0.4 to 0.6",
"     </li>",
"     <li>",
"      Fair agreement &mdash; 0.2 to 0.4",
"     </li>",
"     <li>",
"      Poor agreement &mdash; less than 0.2",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Validity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Validity refers to the extent to which an observation reflects the \"truth\" of the phenomenon being measured. Several types can be measured. In studies involving questionnaire development, for example, types of validity include content (the extent to which the measure reflects the dimensions of a particular problem), construct (the extent to which a measure is affirmed by an external established indicator), and criterion validity (the extent to which a measure can predict an observable phenomenon). These types of validity are useful since the \"truth\" may not be physically verifiable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     MEASURES OF DIAGNOSTIC TEST PERFORMANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common terms used to describe the performance of a diagnostic test are sensitivity and specificity (",
"    <a class=\"graphic graphic_table graphicRef77832 \" href=\"UTD.htm?7/50/7979\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link\">",
"     \"Evaluating diagnostic tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Sensitivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of patients with a positive test who have a disease divided by all patients who have the disease. A test with high sensitivity will not miss many patients who have the disease (ie, few false negative results).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Specificity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of patients who have a negative test and do not have the disease divided by the number of patients who do not have the disease. A test with high specificity will infrequently identify patients as having a disease when they do not (ie, few false positive results).",
"   </p>",
"   <p>",
"    Sensitivity and specificity are properties of tests that should be considered when tests are obtained. In addition, sensitivity and specificity are interdependent. Thus, for a given test, an increase in sensitivity is accompanied by a decrease in specificity and vice versa. This can be illustrated by the following example. Consider two populations of patients: one has chronic hepatitis as defined by a reference standard such as a liver biopsy, and the other does not. The diagnostic test being used to evaluate for chronic hepatitis is the serum alanine aminotransferase (ALT) concentration. The sensitivity and specificity of the ALT depends upon the value chosen as a cutoff (",
"    <a class=\"graphic graphic_figure graphicRef72237 \" href=\"UTD.htm?38/36/39501\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The interdependence of sensitivity and specificity can be depicted graphically using a receiver operating characteristic (ROC) curve. The ROC curve plots sensitivity on the Y axis, and 1-specificity (which is the false positive rate) on the X axis. The area under the ROC curves (the area to the right and below the curve) gives an estimate of the accuracy of a test. An ideal test would have a cutoff value that perfectly discriminated those with disease, and would have an area under the ROC curve of 1.00 (",
"    <a class=\"graphic graphic_figure graphicRef54239 \" href=\"UTD.htm?29/52/30541\">",
"     figure 5",
"    </a>",
"    ). The ROC curve can be adapted to multivariate analysis (such as logistic regression) in which it provides an estimate of the accuracy of the statistical model (ie, how well it predicts an outcome).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Predictive values",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to sensitivity and specificity, the predictive values of a diagnostic test must be considered when interpreting the results of a test (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?35/55/36722?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). The positive predictive value of a test represents the likelihood that a patient with a positive test has the disease. Conversely, the negative predictive value represents the likelihood that a patient who has a negative test is free of the disease (",
"    <a class=\"graphic graphic_table graphicRef77832 \" href=\"UTD.htm?7/50/7979\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The predictive values (and the proportion of positive and negative evaluations that can be expected) depend upon the prevalence of a disease within a population. Thus, for given values of sensitivity and specificity, a patient with a positive test is more likely to truly have the disease if the patient belongs to a population with a high prevalence of the disease (",
"    <a class=\"graphic graphic_figure graphicRef68072 \" href=\"UTD.htm?23/36/24142\">",
"     figure 6",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    This observation has significant implications for screening tests, in which false positive results may lead to expensive and sometimes dangerous testing, and false negative tests may be associated with morbidity or mortality. As an example, a positive stool test for occult blood is much more likely to predict colon cancer in a seventy year-old compared with a twenty year-old. Thus, routine screening of stools in young patients would lead to a high rate of subsequent false positive examinations and is not recommended. The predictive values of a test should be considered when selecting among diagnostic tests for an individual patient in whom demographic or other clinical risk factors influence the likelihood that the disease is present (ie, the \"prior probability\" of the disease).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Likelihood ratio",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, a limitation to predictive values as expressions of test characteristics is their dependence upon disease prevalence. To overcome this limitation, the likelihood ratio has been used increasingly as an expression of the performance of diagnostic tests [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22823/abstract/12\">",
"     12",
"    </a>",
"    ]. Likelihood ratios are an expression of sensitivity and specificity that can be used to estimate the odds that a condition is present or absent (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?10/3/10291?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=see_link\">",
"     \"Evaluating diagnostic tests\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The likelihood ratio represents a measure of the odds of having a disease relative to the prior probability of the disease. The estimate is independent of the disease prevalence. A positive likelihood ratio is calculated by dividing sensitivity by 1 minus specificity",
"    <span class=\"nowrap\">",
"     (sensitivity/(1-specificity)).",
"    </span>",
"    Similarly, a negative likelihood ratio is calculated by dividing 1 minus sensitivity by specificity",
"    <span class=\"nowrap\">",
"     ((1-sensitivity)/specificity).",
"    </span>",
"    Positive and negative likelihood ratios of 9 and 0.25, for example, can be interpreted as meaning that a positive result is seen 9 times as frequently while a negative test is seen 0.25 times as frequently in those with a specific condition than those without it. Likelihood ratios can be established for many cutoff points for a diagnostic test permitting an appreciation for the relative importance of a large versus small increase in a test result.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Accuracy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The performance of a diagnostic test is sometimes expressed as accuracy, which refers to the number of true positives and true negatives divided by the total number of observations (",
"    <a class=\"graphic graphic_table graphicRef55297 \" href=\"UTD.htm?0/18/299\">",
"     table 2",
"    </a>",
"    ). However, accuracy by itself is not a good indicator of test performance since it obscures important information related to its component parts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     EXPRESSIONS USED WHEN MAKING INFERENCES ABOUT DATA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Confidence interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;A point estimate (ie, a single value) from a sample population may not reflect the \"true\" value from the entire population. As a result, it is often helpful to provide a range that is likely to include the true value. A confidence interval is a commonly used estimate. The boundaries of a confidence interval give values within which there is a high probability (95 percent by convention) that the true population value can be found. The calculation of a confidence interval considers the standard deviation of the data and the number of observations. Thus, a confidence interval narrows as the number of observations increases, or its variance (dispersion) decreases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Credible interval",
"    </span>",
"    &nbsp;&mdash;&nbsp;A credible interval is used in Bayesian analysis to describe the range in which a posterior probability estimate is likely to reside. As an example, a 95 percent credible interval for a posterior probability estimate of 40 percent could range from 30 to 50 percent, indicating that there is a 95 percent chance that the true posterior probability estimate lies within the 30 to 50 percent range. There are fundamental differences in how credible intervals are derived compared with the more commonly-used confidence intervals. Nevertheless, their intuitive interpretation is similar.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Errors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two potential errors are commonly recognized when testing a hypothesis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A type I error (also known as alpha) is the probability of incorrectly concluding that there is a statistically significant difference in a dataset. Alpha is the number after a p-value. Thus, a statistically significant difference reported as p&lt;0.05 means that there is less than a 5 percent chance that the difference could have occurred by chance.",
"     </li>",
"     <li>",
"      A type II error (also known as beta) is the probability of incorrectly concluding that there was no statistically significant difference in a dataset. This error often reflects insufficient power of the study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Power",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"power\" (calculated as 1 - beta) refers to the ability of a study to detect a true difference. Negative findings in a study may reflect that the study was underpowered to detect a difference. A \"power calculation\" should be performed prior to conducting a study to be sure that there are a sufficient number of observations to detect a desired degree of difference. The larger the difference, the fewer the number of observations that will be required. As an example, it takes fewer patients to detect a 50 percent difference in blood pressure from a new antihypertensive medication compared with placebo than a 5 percent difference.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TERMS USED IN MULTIVARIATE ANALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of more than one variable often needs to be considered when predicting an outcome. As an example, the effect of smoking status and age needs to be simultaneously considered when assessing the risk of lung cancer.",
"   </p>",
"   <p>",
"    Statistical methods that can simultaneously account for multiple variables are known as \"multivariate\" (or multivariable) analysis. These methods help to \"control\" for variables that are extraneous to the main causal question and might confound it. A commonly encountered form of multivariable analysis, logistic regression, is applied to models in which the outcome is dichotomous (eg, alive or dead, or a complication occurs or does not occur).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     TIME-TO-EVENT ANALYSIS (SURVIVAL ANALYSIS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many examples of medical research deal with an event that may or may not occur in a given period of time (such as death, stroke, myocardial infarction). During the study, several outcomes are possible in addition to the outcome of interest (eg, patients might die of other causes or drop out from the analysis). Furthermore, the duration of follow-up can vary among individuals in the study. A patient who is observed for five years should count more in the statistical analysis than one observed for five months.",
"   </p>",
"   <p>",
"    Several methods are available to account for these considerations. The most commonly used in medical research are Kaplan-Meier and Cox proportional hazards analyses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Kaplan-Meier analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Kaplan-Meier analysis measures the ratio of surviving patients (or those free from an outcome) divided by the total number of patients at risk for the outcome. Every time a patient has an outcome, the ratio is recalculated. Using these calculations, a curve can be generated that graphically depicts the probability of survival as time passes (",
"    <a class=\"graphic graphic_figure graphicRef67914 \" href=\"UTD.htm?20/25/20893\">",
"     figure 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In many studies, the benefit of a drug or intervention on an outcome is compared with a control population, permitting the construction of two or more Kaplan-Meier curves. Curves that are close together or cross are unlikely to reflect a statistically significant difference. Several formal statistical tests can be used to assess a significant difference. Examples include the log-rank test and the Breslow test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Cox proportional hazards analysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cox proportional hazards analysis is similar to logistic regression because it can account for many variables that are relevant for predicting a dichotomous outcome. However, unlike logistic regression, Cox proportional hazards analysis permits time to be included as a variable, and for patients to be counted only for the period of time in which they were observed.",
"   </p>",
"   <p>",
"    The term \"hazard ratio\" is sometimes used when referring to variables included in the analysis. A hazard ratio is analogous to an odds ratio. Thus, a hazard ratio of ten means that group of patients exposed to a specific risk factor has ten times the chance of developing the outcome compared with unexposed controls.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     STUDY DESIGNS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Cohort study",
"    </span>",
"    &nbsp;&mdash;&nbsp;A cohort study starts with an exposure and moves forward to the outcome of interest, even if the data are collected retrospectively. As an example, a group of patients who have variable exposure to a risk factor of interest can be followed over time for an outcome.",
"   </p>",
"   <p>",
"    The Nurses' Health Study is an example of a cohort study. A large number of nurses are followed over time for an outcome such as colon cancer, providing an estimate of the risk of colon cancer in this population. In addition, dietary intake of various components can be assessed, and the risk of colon cancer in those with high and low intake of fiber can be evaluated to determine if fiber is a risk factor (or a protective factor) for colon cancer. The relative risk of colon cancer in those with high or low fiber intakes can be calculated from such a cohort study. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Relative risk'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Case-control study",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case-control study starts with the outcome of interest and works backward to the exposure. For instance, patients with a disease are identified and compared with controls for exposure to a risk factor. This design does not permit measurement of the proportion of the population who were exposed to the risk factor and then developed or did not develop the disease; thus, the relative risk or the incidence of disease cannot be calculated. However, in case-control studies, the odds ratio provides a reasonable estimate of the relative risk (",
"    <a class=\"graphic graphic_figure graphicRef71957 \" href=\"UTD.htm?35/38/36462\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Odds ratio'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If one were to perform a case-control study to assess the role of dietary fiber in colon cancer as noted above for the cohort study, a group of patients with colon cancer could be compared with matched controls without colon cancer; the fiber intake in the two groups would then be compared. The case-control study is most useful for uncommon diseases in which a very large cohort would be required to accumulate enough cases for analysis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Randomized controlled trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;A randomized controlled trial (RCT) is an experimental design in which patients are assigned to two or more interventions. One group of patients is often assigned to a placebo (placebo control) but a randomized trial can involve two active therapies (active control).",
"   </p>",
"   <p>",
"    As an example, patients with a prior colonic polyp could be randomly assigned to take a fiber supplement or a placebo supplement to determine with fiber supplementation decreases the risk of developing colon cancer.",
"   </p>",
"   <p>",
"    RCTs are generally the only type of study that can adequately control for unmeasured confounders, and are generally the best evidence for proving causality. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8500?source=see_link&amp;anchor=H6#H6\">",
"     \"Proof, p-values, and hypothesis testing\", section on 'Explanation for the results of a study'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H153401402\">",
"    <span class=\"h3\">",
"     Intention to treat",
"    </span>",
"    &nbsp;&mdash;&nbsp;The central principle underlying intention-to-treat analysis is that study participants should be analyzed according to the groups in which they were randomized, even if they did not receive or comply with treatment. Such analysis is contrasted to &ldquo;as treated&rdquo; (or &ldquo;per protocol&rdquo;) analysis in which subjects are analyzed according to the actual treatment they received.",
"   </p>",
"   <p>",
"    The theoretical advantage of intention-to-treat analysis is that it preserves the benefits of randomization (ie, assuring that all of the unmeasured factors that could differ in the treatment and control groups remain accounted for in the analysis). For example, it is possible that patients who complied with treatment differed in some important ways than those who did not. Another way to consider the advantage of intention-to-treat analysis is that it better accounts for factors that can influence the outcomes of a prescribed treatment, not just the effects on those who adhered to it. A drug which has serious side-effects but is highly effective, for example, might look favorable in an &ldquo;as treated&rdquo; analysis but less favorable in an intention-to-treat analysis if the majority of patients could not tolerate it.",
"   </p>",
"   <p>",
"    Although conceptually simple, analyzing according to intention-to-treat principles can be complex. For example, optimal methods to account for subjects who were lost to follow-up remain uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22823/abstract/13\">",
"     13",
"    </a>",
"    ]. Such patients could be considered as treatment failures, however, such an approach can be overly punitive for an otherwise promising therapy. Because of these complexities, studies that reported that they performed an intention-to-treat analysis, may not have always done so or have modified the approach in some way [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22823/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Mendelian randomization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mendelian randomization refers to a nonexperimental epidemiologic study design that examines the impact of natural genetic variation in the population on the relationship between an environmental exposure and disease. The primary goal is to establish evidence for a causal association between the exposure and disease.",
"   </p>",
"   <p>",
"    In this design, subjects comprising the study population are classified according to their genotype at a specific polymorphic locus known to modify the exposure of interest but not directly influence susceptibility to the disease of interest. Because subjects are typically unaware of their genotype status, and because a subject's genotypes are randomly assigned during meiosis (according to Mendel's law of independent assortment), this exposure modification can be considered a form of natural randomization. This is therefore referred to as \"Mendelian randomization.\" (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11335?source=see_link\">",
"     \"Mendelian randomization\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dawson-Saunders B, Trapp RG. Basic &amp; Clinical Biostatistics, 2nd ed, Appleton &amp; Lange, 1994.",
"    </li>",
"    <li>",
"     Shott S. Statistics for Health Professionals, WB Saunders, Philadelphia 1990.",
"    </li>",
"    <li>",
"     Hulley SB, Cummings SR. Designing Clinical Research, Williams &amp; Wilkins, Baltimore 1988.",
"    </li>",
"    <li>",
"     Henneckens CH, Buring JE. Epidemiology in Medicine, Little Brown, Boston 1987.",
"    </li>",
"    <li>",
"     Fletcher RH, Fletcher RH, Fletcher EH. Clinical Epidemiology: The Essentials, 2nd ed, Williams &amp; Wilkins, Baltimore 1988.",
"    </li>",
"    <li>",
"     Kleinbaum DG. Logistic Regression, A Self-Learning Text, Springer-Verlag, New York 1994.",
"    </li>",
"    <li>",
"     Kleinbaum DG. Survival analysis. A Self-Learning Text, Springer-Verlag, New York 1996.",
"    </li>",
"    <li>",
"     Hopkins WG. A new view of statistics. Internet Society for Sport Science 2000. Available at: www.sportsci.org/resource/stats/index.html (Accessed on March 07, 2005).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22823/abstract/9\">",
"      Moriarty PM. Relative risk reduction versus number needed to treat as measures of lipid-lowering trial results. Am J Cardiol 1998; 82:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22823/abstract/10\">",
"      Lubsen J, Hoes A, Grobbee D. Implications of trial results: the potentially misleading notions of number needed to treat and average duration of life gained. Lancet 2000; 356:1757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22823/abstract/11\">",
"      de Craen AJ, Vickers AJ, Tijssen JG, Kleijnen J. Number-needed-to-treat and placebo-controlled trials. Lancet 1998; 351:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22823/abstract/12\">",
"      Weissler AM. A perspective on standardizing the predictive power of noninvasive cardiovascular tests by likelihood ratio computation: 1. Mathematical principles. Mayo Clin Proc 1999; 74:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22823/abstract/13\">",
"      Porta N, Bonet C, Cobo E. Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol 2007; 60:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22823/abstract/14\">",
"      Gravel J, Opatrny L, Shapiro S. The intention-to-treat approach in randomized controlled trials: are authors saying what they do and doing what they say? Clin Trials 2007; 4:350.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2759 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-194.187.108.93-69C8FD1B77-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22823=[""].join("\n");
var outline_f22_18_22823=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STATISTICS THAT DESCRIBE HOW DATA ARE DISTRIBUTED",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Measures of central tendency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Measures of dispersion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      TERMS USED TO DESCRIBE THE FREQUENCY OF AN EVENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Person-years",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TERMS USED TO DESCRIBE THE MAGNITUDE OF AN EFFECT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Relative risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Odds ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Absolute risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Number needed to treat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      TERMS USED TO DESCRIBE THE QUALITY OF MEASUREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Reliability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Validity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      MEASURES OF DIAGNOSTIC TEST PERFORMANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Sensitivity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Specificity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Predictive values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Likelihood ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Accuracy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      EXPRESSIONS USED WHEN MAKING INFERENCES ABOUT DATA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Confidence interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Credible interval",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Errors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Power",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TERMS USED IN MULTIVARIATE ANALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      TIME-TO-EVENT ANALYSIS (SURVIVAL ANALYSIS)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Kaplan-Meier analysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Cox proportional hazards analysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      STUDY DESIGNS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Cohort study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Case-control study",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Randomized controlled trial",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H153401402\">",
"      - Intention to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Mendelian randomization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/2759\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2759|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/32/41484\" title=\"figure 1\">",
"      Box and whiskers plot",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?35/38/36462\" title=\"figure 2\">",
"      Relative risk and odds ratio",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/44/34508\" title=\"figure 3\">",
"      Number needed to treat",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/36/39501\" title=\"figure 4\">",
"      Interdependence sens spec",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/52/30541\" title=\"figure 5\">",
"      ROC curve",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/36/24142\" title=\"figure 6\">",
"      Prevalence on PPV and NPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/25/20893\" title=\"figure 7\">",
"      Kaplan meier curves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/2759|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?7/50/7979\" title=\"table 1\">",
"      Sensitivity specificity PPV NPV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/18/299\" title=\"table 2\">",
"      Definition of accuracy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?35/55/36722?source=related_link\" title=\"calculator 1\">",
"      Calculator: Post Test Probability from Pre Test Probability, Sensitivity and Specificity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?10/3/10291?source=related_link\" title=\"calculator 2\">",
"      Calculator: Post-test probability from likelihood ratios and multiple test results",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/52/10054?source=related_link\">",
"      Evaluating diagnostic tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11335?source=related_link\">",
"      Mendelian randomization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/19/8500?source=related_link\">",
"      Proof, p-values, and hypothesis testing",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_18_22824="Biology and normal function of factor VIII and factor IX";
var content_f22_18_22824=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Biology and normal function of factor VIII and factor IX",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22824/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22824/contributors\">",
"     W Keith Hoots, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22824/contributors\">",
"     Amy D Shapiro, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22824/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22824/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22824/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22824/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/18/22824/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 22, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemostasis is the process of blood clot formation at the site of vessel injury. This process begins with the formation of the platelet plug, followed by activation of the clotting cascade and propagation of the clot. The central feature of the clotting cascade is its sequential activation of a series of proenzymes or inactive precursor proteins (zymogens) to active enzymes, resulting in significant stepwise response amplification, (eg, the generation of a small number of factor VIIa molecules will activate many molecules of factor X, which in turn generates even larger numbers of thrombin molecules). The local generation of fibrin meshes and reinforces the platelet plug (",
"    <a class=\"graphic graphic_figure graphicRef69920 \" href=\"UTD.htm?31/51/32574\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    One of the major multicomponent complexes in the coagulation cascade is the intrinsic X-ase (ten-ase). This complex consists of activated factor IX (factor IXa) as the protease, activated factor VIII (factor VIIIa), calcium, and phospholipids as the cofactors, and factor X as the substrate. Factor IXa can be generated by either factor XIa, activation of the intrinsic pathway, or by the tissue",
"    <span class=\"nowrap\">",
"     factor/factor",
"    </span>",
"    VIIa complex. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H14#H14\">",
"     \"Overview of hemostasis\", section on 'Multicomponent complexes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the generation or exposure of tissue factor at the wound site is the primary physiologic event in initiating clotting via the extrinsic pathway, the intrinsic pathway X-ase is important because of the limited amount of tissue factor generated in vivo and the presence of the tissue factor pathway inhibitor which, when complexed with factor Xa, inhibits the tissue",
"    <span class=\"nowrap\">",
"     factor/factor",
"    </span>",
"    VIIa complex. Thus, sustained generation of thrombin depends upon the activation of factor IX and factor VIII. This process is amplified because factor VIII is activated by both factor Xa and thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] and factor IX is activated by factor XIa via thrombin, as well as by factor VIIa; as a result, a progressive increase in factor VIII and factor IX activation occurs as factor Xa and thrombin are formed.",
"   </p>",
"   <p>",
"    The biology of factor VIII and factor IX is reviewed here. Deficiencies in either of these coagulation factors lead to hemophilia (hemophilia A and hemophilia B, respectively), which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hemophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FACTOR VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factor VIII gene is located on the X chromosome. It is one of the largest known genes, divided into 26 exons that span 186,000 base pairs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Factor VIII is synthesized as a single chain polypeptide of 2351 amino acids. A 19-amino acid signal peptide is cleaved by a protease shortly after synthesis so that circulating plasma factor VIII is a heterodimer.",
"   </p>",
"   <p>",
"    Factor VIII circulates in plasma in a noncovalent complex with von Willebrand factor. Cleavage of plasma factor VIII by thrombin or factor Xa at Arg372 and Arg1689 is necessary to activate factor VIII and allow it to participate in the intrinsic pathway X-ase [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Activated factor VIII is inactivated by activated protein C in conjunction with protein S; the site of proteolytic inactivation is Arg336 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Structure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor VIII consists of a heavy chain with A1 and A2 domains; a connecting region with a B domain; and a light chain with A3, C1, and C2 domains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. The functions of factor VIII reflect binding at specific sites within the molecule:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     C2 domain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The C2 domain binds to the procoagulant phospholipid phosphatidylserine on activated platelets and endothelial cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/9,10\">",
"     9,10",
"    </a>",
"    ] and to von Willebrand factor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. An overlap exists in the epitope for both binding functions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. A different site in the C2 domain appears to contain the binding site for factor Xa. In vitro, an antibody directed against this binding site prevents factor VIII activation by factor Xa [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/12\">",
"     12",
"    </a>",
"    ]. A thrombin binding site also is present in the C2 domain that is responsible for factor VIII cleavage at Arg1689 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of the C2 domain is illustrated by observations in nonhemophilic patients with a bleeding tendency caused by acquired autoantibodies against factor VIII. In some of these patients, the antibodies are directed against the C2 domain and prevent interaction with phosphatidylserine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link\">",
"     \"Acquired inhibitors of coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     A2 domain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The A2 domain is a site of factor IXa binding, the active enzyme in the X-ase pathway [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/14-18\">",
"     14-18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     A1/A3-C1-C2 dimer",
"    </span>",
"    &nbsp;&mdash;&nbsp;The",
"    <span class=\"nowrap\">",
"     A1/A3-C1-C2",
"    </span>",
"    dimer also contributes to factor IXa binding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/17,18\">",
"     17,18",
"    </a>",
"    ], a part of which occurs within the A3 domain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/14,18\">",
"     14,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     B domain",
"    </span>",
"    &nbsp;&mdash;&nbsp;The heavily glycosylated B-domain displays no significant homology to any known protein. It serves as a connecting region that separates the second and the third A domains but is not required for clotting activity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/19\">",
"     19",
"    </a>",
"    ]. It may function during protein folding, subunit assembly, and secretion of Factor VIII [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antibodies directed against these domains, occurring in patients with hemophilia or as an acquired disorder in patients without hemophilia, can lead to bleeding episodes or, in patients with severe hemophilia, bleeding that is more difficult to control. In some cases of acquired disease, for example, the antibodies are directed against the C2 domain and prevent interaction with phosphatidylserine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=see_link\">",
"     \"Factor VIII and factor IX inhibitors in patients with hemophilia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=see_link\">",
"     \"Acquired inhibitors of coagulation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Binding to von Willebrand factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor VIII circulates in plasma in a noncovalent complex with von Willebrand factor (VWF). The interaction between factor VIII and VWF has two main effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Binding to VWF protects factor VIII from proteolytic inactivation by activated protein C and its cofactor, protein S [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/21-23\">",
"       21-23",
"      </a>",
"      ]. VWF slows the inactivation of factor VIII 10- to 20-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/22,23\">",
"       22,23",
"      </a>",
"      ], which prolongs its half-life in the circulation fivefold [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Binding to VWF serves to concentrate factor VIII at sites of vascular injury and active hemostasis through the attachment of VWF to subendothelial matrix proteins and adherent platelets. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=see_link\">",
"       \"Biology and normal function of von Willebrand factor\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The C2 domain of factor VIII [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/10,11\">",
"     10,11",
"    </a>",
"    ] binds to the D1 and adjacent D3 domains of VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/22\">",
"     22",
"    </a>",
"    ]. VWF can bind factor VIII only when factor VIII has not been cleaved by thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/24\">",
"     24",
"    </a>",
"    ]. After thrombin cleavage, activated factor VIII (factor VIIIa) is released from VWF and becomes a fully functional, active cofactor in the ongoing generation of thrombin; however, it is also now more susceptible to inactivation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical importance of VWF binding can be illustrated by the findings in type 2N vWD and in some factor VIII mutations leading to decreased binding to VWF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 2N vWD, transmitted as an autosomal recessive trait, is characterized by mutations in VWF within the factor VIII binding domain [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/25,26\">",
"       25,26",
"      </a>",
"      ]. Affected patients present with low levels of factor VIII (usually 5 to 15 percent of normal), because of unimpeded proteolytic cleavage of factor VIII, along with a clinical pattern of bleeding similar to that seen in hemophilia A, rather than that associated with classical vWD (",
"      <a class=\"graphic graphic_table graphicRef77834 \" href=\"UTD.htm?2/43/2748\">",
"       table 1",
"      </a>",
"      ). Type 2N vWD, rather than hemophilia A, should be suspected in females who present with isolated factor VIII deficiency (with normal levels of VWF) and in families in which an autosomal (rather than X-linked) inheritance pattern for factor VIII deficiency is suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/25\">",
"       25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=see_link&amp;anchor=H11#H11\">",
"       \"Classification and pathophysiology of von Willebrand disease\", section on 'Type 2N'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some patients with mutations in the C1 domain of the factor VIII molecule were found to have normal factor VIII specific activity (the ratio between factor VIII coagulant activity and factor VIII antigen) but reduced binding to VWF, resulting in mild to moderate hemophilia A [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Formation of factor VIIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;On exposure to thrombin or factor Xa, a nonessential cleavage at Arg740 transiently converts the heavy chain into 92 kd fragments. Concurrently, cleavage at Arg372 converts the heavy chain into 54 kd and 44 kd fragments. At the same time, a small fragment is cleaved from the light chain to separate factor VIII from VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/24\">",
"     24",
"    </a>",
"    ]. These cleavages produce the activated factor VIII heterotrimer factor VIIIa, which is composed of the 54 kd and 44 kd heavy chain fragments and the 72 kd light chain fragment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Intrinsic pathway X-ase",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physiologic role of factor VIII is to accelerate the cleavage of factor X by factor IXa; the binding sites for factor IXa are in the A2 and A3 domains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/14-18\">",
"     14-18",
"    </a>",
"    ]. As noted above, the intrinsic X-ase complex consists of factor IX; the protease; factor X; the substrate; and the cofactors, factor VIIIa, calcium, and phospholipids [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/2,28\">",
"     2,28",
"    </a>",
"    ]. It has been proposed that factor VIIIa has a stabilizing action that forces the catalytic modules factor IXa and factor X together, markedly accelerating the velocity of the X-ase complex [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, the enzyme and the substrate are concentrated on a phospholipid surface of activated platelets or endothelial cells, decreasing the Km by several orders of magnitude.",
"   </p>",
"   <p>",
"    Factor VIII cannot become part of the X-ase complex until it is released from VWF, because interaction with VWF inhibits its binding to phospholipid surfaces. The separation from VWF requires the cleavage of the factor VIII light chain by thrombin or factor Xa.",
"   </p>",
"   <p>",
"    Although the generation or exposure of tissue factor at the wound site is the primary physiologic event in initiating clotting via the extrinsic pathway, the intrinsic pathway X-ase also is required for normal hemostasis, as illustrated by the bleeding disorders associated with hemophilia A and B. The importance of the intrinsic pathway reflects the limited amount of tissue factor generated in vivo and the presence of tissue factor pathway inhibitor which, when complexed with factor Xa, inhibits the tissue",
"    <span class=\"nowrap\">",
"     factor/factor",
"    </span>",
"    VIIa complex [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/30\">",
"     30",
"    </a>",
"    ]. Thus, sustained generation of thrombin depends upon the activation of both factor IX and factor VIII. This process is amplified because factor VIII is activated by both factor Xa and thrombin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/1,2\">",
"     1,2",
"    </a>",
"    ] and factor IX is activated by thrombin-induced activation of factor XI [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]; as a result, there is a progressive increase in activation of factors VIII and IX as factor Xa and thrombin are formed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/30\">",
"     30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link\">",
"     \"Overview of hemostasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inactivation of factor VIIIa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor VIIIa is an unstable molecule that rapidly loses its cofactor function, in part because it is no longer bound to VWF [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The inactivation of factor VIIIa occurs by subunit dissociation in a process that is initiated by the formation of thrombin. The binding of thrombin to thrombomodulin induces a conformational change in thrombin such that it acquires the ability to activate protein C and no longer promotes platelet activation or the cleavage of fibrinogen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H20#H20\">",
"     \"Overview of hemostasis\", section on 'Activated protein C and protein S'",
"    </a>",
"    .) Activated protein C (APC) proteolytically inactivates factors VIIIa and Va, thereby inactivating the intrinsic X-ase and prothrombinase, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. Factor VIIIa is first cleaved at Arg336 within the A1 subunit and then Arg562, bisecting the A2 subunit [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of APC-mediated inactivation of factor VIIIa is increased several fold by protein S, in concert with APC-inactivated factor V [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/36\">",
"     36",
"    </a>",
"    ], which facilitates cleavage of the A2 subunit; this latter effect is impaired by factor IXa [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/35\">",
"     35",
"    </a>",
"    ]. APC has only a limited effect on non-activated factor VIII, which is protected from catabolism by binding to von Willebrand factor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. Both the A2 and B domains interact with a hepatic receptor low-density lipoprotein receptor-related protein, enabling these fragments to be removed from the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/37-39\">",
"     37-39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4804261\">",
"    <span class=\"h2\">",
"     Elevated levels of factor VIII",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elevated plasma factor VIII coagulant activity is now accepted as an independent marker of increased thrombotic risk. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of the causes of venous thrombosis\", section on 'Factor VIII'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     FACTOR IX",
"    </span>",
"    &nbsp;&mdash;&nbsp;The factor IX gene is located near the terminus of the long arm of the X chromosome. The gene codes for a signal peptide, a propeptide (promoter region), and the mature 415 amino acid protein that circulates in the plasma. Vitamin K-dependent gamma-carboxylation of specific glutamic acid residues occurs as a posttranslational process in the endoplasmic reticulum of the hepatocyte. The propeptide participates in defining a recognition site that designates an adjacent glutamic acid-rich domain for gamma-carboxylation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/40\">",
"     40",
"    </a>",
"    ]. The amino acids of this recognition site bind directly to the vitamin K-dependent carboxylase [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/41\">",
"     41",
"    </a>",
"    ]; disruption of this site leads to deficient or absent gamma-carboxylation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/40\">",
"     40",
"    </a>",
"    ]. The processing steps, through which the signal peptide and the propeptide are removed, occur in the Golgi apparatus prior to secretion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Structure and function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor IX is a two-chain, disulfide-linked molecule, composed of a light chain (MW 18,000) and a heavy chain (MW 28,000). The N-terminal light chain consists of a gamma-carboxyglutamic acid domain containing 12 gamma-carboxyglutamic acid (Gla) residues dependent upon the vitamin K carboxylase system, followed by a short hydrophobic stack domain that is not required for activation, two epidermal growth factor (EGF)-like domains, and the activation peptide and its flanking sequences [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/29,42-44\">",
"     29,42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Gla confers calcium-binding properties on the vitamin K-dependent proteins. The addition of calcium causes factor IX to undergo a structural transition that leads to exposure of a phospholipid binding site [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. The calcium-stabilized form of factor IX binds to membranes, whereas the magnesium-stabilized form does not [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The EGF-like domains share homology with protein C and factor X, and they may function as binding sites for platelet flanking sequences. A calcium-binding region in the EGF-like domains appears to mediate protein-protein interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The first EGF-like domain is required for activation by tissue",
"    <span class=\"nowrap\">",
"     factor/factor",
"    </span>",
"    VIIa but is not essential for activation by factor XIa or for phospholipid binding [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/49\">",
"     49",
"    </a>",
"    ]. The second EGF-like domain is required for the formation of the intrinsic pathway X-ase on the surface of activated platelets [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/50\">",
"     50",
"    </a>",
"    ]. However, the residues responsible for binding to activated platelets are different from those that mediate formation of the X-ase [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The physiologic importance of the EGF-like domains in factor IX function is illustrated by the following observations in humans:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deletion of the first EGF-like domain leads to severe hemophilia B [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Mutations in the second EGF-like domain also are associated with hemophilia B; one such mutation is associated with a 50-fold reduction in activation by factor XIa (compared to wild-type factor IX), a 20-fold reduction in activation by the tissue",
"      <span class=\"nowrap\">",
"       factor/factor",
"      </span>",
"      VIIa complex, and a 14-fold reduction in activation of factor X [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The N-terminal also contains the site for binding of factor IX to the endothelium [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/54\">",
"     54",
"    </a>",
"    ]. The endothelial binding site may be collagen IV.",
"   </p>",
"   <p>",
"    The C-terminal heavy chain comprises the catalytic domain of factor IXa. This domain possesses a trypsin-like serine protease fold consisting of two interconnected domains with the catalytic residues His221, Asp269, and Ser365 found at the interface of the two domains [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, numerous surface loops exist, connecting the secondary structure elements.",
"   </p>",
"   <p>",
"    The serine protease recognizes specific cleavage sites within factor X and is also a target of protease inhibitors, which play an important role in the inactivation of the enzyme. The variable surface loops bordering the substrate binding groove contribute to the specific interaction with both inhibitors and substrates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. Factor VIIIa has a stabilizing action that forces the catalytic modules factor IXa and factor X together, markedly accelerating the velocity of the X-ase complex [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/29\">",
"     29",
"    </a>",
"    ]&nbsp;(see",
"    <a class=\"local\" href=\"#H10\">",
"     'Intrinsic pathway X-ase'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Activation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor IX, like factor VIII, is a zymogen that must be activated to factor IXa in order to participate in coagulation. Activation occurs in two ways:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      By the tissue",
"      <span class=\"nowrap\">",
"       factor/factor",
"      </span>",
"      VIIa complex of the extrinsic pathway X-ase [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/58-60\">",
"       58-60",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      By factor XIa [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/33,61\">",
"       33,61",
"      </a>",
"      ], which is formed during activation of the intrinsic coagulation pathway (",
"      <a class=\"graphic graphic_figure graphicRef69920 \" href=\"UTD.htm?31/51/32574\">",
"       figure 1",
"      </a>",
"      ), or by thrombin [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Factor IX is activated by cleavage of peptide bonds Arg145-Ala146 and Arg180-Val 181, resulting in cleavage of the activation peptide [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/62\">",
"     62",
"    </a>",
"    ]. As noted above, factor IXa is the active protease in the intrinsic pathway X-ase, with factor VIIIa, calcium, and phospholipids as cofactors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/2,28\">",
"     2,28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Inactivation of factor IXa",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factor IXa is inactivated slowly by antithrombin III, a serpin that forms a stable equimolar complex at the Asp359 substrate binding pocket [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/63\">",
"     63",
"    </a>",
"    ]. AT III also neutralizes thrombin and factors Xa, XIa, and XIIa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Gain of function mutation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A case of juvenile thrombophilia associated with a gain-of-function mutation in the gene for factor IX has been described (factor IX-R338L, factor IX Padua) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/64\">",
"     64",
"    </a>",
"    ]. The plasma level of the mutant factor IX was normal, but the clotting activity was approximately 8 times normal. Recombinant factor IX-R338L had an in vitro specific activity that was 5 to 10 times as high as that of recombinant wild-type factor IX.",
"   </p>",
"   <p>",
"    A recombinant factor IX variant has been produced (FIX-Triple) which exhibits significantly enhanced activity both in vitro and in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22824/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8177631\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors VIII and IX are major components in the generation of the intrinsic pathway X-ase (ten-ase) complex, which, in activated forms (ie, factors VIIIa and IXa) in conjunction with calcium and phospholipids, convert factor X to activated factor X (ie, factor Xa). Factors VIIIa and IXa are responsible for amplification of the coagulation cascade after initial thrombin generation through the extrinsic pathway (",
"    <a class=\"graphic graphic_figure graphicRef69920 \" href=\"UTD.htm?31/51/32574\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Intrinsic pathway X-ase'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of hemostasis\", section on 'Clotting cascade and propagation of the clot'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Factor VIII",
"      </strong>",
"      ��� The factor VIII gene is located on the X chromosome. It is one of the largest known genes, divided into 26 exons that span 186,000 base pairs. Mutations of the factor VIII gene are responsible for the sex-linked bleeding disorder hemophilia A. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Factor viii'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33878?source=see_link&amp;anchor=H3#H3\">",
"       \"Genetics of the hemophilias\", section on 'Factor VIII gene'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Factor VIII circulates in plasma in a noncovalent complex with von Willebrand factor. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Binding to von Willebrand factor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cleavage of plasma factor VIII by thrombin or factor Xa is necessary to activate factor VIII and allow it to participate in the intrinsic pathway X-ase complex. Activated factor VIII is inactivated by activated protein C in conjunction with protein S.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Factor IX",
"      </strong>",
"      ��� The factor IX gene is also located on the X chromosome. Mutations of this gene are responsible for the sex-linked bleeding disorder hemophilia B. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Factor ix'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33878?source=see_link&amp;anchor=H6#H6\">",
"       \"Genetics of the hemophilias\", section on 'Factor IX gene'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Factor IX contains 12 gamma-carboxyglutamic acid (Gla) residues dependent upon the vitamin K carboxylase system. Gla confers calcium-binding properties on the vitamin K-dependent proteins, which allows factor IX to bind to phospholipids. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/32/20999?source=see_link&amp;anchor=H2#H2\">",
"       \"Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins\", section on 'Function of gamma-carboxyglutamic acid'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Factor IX must be activated to factor IXa to participate in coagulation. Activation occurs via the tissue",
"      <span class=\"nowrap\">",
"       factor/factor",
"      </span>",
"      VIIa complex of the extrinsic X-ase pathway as well as by factor XIa. Factor IXa is inactivated slowly by antithrombin.",
"     </li>",
"     <li>",
"      A case of juvenile thrombophilia associated with a gain-of-function mutation in the gene for factor IX has been described. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Gain of function mutation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/1\">",
"      Pittman DD, Kaufman RJ. Proteolytic requirements for thrombin activation of anti-hemophilic factor (factor VIII). Proc Natl Acad Sci U S A 1988; 85:2429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/2\">",
"      Butenas S, van 't Veer C, Mann KG. Evaluation of the initiation phase of blood coagulation using ultrasensitive assays for serine proteases. J Biol Chem 1997; 272:21527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/3\">",
"      Gitschier J, Wood WI, Goralka TM, et al. Characterization of the human factor VIII gene. Nature 1984; 312:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/4\">",
"      Toole JJ, Knopf JL, Wozney JM, et al. Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 1984; 312:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/5\">",
"      Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83:1978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/6\">",
"      Scandella D, Gilbert GE, Shima M, et al. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood 1995; 86:1811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/7\">",
"      Saenko EL, Ananyeva NM, Tuddenham EG, Kemball-Cook G. Factor VIII - novel insights into form and function. Br J Haematol 2002; 119:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/8\">",
"      Shen BW, Spiegel PC, Chang CH, et al. The tertiary structure and domain organization of coagulation factor VIII. Blood 2008; 111:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/9\">",
"      Healey JF, Barrow RT, Tamim HM, et al. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII. Blood 1998; 92:3701.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/10\">",
"      Pratt KP, Shen BW, Takeshima K, et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/11\">",
"      Saenko EL, Shima M, Rajalakshmi KJ, Scandella D. A role for the C2 domain of factor VIII in binding to von Willebrand factor. J Biol Chem 1994; 269:11601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/12\">",
"      Nogami K, Shima M, Hosokawa K, et al. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999; 274:31000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/13\">",
"      Nogami K, Shima M, Hosokawa K, et al. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 2000; 275:25774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/14\">",
"      Zhong D, Saenko EL, Shima M, et al. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/15\">",
"      Amano K, Sarkar R, Pemberton S, et al. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII. Blood 1998; 91:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/16\">",
"      Fay PJ, Beattie T, Huggins CF, Regan LM. Factor VIIIa A2 subunit residues 558-565 represent a factor IXa interactive site. J Biol Chem 1994; 269:20522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/17\">",
"      O'Brien LM, Medved LV, Fay PJ. Localization of factor IXa and factor VIIIa interactive sites. J Biol Chem 1995; 270:27087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/18\">",
"      Lamphear BJ, Fay PJ. Factor IXa enhances reconstitution of factor VIIIa from isolated A2 subunit and A1/A3-C1-C2 dimer. J Biol Chem 1992; 267:3725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/19\">",
"      Berntorp E. Second generation, B-domain deleted recombinant factor VIII. Thromb Haemost 1997; 78:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/20\">",
"      Kaufman RJ, Pipe SW, Tagliavacca L, et al. Biosynthesis, assembly and secretion of coagulation factor VIII. Blood Coagul Fibrinolysis 1997; 8 Suppl 2:S3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/21\">",
"      Brinkhous KM, Sandberg H, Garris JB, et al. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci U S A 1985; 82:8752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/22\">",
"      Koppelman SJ, van Hoeij M, Vink T, et al. Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 1996; 87:2292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/23\">",
"      Koedam JA, Meijers JC, Sixma JJ, Bouma BN. Inactivation of human factor VIII by activated protein C. Cofactor activity of protein S and protective effect of von Willebrand factor. J Clin Invest 1988; 82:1236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/24\">",
"      Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263:10451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/25\">",
"      Tuley EA, Gaucher C, Jorieux S, et al. Expression of von Willebrand factor \"Normandy\": an autosomal mutation that mimics hemophilia A. Proc Natl Acad Sci U S A 1991; 88:6377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/26\">",
"      Meyer D, Fressinaud E, Gaucher C, et al. Gene defects in 150 unrelated French cases with type 2 von Willebrand disease: from the patient to the gene. INSERM Network on Molecular Abnormalities in von Willebrand Disease. Thromb Haemost 1997; 78:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/27\">",
"      Jacquemin M, Lavend'homme R, Benhida A, et al. A novel cause of mild/moderate hemophilia A: mutations scattered in the factor VIII C1 domain reduce factor VIII binding to von Willebrand factor. Blood 2000; 96:958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/28\">",
"      Jesty J, Spencer AK, Nemerson Y. The mechanism of activation of factor X. Kinetic control of alternative pathways leading to the formation of activated factor X. J Biol Chem 1974; 249:5614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/29\">",
"      Brandstetter H, Bauer M, Huber R, et al. X-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia B. Proc Natl Acad Sci U S A 1995; 92:9796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/30\">",
"      Broze GJ Jr. Tissue factor pathway inhibitor and the revised theory of coagulation. Annu Rev Med 1995; 46:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/31\">",
"      Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266:7353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/32\">",
"      von dem Borne PA, Meijers JC, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86:3035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/33\">",
"      Sun Y, Gailani D. Identification of a factor IX binding site on the third apple domain of activated factor XI. J Biol Chem 1996; 271:29023.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/34\">",
"      Fulcher CA, Gardiner JE, Griffin JH, Zimmerman TS. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V. Blood 1984; 63:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/35\">",
"      O'Brien LM, Mastri M, Fay PJ. Regulation of factor VIIIa by human activated protein C and protein S: inactivation of cofactor in the intrinsic factor Xase. Blood 2000; 95:1714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/36\">",
"      Dahlb&auml;ck B. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation. Semin Thromb Hemost 1999; 25:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/37\">",
"      Bovenschen N, Rijken DC, Havekes LM, et al. The B domain of coagulation factor VIII interacts with the asialoglycoprotein receptor. J Thromb Haemost 2005; 3:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/38\">",
"      Sarafanov AG, Makogonenko EM, Pechik IV, et al. Identification of coagulation factor VIII A2 domain residues forming the binding epitope for low-density lipoprotein receptor-related protein. Biochemistry 2006; 45:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/39\">",
"      Lacroix-Desmazes S, Navarrete AM, Andr&eacute; S, et al. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 2008; 112:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/40\">",
"      Jorgensen MJ, Cantor AB, Furie BC, et al. Recognition site directing vitamin K-dependent gamma-carboxylation resides on the propeptide of factor IX. Cell 1987; 48:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/41\">",
"      Hubbard BR, Ulrich MM, Jacobs M, et al. Vitamin K-dependent carboxylase: affinity purification from bovine liver by using a synthetic propeptide containing the gamma-carboxylation recognition site. Proc Natl Acad Sci U S A 1989; 86:6893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/42\">",
"      Furie B, Furie BC. The molecular basis of blood coagulation. Cell 1988; 53:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/43\">",
"      Hughes PE, Handford PA, Austen DE, Brownlee GG. Protein engineering of the hydrophobic domain of human factor IX. Protein Eng 1994; 7:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/44\">",
"      Stenflo J. Structure-function relationships of epidermal growth factor modules in vitamin K-dependent clotting factors. Blood 1991; 78:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/45\">",
"      Freedman SJ, Furie BC, Furie B, Baleja JD. Structure of the calcium ion-bound gamma-carboxyglutamic acid-rich domain of factor IX. Biochemistry 1995; 34:12126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/46\">",
"      Li L, Darden TA, Freedman SJ, et al. Refinement of the NMR solution structure of the gamma-carboxyglutamic acid domain of coagulation factor IX using molecular dynamics simulation with initial Ca2+ positions determined by a genetic algorithm. Biochemistry 1997; 36:2132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/47\">",
"      Freedman SJ, Blostein MD, Baleja JD, et al. Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX. J Biol Chem 1996; 271:16227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/48\">",
"      Rao Z, Handford P, Mayhew M, et al. The structure of a Ca(2+)-binding epidermal growth factor-like domain: its role in protein-protein interactions. Cell 1995; 82:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/49\">",
"      Zhong D, Smith KJ, Birktoft JJ, Bajaj SP. First epidermal growth factor-like domain of human blood coagulation factor IX is required for its activation by factor VIIa/tissue factor but not by factor XIa. Proc Natl Acad Sci U S A 1994; 91:3574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/50\">",
"      Wong MY, Gurr JA, Walsh PN. The second epidermal growth factor-like domain of human factor IXa mediates factor IXa binding to platelets and assembly of the factor X activating complex. Biochemistry 1999; 38:8948.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/51\">",
"      Ahmad SS, Wong MY, Rawala R, et al. Coagulation factor IX residues G4-Q11 mediate its interaction with a shared factor IX/IXa binding site on activated platelets but not the assembly of the functional factor X activating complex. Biochemistry 1998; 37:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/52\">",
"      Vidaud M, Chabret C, Gazengel C, et al. A de novo intragenic deletion of the potential EGF domain of the factor IX gene in a family with severe hemophilia B. Blood 1986; 68:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/53\">",
"      Hertzberg MS, Facey SL, Hogg PJ. An Arg/Ser substitution in the second epidermal growth factor-like module of factor IX introduces an O-linked carbohydrate and markedly impairs activation by factor XIa and factor VIIa/Tissue factor and catalytic efficiency of factor IXa. Blood 1999; 94:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/54\">",
"      Cheung WF, van den Born J, K&uuml;hn K, et al. Identification of the endothelial cell binding site for factor IX. Proc Natl Acad Sci U S A 1996; 93:11068.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/55\">",
"      Bode W, Brandstetter H, Mather T, Stubbs MT. Comparative analysis of haemostatic proteinases: structural aspects of thrombin, factor Xa, factor IXa and protein C. Thromb Haemost 1997; 78:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/56\">",
"      Perona JJ, Craik CS. Evolutionary divergence of substrate specificity within the chymotrypsin-like serine protease fold. J Biol Chem 1997; 272:29987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/57\">",
"      Kolkman JA, Christophe OD, Lenting PJ, Mertens K. Surface loop 199-204 in blood coagulation factor IX is a cofactor-dependent site involved in macromolecular substrate interaction. J Biol Chem 1999; 274:29087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/58\">",
"      Osterud B, Rapaport SI. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation. Proc Natl Acad Sci U S A 1977; 74:5260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/59\">",
"      Morrison SA, Jesty J. Tissue factor-dependent activation of tritium-labeled factor IX and factor X in human plasma. Blood 1984; 63:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/60\">",
"      Davie EW, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance, and regulation. Biochemistry 1991; 30:10363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/61\">",
"      Di Scipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61:1528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/62\">",
"      Mann KG, Nesheim ME, Church WR, et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/63\">",
"      Perry DJ. Antithrombin and its inherited deficiencies. Blood Rev 1994; 8:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/64\">",
"      Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009; 361:1671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22824/abstract/65\">",
"      Lin CN, Kao CY, Miao CH, et al. Generation of a novel factor IX with augmented clotting activities in vitro and in vivo. J Thromb Haemost 2010; 8:1773.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1316 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-89.32.226.102-CCFD8525CC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22824=[""].join("\n");
var outline_f22_18_22824=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8177631\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FACTOR VIII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Structure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - C2 domain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - A2 domain",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - A1/A3-C1-C2 dimer",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - B domain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Binding to von Willebrand factor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Formation of factor VIIIa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Intrinsic pathway X-ase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inactivation of factor VIIIa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4804261\">",
"      Elevated levels of factor VIII",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      FACTOR IX",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Structure and function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Activation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Inactivation of factor IXa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Gain of function mutation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8177631\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1316\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1316|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/51/32574\" title=\"figure 1\">",
"      Coagulation cascade",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1316|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/43/2748\" title=\"table 1\">",
"      Features of bleeding disorders",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/4/24650?source=related_link\">",
"      Acquired inhibitors of coagulation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/41/17049?source=related_link\">",
"      Biology and normal function of von Willebrand factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/8/44169?source=related_link\">",
"      Classification and pathophysiology of von Willebrand disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/18/1322?source=related_link\">",
"      Clinical manifestations and diagnosis of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/56/36746?source=related_link\">",
"      Factor VIII and factor IX inhibitors in patients with hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/5/33878?source=related_link\">",
"      Genetics of the hemophilias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/35/27194?source=related_link\">",
"      Overview of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/48/43786?source=related_link\">",
"      Overview of the causes of venous thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/32/20999?source=related_link\">",
"      Vitamin K, gamma carboxyglutamic acid, and the function of coagulation and other proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_18_22825="Treatment of locally advanced, recurrent, or metastatic endometrial cancer";
var content_f22_18_22825=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of locally advanced, recurrent, or metastatic endometrial cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22825/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22825/contributors\">",
"     Susana M Campos, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22825/contributors\">",
"     David Scott Miller, MD, FACOG, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22825/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22825/contributors\">",
"     Barbara Goff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22825/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22825/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22825/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/18/22825/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with advanced, recurrent, or metastatic endometrial cancer are not curable. The goal of treatment is palliative, and the approach must take into account prior therapy received.",
"   </p>",
"   <p>",
"    This topic will review the approach and treatment options for women with advanced, recurrent, or metastatic endometrial cancer. The initial treatment of low-risk, intermediate-risk, and high-risk endometrial cancers are covered separately. In addition, chemotherapy protocols used in the treatment of endometrial cancer is available separately.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link\">",
"       \"Approach to adjuvant treatment of endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=see_link\">",
"       \"Treatment of low-risk endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=see_link\">",
"       \"Adjuvant treatment of intermediate-risk endometrial cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=see_link\">",
"       \"Adjuvant treatment of high-risk endometrial cancers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31043?source=see_link\">",
"       \"Treatment protocols for gynecologic malignancies\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35229224\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who present with advanced disease (ie, extensive pelvic or intra-abdominal tumor involvement), a locoregional relapse, or metastatic disease are not curable. Our approach to treatment varies by the clinical scenario:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with advanced endometrial cancer, we suggest surgical cytoreduction. However, if women are not candidates for surgery, we recommend medical treatment. (See",
"      <a class=\"local\" href=\"#H2110943464\">",
"       'Advanced Disease'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H5234213\">",
"       'Medical treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For women with recurrent disease, we suggest local treatment (ie, surgery or radiation therapy [RT]). For women who are not candidates for local therapy, we recommend medical treatment. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Recurrent disease'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H5234213\">",
"       'Medical treatment'",
"      </a>",
"      below.) &nbsp;",
"     </li>",
"     <li>",
"      For women with metastatic disease, we recommend medical treatment. Treatment options include combination chemotherapy, endocrine therapy, or single-agent chemotherapy. Treatment is based on several factors, including tumor grade, whether or not the tumor expresses hormone receptors, the clinical status of the patient, and if therapy was previously administered (in the adjuvant setting). (See",
"      <a class=\"local\" href=\"#H297984019\">",
"       'Metastatic disease'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110943464\">",
"    <span class=\"h1\">",
"     ADVANCED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women who present with extensive pelvic involvement or intra-abdominal disease have advanced endometrial cancer. The approach to treatment is similar to the one used for women with metastatic disease. (See",
"    <a class=\"local\" href=\"#H297984019\">",
"     'Metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RECURRENT DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with recurrent endometrial cancer, characterization of the relapse is an important determinant in the selection of appropriate treatment. Two patterns of relapse are seen, isolated vaginal and regional recurrences. These are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110942881\">",
"    <span class=\"h2\">",
"     Isolated vaginal recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of an isolated vaginal recurrence varies by whether or not adjuvant radiation therapy (RT) was administered. This was demonstrated in the Postoperative Radiation Therapy after Endometrial Cancer (PORTEC) trial of no further treatment versus adjuvant RT in women with newly diagnosed endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/1\">",
"     1",
"    </a>",
"    ]. Women treated with adjuvant RT had a lower incidence of a vaginal recurrence compared to those who were not treated with adjuvant RT (2 versus 8 percent, respectively).",
"   </p>",
"   <p>",
"    Our treatment approach takes into account whether or not prior RT was administered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110943027\">",
"    <span class=\"h3\">",
"     No prior radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with a recurrence isolated to the vaginal vault, we suggest RT. Treatment with RT alone is associated with excellent outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. As an example, among 32 women with a vaginal recurrence originally assigned to the control arm in the PORTEC trial, 87 percent had a complete response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/1\">",
"     1",
"    </a>",
"    ]. The three-year overall survival (OS) for these patients was 65 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110943071\">",
"    <span class=\"h3\">",
"     Prior radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vaginal recurrences are less common in women treated with prior RT, but are associated with a poor prognosis. In the PORTEC trial, there were only seven vaginal recurrences out of 354 women treated with RT (eight-year recurrence rate, 2 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the actuarial OS rate at three years among these patients was 43 percent. Treatment options among these women depend on whether surgery is an option.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Operative candidates",
"      </strong>",
"      &mdash; We suggest surgical resection if technically feasible and patients are appropriate surgical candidates. Resection of recurrent disease in a previously irradiated area may require that the patient undergo a pelvic exenteration to ensure complete excision. However, the decision to proceed with pelvic exenteration should be considered carefully due to the associated short- and long-term morbidity, including urinary tract and bowel dysfunction, the need for diversion (colostomy",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nephrostomy), and sexual dysfunction. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31689?source=see_link&amp;anchor=H9#H9\">",
"       \"Exenteration for gynecologic cancer\", section on 'Patient selection'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      We generally restrict surgery to highly motivated, otherwise healthy women in whom a complete resection of disease is technically feasible. Data on the outcomes of women following pelvic exenteration for recurrent endometrial cancer are limited. In many case series, women with pelvic sidewall disease",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      positive pelvic or paraaortic lymph nodes were included [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/4-7\">",
"       4-7",
"      </a>",
"      ]. As a result, the reported five-year OS rates for pelvic exenteration range from 14 to 50 percent. In the largest series of 44 women with recurrent endometrial cancer, the median OS was 10.2 months and five-year OS was 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/5\">",
"       5",
"      </a>",
"      ]. Details of the procedure and postoperative care and complications of pelvic exenteration for gynecologic cancer are discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31689?source=see_link\">",
"       \"Exenteration for gynecologic cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Non-operative candidates",
"      </strong>",
"      &mdash; In general, reirradiation is not an option for women with a vaginal recurrence, particularly after pelvic radiation, given the risks to the normal surrounding tissue. However, tailored treatment approaches may allow for re-treatment with limited toxicity to surrounding normal tissue [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/8-12\">",
"       8-12",
"      </a>",
"      ]. As an example, a case series of 27 patients treated with stereotactic RT after conventional RT found no serious (grade 3, 4, or 5) toxicity associated with re-treatment, and a 96 percent symptomatic response (measured by reduced tumor size, decrease in pain, or decrease in bleeding) was reported [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/12\">",
"       12",
"      </a>",
"      ]. Unfortunately, the experience with tailored RT approaches is limited and expertise may not be available in many places to allow consideration of this approach.",
"      <br/>",
"      <br/>",
"      For women who are not candidates for either a surgical or RT approach, we recommend medical treatment. (See",
"      <a class=\"local\" href=\"#H5234213\">",
"       'Medical treatment'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110942854\">",
"    <span class=\"h2\">",
"     Regional recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with recurrent disease involving the pelvic structures are considered to have a regional recurrence. The approach to treatment is similar to the one used for patients with metastatic disease. (See",
"    <a class=\"local\" href=\"#H297984019\">",
"     'Metastatic disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H297984019\">",
"    <span class=\"h1\">",
"     METASTATIC DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5234939\">",
"    <span class=\"h2\">",
"     Surgical cytoreduction",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with recurrent pelvic or intra-abdominal disease, we suggest cytoreduction. High quality data are lacking regarding cytoreduction for recurrent endometrial cancer. The best available data are from a meta-analysis of 14 retrospective case series that included four studies of women with recurrent disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/13\">",
"     13",
"    </a>",
"    ]. A complete cytoreduction was associated with a significant increase in survival, which ranged widely from 9 to 35 months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=see_link&amp;anchor=H14#H14\">",
"     \"Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment\", section on 'Cytoreduction'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5234213\">",
"    <span class=\"h2\">",
"     Medical treatment",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8007524\">",
"    <span class=\"h3\">",
"     Initial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women with metastatic endometrial cancer who were not previously treated with adjuvant chemotherapy, we suggest a platinum-based combination regimen rather than single agent chemotherapy or endocrine therapy as first-line treatment. The two most commonly used regimens to treat metastatic endometrial cancer are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    or the triple drug combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    , plus paclitaxel (TAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Of these, we suggest carboplatin and paclitaxel because it has similar activity as TAP but is associated with less toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of multi-agent chemotherapy for advanced, recurrent, or metastatic endometrial cancer was shown in a 2012 meta-analysis of trials that compared administration of two or more agents (&ldquo;more intensive&rdquo; regimens) to one agent or two agent combinations (&ldquo;less intensive&rdquo; regimens), which came to the following major conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/16\">",
"     16",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Compared to the administration of &ldquo;less intensive&rdquo; regimens, the use of &ldquo;more intensive&rdquo; regimens (eight trials, n=1519) resulted in an improvement in progression free survival (PFS, from six to seven months, hazard ratio [HR] 0.82, 95% CI 0.74-0.90) and OS (from 9 to 10.5 months, HR 0.86, 95% CI 0.77-0.96). Trials that compared",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (or doxorubicin plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ) with or without additional drugs favored the arms incorporating additional chemotherapy.",
"     </li>",
"     <li>",
"      The administration of &ldquo;more intensive&rdquo; chemotherapy significantly increased the risk of serious nausea and vomiting (odds ratio [OR] 2.64, 95% CI 1.71-4.09) and diarrhea (OR 2.25, 95% CI 1.09-4.63).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the data from this meta-analysis support the use of multi-agent chemotherapy, it did not include the results from GOG 209, which compared a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -based triplet regimen to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    . These and other data to support commonly administered regimens is discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H99029909\">",
"    <span class=\"h4\">",
"     Cisplatin, doxorubicin, plus paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;The benefit of a &ldquo;more intensive&rdquo; regimen was shown in GOG 177, which enrolled 273 women with previously untreated stage",
"    <span class=\"nowrap\">",
"     III/IV",
"    </span>",
"    or recurrent endometrial cancer and randomized them to treatment with AP (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    [50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </span>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    [60",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     ]",
"    </span>",
"    administered on day 1 every three weeks) or to TAP (doxorubicin [45",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1], cisplatin [50",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    on day 1] plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    [160",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    over three hours on day 2] every three weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/17\">",
"     17",
"    </a>",
"    ]. Compared to AP, TAP resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A significant improvement in the overall response rate (ORR, 57 versus 34 percent).",
"     </li>",
"     <li>",
"      A significant improvement in PFS (median, 8 versus 5 months).",
"     </li>",
"     <li>",
"      A significant improvement in OS (median, 15 versus 12 months).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, TAP also resulted in an increased incidence of serious (grade 3) neuropathy (12 versus 1 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355002112\">",
"    <span class=\"h4\">",
"     Carboplatin plus paclitaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the toxicity associated with TAP,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    -based therapy has been evaluated as an alternative regimen. In GOG 209 (which was not included in the 2012 meta-analysis discussed above), carboplatin (area under curve=6) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    (175",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    administered every 21 days was compared to TAP in a trial that enrolled 1300 women with chemotherapy naive stage III, IV, or recurrent endometrial carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/14\">",
"     14",
"    </a>",
"    ]. Based on the presentation of GOG 209 during the 2012 Society of Gynecologic Oncologists Annual Meeting, carboplatin plus paclitaxel resulted in:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Similar ORR compared to TAP (51 percent in each arm)",
"     </li>",
"     <li>",
"      Similar PFS (median, 13 months in each arm, HR for recurrence 1.05)",
"     </li>",
"     <li>",
"      Similar OS (median, 37 versus 40 months)",
"     </li>",
"     <li>",
"      A statistically significant reduction in the incidence of grade 2 or greater toxicity, including sensory neuropathy (19 versus 26 percent), thrombocytopenia (12 versus 23 percent), emesis (4 versus 7 percent), diarrhea (2 versus 6 percent), and metabolic derangements (8 versus 14 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These results support administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    as the preferred regimen for the first-line treatment of recurrent, advanced, or metastatic endometrial cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H533558493\">",
"    <span class=\"h4\">",
"     Endocrine therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because treatment of metastatic endometrial cancer is palliative and not curative, endocrine therapy is a reasonable alternative to chemotherapy. It is well tolerated and lacks the usual toxicities associated with cytotoxic chemotherapy. Approximately 15 to 30 percent of women respond to endocrine therapy, with responses most frequent in low-grade tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/18\">",
"     18",
"    </a>",
"    ]. While most remissions are partial and relatively brief in duration, some patients may remain progression-free for extended periods of time (&gt;2 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/19\">",
"     19",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    We suggest endocrine therapy as initial treatment for patients with any of the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade 1 or 2 endometrial cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Positive expression of estrogen (ER) and progesterone (PR) receptors. Several studies suggest that hormone receptor positive cancers are more likely to respond to endocrine treatment, though the data are not consistent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/18,20-22\">",
"       18,20-22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Asymptomatic or minimally symptomatic disease.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If endocrine therapy is administered, we suggest",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    alternating in sequence with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . The benefit of sequential therapy was demonstrated in a phase II study conducted by the GOG that enrolled 56 women assigned treatment with megestrol acetate (160 mg orally for three weeks), alternating with tamoxifen (40 mg daily for three weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/23\">",
"     23",
"    </a>",
"    ]. Treatment resulted in an overall response rate of 27 percent with a median progression-free survival of 2.7 months and median overall survival of 14 months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/23\">",
"     23",
"    </a>",
"    ]. Interestingly, the response rate among women with grade 3 tumors was 22 percent, presumably due to tamoxifen induction of progesterone receptors.",
"   </p>",
"   <p>",
"    In light of the limited evidence to support the use of sequential",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"     megestrol acetate",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    , other options for endocrine treatment are available. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Progestins",
"      </strong>",
"      &mdash; Progesterone was first shown to be an effective anticancer agent for women with advanced disease in 1951 and contemporary trials report an ORR between 15 and 20 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/24-30\">",
"       24-30",
"      </a>",
"      ]. There is no evidence of a dose-response relationship with progestins. This was shown in a 2010 meta-analysis where",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/24/1417?source=see_link\">",
"       medroxyprogesterone acetate",
"      </a>",
"      at 1000",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      was associated with a higher risk of disease progression (HR 1.35, 95% CI 1.07-1.71) and death (HR 1.31, 95% CI 1.04-1.66) compared to a lower dose (200",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       Tamoxifen",
"      </a>",
"      &mdash; Tamoxifen is the only selective estrogen receptor modulator that has demonstrated activity in this population. When used for women with hormone receptor positive tumors, response rates ranging from 10 to 46 percent have been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/20,31-34\">",
"       20,31-34",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The aromatase inhibitors have little activity in endometrial cancer. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/26/36261?source=see_link\">",
"     letrozole",
"    </a>",
"    and anastrazole were tested in phase II clinical trials of women with advanced, recurrent, or persistent endometrial cancer and had response rates of less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In addition, the presence of hormone receptors does not appear to predict treatment outcomes. This was demonstrated in a trial of letrozole conducted by the National Cancer Institute of Canada [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/35\">",
"     35",
"    </a>",
"    ]. Among 22 patients with available tissue, the majority were positive for progesterone receptors (86 percent), estrogen receptors (86 percent), and PTEN (82 percent). However, no biomarker was associated with outcomes.",
"   </p>",
"   <p>",
"    Patients who progress following endocrine therapy should receive platinum-based combination chemotherapy. This is discussed above. (See",
"    <a class=\"local\" href=\"#H99029909\">",
"     'Cisplatin, doxorubicin, plus paclitaxel'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H135449528\">",
"    <span class=\"h3\">",
"     Second-line therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who received adjuvant chemotherapy, our approach to second-line treatment depends on the interval between the end of adjuvant treatment and the diagnosis of relapse (ie, treatment-free interval).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with a long treatment-free interval (ie, six months or longer), we suggest repeat treatment with a platinum-based combination. There is limited evidence that the treatment-free interval predicts response to second-line treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/37,38\">",
"       37,38",
"      </a>",
"      ]. In the largest study conducted by the GOG, a treatment-free interval of six months or longer was associated with a significant reduction in the risk of death after second-line chemotherapy (HR 0.70, 95% CI 0.59-0.84) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/38\">",
"       38",
"      </a>",
"      ]. Although there is no evidence that a platinum-based combination results in improved outcomes compared to single-agent therapy in this context, the use of a platinum-based combination in the second-line treatment in this population is extrapolated from the treatment of platinum-sensitive recurrent ovarian cancer. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=see_link\">",
"       \"Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For women with a short treatment-free interval (&lt;6 months), we suggest single agent therapy rather than a combination chemotherapy regimen. We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      (60",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks or 20",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for three weeks followed by one week rest) if doxorubicin-naive and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      (175",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      every three weeks or 60 to 80",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      weekly for three weeks followed by one week rest) in all other patients because these agents are among the most active in endometrial cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women who experience disease progression after first-line chemotherapy with a platinum-based regimen, we suggest single agent chemotherapy. A choice between them depends on patient and provider preference. While responses are observed with single agent therapy, these are often short-lived and median overall survival across studies is typically less than one year.",
"   </p>",
"   <p>",
"    Commonly used agents include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110944455\">",
"    <span class=\"h4\">",
"     Ifosfamide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/25/38297?source=see_link\">",
"     Ifosfamide",
"    </a>",
"    (1.2",
"    <span class=\"nowrap\">",
"     g/m",
"     <sup>",
"      2",
"     </sup>",
"     /day",
"    </span>",
"    for five days, repeated every four weeks) resulted in an ORR of 15 percent in a study involving 52 women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/39\">",
"     39",
"    </a>",
"    ]. Serious (grade",
"    <span class=\"nowrap\">",
"     3/4)",
"    </span>",
"    toxicity was limited to neutropenia in 53 percent and neuropathy in 11 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113485140\">",
"    <span class=\"h4\">",
"     Ixabepilone",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"     Ixabepilone",
"    </a>",
"    is an epothilone B analogue approved for treatment of metastatic breast cancer. In GOG 129P, 50 women (majority previously treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) were treated with ixabepilone (40",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/40\">",
"     40",
"    </a>",
"    ]. The ORR was 12 percent and the median PFS was three months. Serious (grade 3) toxicities included neutropenia, leukopenia, gastrointestinal, neurologic, constitutional, and infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113485173\">",
"    <span class=\"h4\">",
"     Docetaxel",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weekly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    (36",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    IV on days 1, 8, and 15 every 28 days) resulted in an ORR of 7.7 percent in a phase II GOG study involving 27 women (the majority of whom previously received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/41\">",
"     41",
"    </a>",
"    ]. The most frequently reported adverse events were leucopenia, neutropenia, gastrointestinal, constitutional, and peripheral neuropathy. Given the low response rate, the study was terminated early.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2110944476\">",
"    <span class=\"h4\">",
"     Topotecan",
"    </span>",
"    &nbsp;&mdash;&nbsp;A prospective, phase II clinical trial of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/2/32807?source=see_link\">",
"     Topotecan",
"    </a>",
"    suspended because of unexpected toxicities (ie, sepsis and bleeding), but was reopened using a lower doses of topotecan (1.0",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    or 0.8",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    for patients with prior radiation therapy). The ORR among 44 patients was 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/42\">",
"     42",
"    </a>",
"    ]. The median OS was 6.5 months. The major toxicities were hematologic and gastrointestinal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H113485206\">",
"    <span class=\"h4\">",
"     Oxaliplatin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/11/2233?source=see_link\">",
"     Oxaliplatin",
"    </a>",
"    (130",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    every three weeks) resulted in an ORR of 14 percent in a study involving 50 women [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/43\">",
"     43",
"    </a>",
"    ]. Major toxicities were nausea, vomiting, and neurotoxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355002490\">",
"    <span class=\"h2\">",
"     Special populations",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355002497\">",
"    <span class=\"h3\">",
"     Older women",
"    </span>",
"    &nbsp;&mdash;&nbsp;While age is used to stratify women with either high- versus low- intermediate-risk endometrial cancer, older age has been associated with higher rates of clinical relapse and decreased survival. The decision to use chemotherapy in older women is complicated due to an increased number of comorbidities. Prior to making a decision regarding chemotherapy, we suggest a comprehensive geriatric assessment in order to help guide discussions on primary and adjuvant treatment. This topic is addressed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=see_link&amp;anchor=H215731105#H215731105\">",
"     \"Approach to adjuvant treatment of endometrial cancer\", section on 'Influence of age'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=see_link\">",
"     \"Comprehensive geriatric assessment for patients with cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     Obese women",
"    </strong>",
"    &nbsp;&mdash;&nbsp;Although clinical practice varies, overweight or obese women often receive intentionally reduced doses based upon ideal rather than actual body weight. There are no data to support this practice, and it may contribute to the worse outcomes seen in obese women. Standard, weight-based drug doses should be administered to all patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355002504\">",
"    <span class=\"h3\">",
"     Patients with cardiac risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of chemotherapy-related cardiotoxicity is associated with cumulative doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    &nbsp;greater than 550",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"     .",
"    </span>",
"    Older age, prior history of cardiac disease and chest wall radiation therapy are also risk factors for treatment-related cardiotoxicity. For patients with cardiac risk factors who are candidates for adjuvant treatment, we recommend",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"     carboplatin",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"     paclitaxel",
"    </a>",
"    rather than a doxorubicin-containing regimen. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link&amp;anchor=H25#H25\">",
"     \"Cardiotoxicity of anthracycline-like chemotherapy agents\", section on 'Pretreatment assessment and subsequent monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H355002674\">",
"    <span class=\"h2\">",
"     Novel agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of agents are being evaluated in clinical trials with the aim of increasing the treatment options for women with endometrial carcinoma. As with most settings in oncology, we encourage participation in clinical trials. A representation of agents being specifically evaluated in endometrial carcinoma is discussed below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Arzoxifene",
"      </strong>",
"      &mdash; Arzoxifene is a third generation selective estrogen receptor modulator (SERM), which unlike",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      , has estrogen antagonist activity in the uterus [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/44\">",
"       44",
"      </a>",
"      ]. A GOG trial of 37 women with well- to moderately-differentiated recurrent endometrial cancer or ER",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      PR positive disease received arzoxifene (20 mg daily orally). The ORR was 31 percent and the median duration of response was 14 months. Median PFS was four months. There were no serious toxicities. The most common minor toxicity (grade",
"      <span class=\"nowrap\">",
"       1/2)",
"      </span>",
"      was hot flashes. All responders had previously responded to progestins.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/20/2377?source=see_link\">",
"       Bevacizumab",
"      </a>",
"      &mdash; The anti-VEGF monoclonal antibody bevacizumab appears to be an active agent in endometrial cancer. The GOG enrolled 53 women who had received up to two prior treatments for endometrial cancer and treated them with bevacizumab (15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      IV every three weeks) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/45\">",
"       45",
"      </a>",
"      ]. The ORR was 15 percent with 36 percent progression-free at six months. The median PFS and OS were four and 11 months, respectively. There were no episodes of gastrointestinal perforation.",
"      <br/>",
"      <br/>",
"      Bevacizumab is currently being evaluated in a three-arm randomized phase II",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00977574\">",
"       GOG study (GOG 86P)",
"      </a>",
"      in this population. All patients are randomly assigned to treatment on one of three arms using:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      plus bevacizumab; carboplatin and paclitaxel plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      ; or carboplatin and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10423?source=see_link\">",
"       ixabepilone",
"      </a>",
"      plus bevacizumab.",
"     </li>",
"     <li>",
"      <strong>",
"       Epidermal growth factor receptor (EGFR) inhibitors",
"      </strong>",
"      &mdash; The epidermal growth factor receptor (EGFR) is frequently overexpressed in endometrial carcinoma and these have also been evaluated in patients with endometrial cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/46\">",
"       46",
"      </a>",
"      ]:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/13/36056?source=see_link\">",
"       Erlotinib",
"      </a>",
"      (150 mg daily) was given to 34 women with recurrent or metastatic endometrial carcinomas who had been treated with one prior endocrine therapy but were chemotherapy naive [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/46\">",
"       46",
"      </a>",
"      ]. The ORR was 13 percent with stable disease achieved in 47 percent. It was well tolerated with few grade",
"      <span class=\"nowrap\">",
"       3/4",
"      </span>",
"      events noted. &nbsp;",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/12/19654?source=see_link\">",
"       Gefitinib",
"      </a>",
"      (500 mg daily) was administered to 26 women who had received up to two prior chemotherapy regimens for recurrent or persistent disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/47\">",
"       47",
"      </a>",
"      ]. The ORR was 4 percent with stable disease in 27 percent.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mammalian target of rapamycin (mTOR) inhibitors",
"      </strong>",
"      &mdash; Mutation of the gene encoding the phosphatase and tensin homologue (PTEN), a regulator of the",
"      <span class=\"nowrap\">",
"       PI3K/AKT/mammalian",
"      </span>",
"      target of rapamycin (mTOR) pathway, is commonly encountered in endometrioid-type endometrial cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/48\">",
"       48",
"      </a>",
"      ]. Clinical trials with mTOR inhibitors have shown promising results in women with endometrial cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       Temsirolimus",
"      </a>",
"      (25 mg IV weekly) was administered to 27 women with previously treated recurrent or metastatic endometrial carcinoma [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/49\">",
"       49",
"      </a>",
"      ]. The overall response rate was seven percent, but 44 percent had stable disease. Eight patients experienced serious (grade",
"      <span class=\"nowrap\">",
"       3/4)",
"      </span>",
"      toxicities (pneumonitis, mucositis, fatigue, gastrointestinal, and pain).",
"     </li>",
"     <li>",
"      Deforolimus (12.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      for five days every other week) was given to 45 patients with advanced endometrial carcinoma (34 previously treated with chemotherapy) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/50\">",
"       50",
"      </a>",
"      ]. Although the overall response rate was low (7.4 percent), stable disease was noted in 26 percent. A third of the patients treated experienced grade 3 fatigue and seven percent experienced grade 3 hyperglycemia.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       Everolimus",
"      </a>",
"      (10",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      was administered to 29 patients with recurrent endometrial carcinoma (previously treated with up to two prior chemotherapy regimens) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/51\">",
"       51",
"      </a>",
"      ]. No objective responses were seen, although 38 percent had stable disease lasting for a median of four months. The most common adverse events were abdominal pain (28 percent) and",
"      <span class=\"nowrap\">",
"       nausea/vomiting",
"      </span>",
"      (21 percent).",
"     </li>",
"     <li>",
"      As discussed earlier,",
"      <a class=\"external\" href=\"file://clinicaltrials.gov/ct2/show/NCT00977574\">",
"       GOG 86P",
"      </a>",
"      incorporates the mTOR inhibitor",
"      <a class=\"drug drug_general\" href=\"UTD.htm?14/1/14360?source=see_link\">",
"       temsirolimus",
"      </a>",
"      in to one of three treatment arms for women with advanced, recurrent, or metastatic endometrial cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Angiokinase inhibitors",
"      </strong>",
"      &mdash; New drugs that target angiogenesis and other pathways are in phase II clinical trials for this population of patients with previously treated endometrial cancer:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Brivanib is a dual tyrosine kinase inhibitor of vascular endothelial growth factor receptors (VEGFR2 and VEGFR3) and fibroblast growth factor receptors (FGFR1, FGFR2, and FGFR3).",
"     </li>",
"     <li>",
"      BIBF1120 is an angiokinase inhibitor of VEGF receptors (VEGFR1, VEGFR2, and VEGFR3); platelet derived growth factor receptors (PDGFR alpha and beta); and FGF receptors (FGFR1, FGFR3).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7029873\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prognosis is determined by the clinical scenario and by prior treatment following surgery. This was demonstrated in the postoperative radiation therapy (RT) in endometrial carcinoma (PORTEC) study of pelvic RT versus observation in 715 women with early endometrial cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22825/abstract/1\">",
"     1",
"    </a>",
"    ]. The actuarial three-year overall survival was:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      72 percent following a vaginal recurrence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      8 percent after a pelvic recurrence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      14 percent following development of distant metastases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For women who relapse following first- or second-line chemotherapy, however, the prognosis is poorer. The median overall survival in clinical trials of first- or second-line agents is generally 12 months or less.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with inoperable stage III or IV disease, those who relapse following an initial diagnosis of endometrial cancer, have persistent disease despite adjuvant treatment, or recur with locally advanced or metastatic disease are not curable. Treatment options are dependent on prior therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with endometrial carcinoma who originally present with extensive pelvic involvement or intra-abdominal disease are considered to have advanced endometrial cancer. We suggest surgical cytoreduction rather than RT or medical therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). If women are not amenable to surgical cytoreduction, we recommend medical treatment. (See",
"      <a class=\"local\" href=\"#H2110943464\">",
"       'Advanced Disease'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H99029909\">",
"       'Cisplatin, doxorubicin, plus paclitaxel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with recurrent disease, our approach depends on the location of the recurrence and prior treatment received:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women with an isolated vaginal recurrence who did not receive adjuvant RT following their original surgery, we suggest RT rather than surgery or medical treatment (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For women who decline RT or are not candidates for RT, surgical resection is a reasonable alternative. (See",
"      <a class=\"local\" href=\"#H2110943027\">",
"       'No prior radiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a vaginal recurrence who have been previously treated with RT, we suggest surgical resection rather than medical therapy if surgery technically feasible and patients are appropriate surgical candidates (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For women who are not surgical candidates (due to disease location or medical contraindications), we suggest re-irradiation provided the local expertise is available (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2110943071\">",
"       'Prior radiation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are not candidates for local therapy, we recommend medical treatment. The options for medical treatment are similar to the options for women with metastatic disease. (See",
"      <a class=\"local\" href=\"#H5234213\">",
"       'Medical treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women with metastatic endometrial cancer who did not receive adjuvant chemotherapy, we suggest a platinum-based combination regimen rather than endocrine therapy or single agent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H8007524\">",
"       'Initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who are candidates for platinum-based combination chemotherapy, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/61/38873?source=see_link\">",
"       carboplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      rather than a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      -based combination (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H355002112\">",
"       'Carboplatin plus paclitaxel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For some women with metastatic endometrial cancer, endocrine therapy is a reasonable alternative to combination chemotherapy as initial treatment if any of the following factors are present: grade 1 or 2 endometrial cancer, tumors positive for estrogen (ER) and progesterone (PR) receptors, and women without (or with minimal) cancer-related symptoms. If endocrine therapy is administered, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/55/33653?source=see_link\">",
"       megestrol acetate",
"      </a>",
"      alternating with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H533558493\">",
"       'Endocrine therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who experience disease progression on endocrine therapy, we suggest platinum-based combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H355002112\">",
"       'Carboplatin plus paclitaxel'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who received adjuvant chemotherapy, our approach to second-line treatment depends on the interval between the end of adjuvant treatment and the diagnosis of relapse (ie, treatment-free interval) (see",
"      <a class=\"local\" href=\"#H135449528\">",
"       'Second-line therapy'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For women who experience a long treatment-free interval (eg, &ge;6 months), we suggest platinum-based combination chemotherapy rather than single agent therapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ) (See",
"      <a class=\"local\" href=\"#H135449528\">",
"       'Second-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with a treatment-free interval (&lt;6 months) from prior adjuvant therapy, we suggest single agent therapy rather than combination chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      )y. We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      if doxorubicin-naive and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      in all other patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For women who may not be candidates for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?16/58/17320?source=see_link\">",
"       paclitaxel",
"      </a>",
"      or who previously had disease progression despite these agents, other agents are available. (See",
"      <a class=\"local\" href=\"#H135449528\">",
"       'Second-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For women who experience disease progression after first-line chemotherapy, we suggest single agent chemotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). A choice between them depends on patient and provider preference. (See",
"      <a class=\"local\" href=\"#H135449528\">",
"       'Second-line therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women who relapse following first- or second-line chemotherapy, have a poor prognosis. The median overall survival in clinical trials of first- or second-line agents is generally 12 months or less. (See",
"      <a class=\"local\" href=\"#H7029873\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/1\">",
"      Creutzberg CL, van Putten WL, Koper PC, et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003; 89:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/2\">",
"      Huh WK, Straughn JM Jr, Mariani A, et al. Salvage of isolated vaginal recurrences in women with surgical stage I endometrial cancer: a multiinstitutional experience. Int J Gynecol Cancer 2007; 17:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/3\">",
"      Lin LL, Grigsby PW, Powell MA, Mutch DG. Definitive radiotherapy in the management of isolated vaginal recurrences of endometrial cancer. Int J Radiat Oncol Biol Phys 2005; 63:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/4\">",
"      Khoury-Collado F, Einstein MH, Bochner BH, et al. Pelvic exenteration with curative intent for recurrent uterine malignancies. Gynecol Oncol 2012; 124:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/5\">",
"      Barakat RR, Goldman NA, Patel DA, et al. Pelvic exenteration for recurrent endometrial cancer. Gynecol Oncol 1999; 75:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/6\">",
"      Barber HR, Brunschwig A. Treatment and results of recurrent cancer of corpus uteri in patients receiving anterior and total pelvic exenteration 1947-1963. Cancer 1968; 22:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/7\">",
"      Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. Gynecol Oncol 1996; 60:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/8\">",
"      Viswanathan AN, Cormack R, Holloway CL, et al. Magnetic resonance-guided interstitial therapy for vaginal recurrence of endometrial cancer. Int J Radiat Oncol Biol Phys 2006; 66:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/9\">",
"      Nag S, Mart&iacute;nez-Monge R, Copeland LJ, et al. Perineal template interstitial brachytherapy salvage for recurrent endometrial adenocarcinoma metastatic to the vagina. Gynecol Oncol 1997; 66:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/10\">",
"      Dewas S, Bibault JE, Mirabel X, et al. Robotic image-guided reirradiation of lateral pelvic recurrences: preliminary results. Radiat Oncol 2011; 6:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/11\">",
"      Deodato F, Macchia G, Grimaldi L, et al. Stereotactic radiotherapy in recurrent gynecological cancer: a case series. Oncol Rep 2009; 22:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/12\">",
"      Abusaris H, Hoogeman M, Nuyttens JJ. Re-irradiation: outcome, cumulative dose and toxicity in patients retreated with stereotactic radiotherapy in the abdominal or pelvic region. Technol Cancer Res Treat 2012; 11:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/13\">",
"      Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010; 118:14.",
"     </a>",
"    </li>",
"    <li>",
"     Miller DS, Filiaci G, Mannel R, et al. Randomized Phase III Noninferiority Trial of First Line Chemotherapy for Metastatic or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study. LBA2. Presented at the 2012 Society of Gynecologic Oncology Annual Meeting, Austin, TX.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/15\">",
"      Fleming GF. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J Clin Oncol 2007; 25:2983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/16\">",
"      Vale CL, Tierney J, Bull SJ, Symonds PR. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 2012; 8:CD003915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/17\">",
"      Fleming GF, Brunetto VL, Cella D, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22:2159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/18\">",
"      Decruze SB, Green JA. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007; 17:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/19\">",
"      Markman M. Hormonal therapy of endometrial cancer. Eur J Cancer 2005; 41:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/20\">",
"      Singh M, Zaino RJ, Filiaci VJ, Leslie KK. Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2007; 106:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/21\">",
"      Temkin SM, Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control 2009; 16:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/22\">",
"      Obel JC, Friberg G, Fleming GF. Chemotherapy in endometrial cancer. Clin Adv Hematol Oncol 2006; 4:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/23\">",
"      Fiorica JV, Brunetto VL, Hanjani P, et al. Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/24\">",
"      KELLEY RM, BAKER WH. Progestational agents in the treatment of carcinoma of the endometrium. N Engl J Med 1961; 264:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/25\">",
"      Piver MS, Barlow JJ, Lurain JR, Blumenson LE. Medroxyprogesterone acetate (Depo-Provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 1980; 45:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/26\">",
"      Reifenstein EC Jr. The treatment of advanced endometrial cancer with hydroxyprogesterone caproate. Gynecol Oncol 1974; 2:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/27\">",
"      Podratz KC, O'Brien PC, Malkasian GD Jr, et al. Effects of progestational agents in treatment of endometrial carcinoma. Obstet Gynecol 1985; 66:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/28\">",
"      Elit L, Hirte H. Current status and future innovations of hormonal agents, chemotherapy and investigational agents in endometrial cancer. Curr Opin Obstet Gynecol 2002; 14:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/29\">",
"      Thigpen JT, Brady MF, Alvarez RD, et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17:1736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/30\">",
"      Lentz SS, Brady MF, Major FJ, et al. High-dose megestrol acetate in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 1996; 14:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/31\">",
"      Thigpen T, Brady MF, Homesley HD, et al. Tamoxifen in the treatment of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2001; 19:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/32\">",
"      Swenerton KD. Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep 1980; 64:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/33\">",
"      Slavik M, Petty WM, Blessing JA, et al. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep 1984; 68:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/34\">",
"      Rendina GM, Donadio C, Fabri M, et al. Tamoxifen and medroxyprogesterone therapy for advanced endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol 1984; 17:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/35\">",
"      Ma BB, Oza A, Eisenhauer E, et al. The activity of letrozole in patients with advanced or recurrent endometrial cancer and correlation with biological markers--a study of the National Cancer Institute of Canada Clinical Trials Group. Int J Gynecol Cancer 2004; 14:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/36\">",
"      Rose PG, Brunetto VL, VanLe L, et al. A phase II trial of anastrozole in advanced recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2000; 78:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/37\">",
"      Ueda Y, Miyake T, Egawa-Takata T, et al. Second-line chemotherapy for advanced or recurrent endometrial carcinoma previously treated with paclitaxel and carboplatin, with or without epirubicin. Cancer Chemother Pharmacol 2011; 67:829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/38\">",
"      Moore KN, Tian C, McMeekin DS, et al. Does the progression-free interval after primary chemotherapy predict survival after salvage chemotherapy in advanced and recurrent endometrial cancer?: a Gynecologic Oncology Group ancillary data analysis. Cancer 2010; 116:5407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/39\">",
"      Sutton GP, Blessing JA, DeMars LR, et al. A phase II Gynecologic Oncology Group trial of ifosfamide and mesna in advanced or recurrent adenocarcinoma of the endometrium. Gynecol Oncol 1996; 63:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/40\">",
"      Dizon DS, Blessing JA, McMeekin DS, et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: gynecologic oncology group trial 129-P. J Clin Oncol 2009; 27:3104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/41\">",
"      Garcia AA, Blessing JA, Nolte S, et al. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol 2008; 111:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/42\">",
"      Wadler S, Levy DE, Lincoln ST, et al. Topotecan is an active agent in the first-line treatment of metastatic or recurrent endometrial carcinoma: Eastern Cooperative Oncology Group Study E3E93. J Clin Oncol 2003; 21:2110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/43\">",
"      Fracasso PM, Blessing JA, Molpus KL, et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 103:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/44\">",
"      McMeekin DS, Gordon A, Fowler J, et al. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol Oncol 2003; 90:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/45\">",
"      Aghajanian C, Sill MW, Darcy KM, et al. Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2011; 29:2259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/46\">",
"      Oza AM, Eisenhauer EA, Elit L, et al. Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148. J Clin Oncol 2008; 26:4319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/47\">",
"      Leslie KK, Sill MW, Fischer E, et al. A Phase II Evaluation of Gefitinib in the Treatment of Persistent or Recurrent Endometrial Cancer: A Gynecologic Oncology Group Study. Gynecol Oncol 2013; Online 2/21/2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/48\">",
"      Delmonte A, Sessa C. Molecule-targeted agents in endometrial cancer. Curr Opin Oncol 2008; 20:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/49\">",
"      Oza AM, Elit L, Tsao MS, et al. Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011; 29:3278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/50\">",
"      Colombo N, McMeekin S, Schwartz P, et al. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. J Clin Oncol 2007; 25:5516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22825/abstract/51\">",
"      Slomovitz BM, Lu KH, Johnston T, et al. A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma. Cancer 2010; 116:5415.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3186 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-61.234.146.186-ECB61E16A9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22825=[""].join("\n");
var outline_f22_18_22825=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35229224\">",
"      OVERVIEW OF TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2110943464\">",
"      ADVANCED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RECURRENT DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2110942881\">",
"      Isolated vaginal recurrence",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2110943027\">",
"      - No prior radiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2110943071\">",
"      - Prior radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2110942854\">",
"      Regional recurrence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H297984019\">",
"      METASTATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5234939\">",
"      Surgical cytoreduction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5234213\">",
"      Medical treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8007524\">",
"      - Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H99029909\">",
"      Cisplatin, doxorubicin, plus paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H355002112\">",
"      Carboplatin plus paclitaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H533558493\">",
"      Endocrine therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H135449528\">",
"      - Second-line therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2110944455\">",
"      Ifosfamide",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H113485140\">",
"      Ixabepilone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H113485173\">",
"      Docetaxel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H2110944476\">",
"      Topotecan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H113485206\">",
"      Oxaliplatin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H355002490\">",
"      Special populations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355002497\">",
"      - Older women",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H355002504\">",
"      - Patients with cardiac risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H355002674\">",
"      Novel agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7029873\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/0/41991?source=related_link\">",
"      Adjuvant treatment of high-risk endometrial cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13287?source=related_link\">",
"      Adjuvant treatment of intermediate-risk endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/41/8855?source=related_link\">",
"      Approach to adjuvant treatment of endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/56/41864?source=related_link\">",
"      Comprehensive geriatric assessment for patients with cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/23/18810?source=related_link\">",
"      Endometrial carcinoma: Pretreatment evaluation, staging and surgical treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31689?source=related_link\">",
"      Exenteration for gynecologic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/21/37209?source=related_link\">",
"      Medical treatment for relapsed epithelial ovarian, fallopian tubal, or peritoneal cancer: Platinum-sensitive disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/23/7542?source=related_link\">",
"      Treatment of low-risk endometrial cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/20/31043?source=related_link\">",
"      Treatment protocols for gynecologic malignancies",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_18_22826="Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis";
var content_f22_18_22826=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22826/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22826/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22826/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22826/contributors\">",
"     Kathleen J Motil, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22826/contributors\">",
"     Jan E Drutz, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/18/22826/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/18/22826/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/18/22826/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency (ID) is the most common nutritional deficiency in children. The World Health Organization estimates that anemia affects one quarter of the world's population and is concentrated within pre-school age children and women. Iron deficiency is a particularly challenging problem for developing nations in Asia and Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Rates of iron deficiency in the United States and other resource-rich countries are somewhat lower and are gradually improving, but iron deficiency is still common and can have important consequences to health and development.",
"   </p>",
"   <p>",
"    The United States Department of Health and Human Services has set a target of reducing iron deficiency by 10 percent by 2020 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/3\">",
"     3",
"    </a>",
"    ]. Despite the decrease in prevalence of iron deficiency over the last decade, reaching this goal will be challenging, especially in children who are at-risk for iron deficiency. &nbsp;",
"   </p>",
"   <p>",
"    Issues related to iron metabolism and the clinical manifestations, diagnosis, and treatment of iron deficiency in infants and young children are reviewed here. The treatment of iron deficiency in infants and children, and the problem of iron deficiency in adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=see_link\">",
"     \"Iron deficiency in infants and young children: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link\">",
"     \"Iron requirements and iron deficiency in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5261086\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the United States, about 9 percent of toddlers (one to three years old) have iron deficiency (ID) and 2 to 3 percent have iron deficiency anemia (IDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. Rates decrease with advancing age until adolescence, when up to 16 percent of girls develop ID and 3 percent have IDA. The overall rate of ID in young children has declined only slightly during the past four decades, but improved markedly in some subgroups. As an example, rates of iron deficiency among children 12 to 24 months old declined from 23 to 11 percent between two study periods (1976 to 1980, and 1999 to 2002) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, the prevalence of iron deficiency is higher among children living at or below the poverty level, and in Black and Hispanic children. As an example, in a population survey the prevalence of IDA in low-income preschool aged children was 16, 13, 13, and 10 percent for children at 12, 18, 24, and 36 months of age, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/7\">",
"     7",
"    </a>",
"    ]. The prevalence was particularly high in African-American children. Other risk factors for IDA include childhood obesity and a history of prematurity or low-birth-weight [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/4,7,8\">",
"     4,7,8",
"    </a>",
"    ]. In addition, many immigrant groups have higher risks for IDA. This was illustrated in a cohort study of 122 asylum-seekers' children in the Netherlands, where 20 percent of the children had iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/9\">",
"     9",
"    </a>",
"    ]. These findings demonstrate the need for ongoing surveillance and early intervention to prevent iron deficiency during infancy and early childhood, particularly among high risk groups. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IRON BALANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron is an essential nutrient. The majority of iron (75 percent) is bound in heme proteins (hemoglobin and myoglobin). The remainder is bound in the storage proteins ferritin and hemosiderin, with a small portion (3 percent) bound in critical enzyme systems, such as catalase and cytochromes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/10\">",
"     10",
"    </a>",
"    ]. In normal subjects, only a small amount of iron enters and leaves the body on a daily basis. Most iron is recycled from the breakdown of old red blood cells by macrophages of the reticuloendothelial system.",
"   </p>",
"   <p>",
"    The steps involved in the regulation of iron metabolism are discussed in detail separately. Summarized briefly, iron balance is achieved primarily by mechanisms affecting intestinal absorption and transport, rather than urinary or fecal excretion. In adults, 5 percent of daily iron needs comes from dietary sources and equals the iron loss that primarily occurs from the gastrointestinal tract. However, in infants and children, 30 percent of daily iron needs must come from diet because of the growth spurt and increase in body (muscle) mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Intestinal iron absorption is a function of three principal factors: body iron stores (transferrin and ferritin), erythropoietic rate, and bioavailability of dietary iron. Low iron stores increase receptors in the intestinal mucosa to facilitate increased iron uptake. Iron absorption also is increased when there is increased erythropoiesis and reticulocytosis or ineffective erythropoiesis, as in beta thalassemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=see_link\">",
"     \"Regulation of iron balance\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Heme dietary sources (fish, poultry, and meat) have a higher bioavailability of iron than do non-heme (vegetable) sources (30 versus 10 percent) (",
"    <a class=\"graphic graphic_table graphicRef83735 \" href=\"UTD.htm?25/13/25822\">",
"     table 1",
"    </a>",
"    ). In addition, intraluminal factors can affect absorption (",
"    <a class=\"graphic graphic_table graphicRef64874 \" href=\"UTD.htm?26/5/26715\">",
"     table 2",
"    </a>",
"    ). Ascorbic acid enhances the absorption of non-animal sources of iron such as cereal, breads, fruits, and vegetables, whereas tannates (teas), bran foods rich in phosphates, and phytates (plant fiber, especially in seeds and grains) inhibit iron absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/10-15\">",
"     10-15",
"    </a>",
"    ]. Thus, iron deficiency may be a particular problem in vegetarian children. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8266?source=see_link&amp;anchor=H14#H14\">",
"     \"Vegetarian diets for children\", section on 'Iron'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Perinatal risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;At birth, healthy term infants have iron stores of approximately 75",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    two-thirds of which is bound in hemoglobin, and mean hemoglobin concentrations are 15 to 17",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    These infants generally remain iron replete for the first five to six months of life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/16,17\">",
"     16,17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several conditions in the perinatal period can increase the risk for IDA during the first three to six months of life, by reducing the iron stores at birth or through other mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Maternal iron deficiency",
"     </li>",
"     <li>",
"      Prematurity",
"     </li>",
"     <li>",
"      The administration of erythropoietin (EPO) for anemia of prematurity",
"     </li>",
"     <li>",
"      Fetal-maternal hemorrhage (FMH)",
"     </li>",
"     <li>",
"      Twin-twin transfusion syndrome (TTS)",
"     </li>",
"     <li>",
"      Other perinatal hemorrhagic events",
"     </li>",
"     <li>",
"      Insufficient dietary intake of iron during early infancy &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk for infant iron deficiency conferred by maternal iron deficiency was demonstrated in a study from India of 55 mothers with anemia, in which the iron content of cord blood sample correlated with maternal hemoglobin and serum ferritin levels [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/18\">",
"     18",
"    </a>",
"    ]. Breast milk iron was also significantly reduced in mothers with severe anemia but appeared to be preserved in mothers with mild-to-moderate anemia.",
"   </p>",
"   <p>",
"    Premature infants are at increased risk of IDA in early infancy because of a smaller total blood volume at birth, increased loss through phlebotomy, and poor gastrointestinal absorption despite decreased ferritin concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/19\">",
"     19",
"    </a>",
"    ]. The use of erythropoietin to prevent and treat the anemia of prematurity further increases the risk for iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/17\">",
"     17",
"    </a>",
"    ]. After chronic FMH or TTS, term or premature infants may develop a microcytic hypochromic anemia early in infancy as the chronic heme losses prevent the attainment of sufficient iron stores at birth. Therefore, iron supplementation is recommended for preterm infants who are breastfed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=see_link&amp;anchor=H10#H10\">",
"     \"Anemia of prematurity\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dietary factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary issues contribute significantly to the evolution of IDA in infancy and early childhood. Common factors leading to an imbalance in iron metabolism include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/20\">",
"     20",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Insufficient iron intake",
"     </li>",
"     <li>",
"      Decreased absorption due to poor dietary sources of iron",
"     </li>",
"     <li>",
"      Introduction of unmodified cow's milk (non-formula cow&rsquo;s milk) before 12 months of age [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/21-25\">",
"       21-25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Occult blood loss secondary to cow's milk protein-induced colitis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Unmodified cow's milk increases intestinal blood loss in infants as compared to formula feeding or breast feeding. In one study of infants five to six months of age, for example, switching to cow's milk increased the proportion of guaiac-positive stools (from 3 to 30 percent) during the first 28 days, whereas the proportion of positive stools remained low (5 percent) with the feeding of formula [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a report from Chile of over 800 infants who were nine months of age, the prevalence of IDA was highest in infants fed cow's milk formula without added iron (20 percent), intermediate in the group fed human milk (15 percent), and much lower in those fed cow's milk formula with added iron (0.6 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/22\">",
"     22",
"    </a>",
"    ]. Similar results were seen in an observational study from the Avon Longitudinal Study of Parents and Children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/24\">",
"     24",
"    </a>",
"    ]. In this study, an increased risk of anemia at 8 and 12 months of age was associated with either an intake of non-formula cows' milk &gt;600",
"    <span class=\"nowrap\">",
"     mL/day",
"    </span>",
"    or &gt;6 breast",
"    <span class=\"nowrap\">",
"     feeds/day,",
"    </span>",
"    as compared to feeding iron-fortified formula. In addition, breast milk without iron supplementation has been associated with iron deficiency in infants at four months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is an increased risk of iron deficiency with continued bottle-feeding compared to cup feeding in the second and third year of life (adjusted relative risk 2.5, 95% CI 2.46-2.53) probably due to greater volumes of cow milk consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/27\">",
"     27",
"    </a>",
"    ]. This effect was particularly evident among Mexican American infants (odds ratio 2.9, 95% CI 1.5-5.6), and may reflect a lack of adequate educational interventions from healthcare providers [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Drinking more than 24 oz (720 mL) of milk daily is associated with an increased risk for iron deficiency among pre-school aged children, because of the low concentration and bioavailability of iron in cow&rsquo;s milk, and possibly due to increased intestinal blood loss [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5260705\">",
"    <span class=\"h2\">",
"     Gastrointestinal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary iron is absorbed throughout the intestine, but especially in the duodenum. Gastrointestinal malabsorption of iron occurs in diseases that affect this segment of the intestine and cause, including active celiac disease, Crohn&rsquo;s disease, giardiasis, or resection of the proximal small intestine [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Conditions that cause gastrointestinal blood loss, such as cow&rsquo;s milk protein-induced colitis, inflammatory bowel disease or chronic use of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/10/19624?source=see_link\">",
"     aspirin",
"    </a>",
"    or nonsteroidal antiinflammatory drugs, are also associated with iron deficiency. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     REQUIREMENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Requirements for absorbed iron in otherwise uncomplicated states approximate 0.5 to 0.8",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    However, only a fraction of dietary iron is absorbed, and the dietary iron requirement is considerably higher and depends on the bioavailability of the iron in the food. As an example, breast milk contains only 0.3 to 1.0",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    iron, but has a high bioavailability (50 percent); in comparison, proprietary, iron-containing formulas with 12",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    iron have only 4 to 6 percent bioavailability [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based upon these and other observations, the recommended dietary allowances for iron are [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/6,34,35\">",
"     6,34,35",
"    </a>",
"    ]: &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants: The requirements listed below are supplied by an appropriate iron-supplemented formula. For breastfed infants, an additional source of iron (complementary foods or iron supplement) should be added at the following doses and times:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Full-term: 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 15 mg), start iron supplements at four months in breastfed infants, and continue until the infant is taking sufficient quantities of iron-rich complementary foods such as infant cereal.",
"     </li>",
"     <li>",
"      Premature: 2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 15 mg), start supplementation by one month of age in breastfed infants (as an iron supplement). Iron-fortified preterm formulas provide sufficient iron for most preterm infants without supplementation, although up to 14 percent of these infants will develop iron deficiency during the second six months of life [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children 1 to 3 years old: 7",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Children 4 to 8 years old: 10",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"     <li>",
"      Children 9 to 13 years old: 8",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical trials show beneficial effects of supplementation to meet these targets in infants who are at risk for iron deficiency. As examples, in a randomized trial involving four to six month old exclusively breast fed infants in India, oral iron supplementation resulted in better growth velocity, especially those infants who were nutritionally compromised or anemic [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/37\">",
"     37",
"    </a>",
"    ]. In another trial, low birthweight infants were given either early iron supplementation (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/62/15334?source=see_link\">",
"     ferrous sulfate",
"    </a>",
"    2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day begun as soon as enteral feedings reached 100",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per day) or later supplementation (begun at 61 days of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/38\">",
"     38",
"    </a>",
"    ]. Infants who received early iron supplementation had a reduced risk of infection and number of blood transfusions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/38\">",
"     38",
"    </a>",
"    ], and appeared to have a better neurodevelopment outcome at a median corrected age of 5.3 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H20317270\">",
"     'Neurodevelopmental'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    During childhood, iron stores are primarily determined by dietary iron intake. This was illustrated in a study of 800 Bolivian mothers and their children (below five years of age), that demonstrated total body iron stores were closely correlated between mother and child [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/40\">",
"     40",
"    </a>",
"    ]. These results underscore the importance of household dietary iron in determining the iron status of each family member [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iron requirements in adolescents are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link&amp;anchor=H4#H4\">",
"     \"Iron requirements and iron deficiency in adolescents\", section on 'Iron requirements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Prevention of iron deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the prevention of iron deficiency in infants include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Encourage breastfeeding exclusively for first four to six months. After four months of age, an additional source of iron should be added, first as an iron supplement, then transitioning to iron-fortified infant cereals [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/26,41\">",
"       26,41",
"      </a>",
"      ]. Two or more servings per day of these complementary foods meet an infant's requirement for iron.",
"     </li>",
"     <li>",
"      For infants younger than 12 months of age who are not breastfed or are partially breastfed, use only iron-fortified formulas (12 mg of iron per liter) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/42\">",
"       42",
"      </a>",
"      ]. The American Academy of Pediatrics has recommended against the manufacture of low-iron infant formulas (which are defined as providing less than 6.7",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      of iron, but often contain 1 to 2",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      of iron) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/43\">",
"       43",
"      </a>",
"      ]. At least four studies have shown no adverse effects from use of iron-fortified formulas as compared to low iron formulas [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/6\">",
"       6",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      At age six months, encourage one feeding per day of foods rich in vitamin C (eg, citrus fruits and juices, cantaloupe, strawberries, tomatoes, and dark green vegetables) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      After age six months, or when developmentally ready, consider introducing pureed meats. The heme iron in meats is more bioavailable than nonheme iron and also increases the absorption of nonheme iron [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/44,45\">",
"       44,45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Avoid feeding unmodified (nonformula) cow's milk until age 12 months [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Children aged one to five years should consume no more than 600 mL (20 oz) of milk per day. We suggest this limit because the risk of iron deficiency increases in young children drinking more than 24 oz of milk per day [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/30\">",
"       30",
"      </a>",
"      ]. They should also consume an adequate amount of iron-containing foods to meet daily requirements. Children who eat less than three servings of iron-rich foods daily (eg, fortified breakfast cereal, 3 oz of meat, or 4 oz of tofu) usually have suboptimal iron intake and may benefit from an iron supplement [",
"      <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/46\">",
"       46",
"      </a>",
"      ]. &nbsp; &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Maternal iron deficiency during pregnancy increases the risk of iron deficiency in the infant. In less developed countries, the prevalence of iron deficiency during pregnancy is higher than in developed countries, and iron supplementation during pregnancy is beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/47\">",
"     47",
"    </a>",
"    ]. Other strategies to reduce iron deficiency among pregnant women and their offspring include iron fortification of whole maize flour and subsidized programs providing iron-fortified milk, noodles, or rice, or as part of a multiple micronutrient powder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20317248\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency anemia (IDA) is a microcytic, hypochromic, and hypoproductive state. The features of the natural evolution of this disorder from storage iron deficiency to iron-limited erythropoiesis to IDA are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef57739 \" href=\"UTD.htm?25/57/26523\">",
"     table 3",
"    </a>",
"    ). With storage iron deficiency, storage sites are depleted but there is sufficient iron in the \"labile\" iron pool from the daily turnover of red cells for normal hemoglobin synthesis unless further iron losses occur. IDA is the last stage in this evolution and, therefore, is the first to recover with iron repletion.",
"   </p>",
"   <p>",
"    The most common presentation of IDA is an otherwise asymptomatic, well nourished infant or child who has a mild to moderate microcytic, hypochromic anemia (",
"    <a class=\"graphic graphic_picture graphicRef64267 \" href=\"UTD.htm?21/45/22232\">",
"     picture 1",
"    </a>",
"    ). Much less frequent are infants with severe anemia, who present with lethargy, pallor, irritability, cardiomegaly, poor feeding, and tachypnea.",
"   </p>",
"   <p>",
"    Although IDA typically presents as a nutritional anemia, it also may be caused by an underlying medical problem such as gastrointestinal blood loss, malabsorption syndrome, or a chronic inflammatory disease. As an example, refractory IDA can be the presenting symptom of celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/53\">",
"     53",
"    </a>",
"    ], helicobacter pylori infection [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/54\">",
"     54",
"    </a>",
"    ], or may be a confounding finding in anemia of chronic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=see_link&amp;anchor=H24#H24\">",
"     \"Clinical manifestations and diagnosis of celiac disease in children\", section on 'Iron deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=see_link&amp;anchor=H21#H21\">",
"     \"Anemia in children due to decreased red blood cell production\", section on 'Anemia of chronic disease'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20317270\">",
"    <span class=\"h2\">",
"     Neurodevelopmental",
"    </span>",
"    &nbsp;&mdash;&nbsp;Impaired psychomotor",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    mental development are well described in iron-deficient infants, and cognitive impairment can occur in adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/35,57-60\">",
"     35,57-60",
"    </a>",
"    ]. Iron deficiency may also negatively impact infant social-emotional behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/61,62\">",
"     61,62",
"    </a>",
"    ] and may contribute to the development of attention deficit hyperactivity disorder. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=see_link&amp;anchor=H17#H17\">",
"     \"Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis\", section on 'Iron deficiency'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In randomized trials in infants and in toddlers, iron supplementation prevented or corrected impairments in psychomotor development [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/63-67\">",
"     63-67",
"    </a>",
"    ]. In one of these studies, for example, high-risk infants at two months of age were randomly assigned to receive formula with or without iron. The incidence of iron deficiency and IDA was significantly higher in infants fed non-fortified formula (53 versus 28 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/64\">",
"     64",
"    </a>",
"    ]. Psychomotor development declined in the non-fortified group at 9 and 12 months, but the difference was no longer significant at 15 months. Mental development and behavior were not affected.",
"   </p>",
"   <p>",
"    Other studies suggest that psychomotor development may not completely recover in children with moderate to severe IDA after correction of iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/65,68-70\">",
"     65,68-70",
"    </a>",
"    ]. In one of these studies, long-term follow-up demonstrated that the group with chronic iron deficiency when enrolled at 12 to 23 months of age continued to have lower cognitive test scores when evaluated at school-age and adolescence as compared to those with good iron balance at enrollment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/68\">",
"     68",
"    </a>",
"    ]. In a separate subset of patients from the same study, individuals identified and treated for iron deficiency during infancy performed less well on electrophysiologic tests of recognition memory at 10 years of age, as compared to a control group of individuals without iron deficiency in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/70\">",
"     70",
"    </a>",
"    ]. The electrophysiologic measures were able to detect subtle abnormalities of cognitive processing and neuronal timing that affect recognition memory. Behavioral tests, which are less sensitive, did not differ between the two groups. &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Cross-sectional data regarding iron status from the NHANES III (1988-1994) were compared with standardized test scores for 5398 children aged 6 to 16 years [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/59\">",
"     59",
"    </a>",
"    ]. Three percent of the children in this sample were iron deficient (abnormal values for any two of the following: free transferrin saturation, erythrocyte protoporphyrin, and serum ferritin). Compared to children with normal iron status, children with iron deficiency had lower average math scores (93.7 versus 86.4 and 87.4 percent for iron deficient children with and without anemia, respectively). Reading, verbal, and performance scores did not differ between the groups. A meta-analysis of randomized trials in older children and adults showed evidence of modest improvement of attention, concentration, and cognitive function with iron supplementation, but recommended larger controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iron deficiency in infancy is associated with persistent changes in transmission through the auditory and visual systems, suggesting that myelination may be impaired. In one study, auditory brainstem responses (ABR) and visual evoked potentials (VEP) were measured at age four years in Chilean children treated for iron deficiency anemia in infancy and nonanemic controls who also received iron supplementation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/72\">",
"     72",
"    </a>",
"    ]. ABR and VEP latencies were significantly longer in the children who were formerly anemic compared to controls, suggesting the continued presence of subtle auditory and visual dysfunction.",
"   </p>",
"   <p>",
"    Evidence is conflicting about whether there is an association between iron deficiency and the risk for febrile seizures. Several studies suggest a positive correlation between iron deficiency and febrile seizures; the iron dependent metabolism of several neurotransmitters has been suggested as a possible mechanism for this association [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. Conversely, other studies have suggested a negative association or no association between iron deficiency and febrile seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/76\">",
"     76",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Finally, a review reported on studies of iron supplementation in breath&ndash;holding attacks in children, a condition affecting approximately 5 percent of healthy children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/77\">",
"     77",
"    </a>",
"    ]. This meta-analysis suggested that iron supplementation at 5",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    for 16 weeks significantly reduced the frequency and severity of breath-holding attacks, particularly in children with known IDA.",
"   </p>",
"   <p>",
"    One study raises the possibility that iron supplementation might be disadvantageous for the subset of infants with high hemoglobin levels. In a large randomized trial in Chile, infants without iron deficiency anemia (Hgb &gt;10",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    were randomized to either low-iron or high-iron formula [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/78\">",
"     78",
"    </a>",
"    ]. For the majority of infants, the formula type had no effect on cognitive outcomes at ten years of age. However, for the small subgroup with high hemoglobin levels at baseline (Hgb &gt;12.8",
"    <span class=\"nowrap\">",
"     mg/dL),",
"    </span>",
"    cognitive outcomes at ten years of age were worse for those fed high-iron formula as compared with those fed low-iron formula. The study was limited by high loss to follow up and the small number of infants in the high-Hgb subgroup (n=26), and the possibility of unmeasured confounders. The implications for populations with higher proportions of infants with high Hgb levels are unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20317292\">",
"    <span class=\"h2\">",
"     Immunity and infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron appears to have mixed effects on immune function and susceptibility to infection. On the one hand, iron deficiency in children has been associated with mild to moderate defects in leukocyte and lymphocyte function, including defective IL-2 and IL-6 production [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/79-83\">",
"     79-83",
"    </a>",
"    ]. On the other hand, other mechanisms may increase the risk for bacterial infection under conditions of maximal iron saturation. This is because iron-binding proteins in humans (transferrin and lactoferrin) have bacteriostatic effects, which are lost when they are saturated with iron. These proteins have a competitive advantage for binding iron over iron-binding siderophores in bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Consistent with these observations, clinical studies suggest that iron supplementation has mixed effects on susceptibility to infection in populations with high rates of iron deficiency. There is some evidence that supplementation with iron results in rapid saturation of iron-binding proteins and increased susceptibility to or reactivation of dormant infections, such as malaria or tuberculosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/84\">",
"     84",
"    </a>",
"    ]. Other studies suggest the susceptibility to malaria is only relevant in endemic areas and high-transmission seasons; other than this group, standard doses of iron supplements do not appear to significantly increase the risk for malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/83\">",
"     83",
"    </a>",
"    ]. In confirmation of this finding, a large meta-analysis found that iron supplementation does not increase the risk of clinical malaria or death when regular malaria surveillance and treatment services are provided [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/85\">",
"     85",
"    </a>",
"    ]. Furthermore, in a systematic review of randomized controlled trials, iron supplementation had no apparent harmful effect on the incidence of infectious illnesses in children, although it was associated with a higher risk of diarrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/86\">",
"     86",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20317306\">",
"    <span class=\"h2\">",
"     Exercise capacity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Moderately severe IDA is associated with decreased work capacity, in part because iron is an essential cofactor for enzyme-driven aerobic metabolism. Decreased iron stores, in the absence of anemia, is associated with decreased exercise performance in laboratory animals. Similar findings have been noted in children, particularly adolescent athletes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link&amp;anchor=H10#H10\">",
"     \"Iron requirements and iron deficiency in adolescents\", section on 'Physical performance'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20317313\">",
"    <span class=\"h2\">",
"     Pica and pagophagia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pica refers to a perverted appetite for substances not fit as food, such as clay or paper products. Various forms of pica have been associated with iron deficiency, including pica for clay or dirt, starch, or raw rice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/87\">",
"     87",
"    </a>",
"    ]. Pagophagia, or pica for ice, is particularly common and specific for the iron-deficiency state. It may be present in children who are not anemic and responds rapidly to treatment with iron, often before any increase is noted in the hemoglobin concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/88,89\">",
"     88,89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism through which iron deficiency causes pica is not known. Pica also occurs in children between the ages of two and three with developmental disabilities including autism and intellectual disability (mental retardation), and is not consistently associated with iron deficiency in this population [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/90\">",
"     90",
"    </a>",
"    ]. Pica may also present in children with brain injury that has affected their development. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=see_link\">",
"     \"Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35097?source=see_link&amp;anchor=H13#H13\">",
"     \"Surveillance and screening for autism spectrum disorders in primary care\", section on 'Guidelines for surveillance and screening'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=see_link&amp;anchor=H3#H3\">",
"     \"Clinical features of autism spectrum disorders\", section on 'Autistic disorder'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20317320\">",
"    <span class=\"h2\">",
"     Thrombosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency anemia has been reported to be associated with cerebral vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/91\">",
"     91",
"    </a>",
"    ]. In a large case-control study from a comprehensive Stroke Registry in Canada, previously healthy children with stroke (arterial or venous) were 10 times more likely to have IDA than healthy children without stroke [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/92\">",
"     92",
"    </a>",
"    ]. The mechanisms for this unusual complication are not clear, but may be related to thrombocytosis (platelet counts approaching 1",
"    <span class=\"nowrap\">",
"     million/uL)",
"    </span>",
"    that can be seen in IDA.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SCREENING RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anemia (hemoglobin level &lt;11",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    is neither a sensitive nor a specific screen for iron deficiency, as demonstrated by analysis of the NHANES database [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/93\">",
"     93",
"    </a>",
"    ]. Anemia is not a sensitive screen for iron deficiency because about two-thirds of iron deficient children are not anemic (In the United States, about 9 percent of children have iron deficiency whereas only 3 percent have iron deficiency anemia). Conversely, detection of anemia is not specific for iron deficiency, because about two-thirds of anemic children have a cause other than iron deficiency for their anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link\">",
"     \"Approach to the child with anemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because of the limited sensitivity and specificity of laboratory screening, risk assessment is an important component of screening for iron deficiency. The American Academy of Pediatrics recommends the following steps [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/6,35\">",
"     6,35",
"    </a>",
"    ]:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20316585\">",
"    <span class=\"h2\">",
"     Risk assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In all infants, risk assessment for iron deficiency through a brief review of dietary risk factors is recommended at 4, 18, and 24 months of age, and annually thereafter. Infants with a history of prematurity or low birth weight are also considered at risk for iron deficiency.",
"   </p>",
"   <p>",
"    A focused dietary history is currently the most important screening test and is more useful than hemoglobin levels. The primary dietary risk factors for iron deficiency are [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/35\">",
"     35",
"    </a>",
"    ]: (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Prevention of iron deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants, use of low iron formula, or feeding of non-formula cow&rsquo;s milk, goat&rsquo;s milk, or soy milk for the milk based part of the diet before 12 months of age, or fewer than two",
"      <span class=\"nowrap\">",
"       servings/day",
"      </span>",
"      of iron rich foods (meats or fortified infant cereal) after six months of age.",
"     </li>",
"     <li>",
"      For pre-school aged children, milk intake of more than 24 oz daily or fewer than three servings daily of iron-rich foods (eg, iron-fortified breakfast cereal or meats). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Dietary factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The value of a brief dietary history was illustrated in a report of 305 healthy, African-American inner city children between the ages of one and five years. A brief dietary history identified children at low risk of microcytic anemia 97 percent of the time [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/94\">",
"     94",
"    </a>",
"    ]. In this study, dietary risk for iron deficiency was defined as one or more of the following: less than five servings each of meat, grains, vegetables, and fruit per week; more than 480 mL (16 oz) of milk per day; or daily intake of fatty snacks, sweets, or more than 480 mL (16 oz) of soft drink.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20316572\">",
"    <span class=\"h2\">",
"     Laboratory screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The American Academy of Pediatrics currently suggests universal laboratory screening for iron deficiency at approximately one year of age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/6,35\">",
"     6,35",
"    </a>",
"    ]. This is particularly important in populations with increased risks of iron deficiency, including communities with low income levels (eg, those who receive support from the Women, Infants and Children [WIC] program). &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Universal laboratory screening",
"      </strong>",
"      for iron deficiency is recommended for all children at 9 to 12 months of age.",
"     </li>",
"     <li>",
"      <strong>",
"       Additional laboratory screening",
"      </strong>",
"      for iron deficiency is recommended at later ages for patients with risk factors for iron deficiency. These include each of the following groups:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For children with risk factors for iron deficiency (eg, history of prematurity, or dietary risk factors), screen again (eg, at 15 to 18 months of age or when risk is identified).",
"     </li>",
"     <li>",
"      For children with special health needs (chronic infection, inflammatory disorders, chronic gastrointestinal dysfunction, or restricted diets), repeat laboratory screening (eg, between two to five years of age).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The minimum laboratory screen for iron deficiency anemia is a hemoglobin level; levels &lt;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    are abnormal. In most clinical settings, the simplest and most cost-effective measurement is a Complete Blood Count (CBC), which will include measurements of hemoglobin, hematocrit, mean corpuscular volume, and red blood cell distribution width (RDW; a measure of variability in red cell size).",
"   </p>",
"   <p>",
"    For children with substantial risk factors for iron deficiency, measuring serum ferritin at the time of the initial screen facilitates the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/6\">",
"     6",
"    </a>",
"    ]. However, the results must be interpreted with caution, because ferritin is an acute phase reactant and is increased by inflammatory conditions. A measure of inflammation, such as C-reactive protein (CRP), can be included to validate the results of serum ferritin. More specific and cost-effective screening approaches for iron deficiency, including reticulocyte hemoglobin concentration, or the combination of serum hemoglobin and soluble transferrin receptor concentrations, are under consideration [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/35,95\">",
"     35,95",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19509677\">",
"     'Additional laboratory testing'",
"    </a>",
"    below.) &nbsp; &nbsp; &nbsp;",
"   </p>",
"   <p>",
"    Screening recommendations for adolescents are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=see_link&amp;anchor=H22449339#H22449339\">",
"     \"Iron requirements and iron deficiency in adolescents\", section on 'Screening'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;If laboratory screening suggests iron deficiency, the clinician should review the dietary history and assess risk factors for lead exposure. We also suggest screening for lead toxicity using a blood lead level if lead toxicity was not recently excluded by routine screening [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/20,96,97\">",
"     20,96,97",
"    </a>",
"    ]. If dietary deficiency seems likely and there is no evidence of lead toxicity, an empiric trial of oral iron supplementation is performed. In some cases, additional laboratory testing is appropriate before the therapeutic trial, as described below: &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509670\">",
"    <span class=\"h2\">",
"     Presumptive diagnosis and empiric trial",
"    </span>",
"    &nbsp;&mdash;&nbsp;For infants up to 24 months of age presenting with a mild microcytic anemia and a presumptive diagnosis of iron deficiency anemia (IDA) based on screening results, the most cost effective strategy is a therapeutic trial of iron [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/57\">",
"     57",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/62/15334?source=see_link\">",
"     Ferrous sulfate",
"    </a>",
"    is an inexpensive and convenient form of iron; this is given at 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    of elemental iron, given once or twice daily between meals (ie, 3 to 6",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    total) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/35\">",
"     35",
"    </a>",
"    ]. If four weeks of this treatment produces a hemoglobin rise of greater than 1",
"    <span class=\"nowrap\">",
"     gm/dL,",
"    </span>",
"    this confirms the diagnosis of iron deficiency. Once the response is confirmed, iron supplementation and monitoring should be continued for several months after the hemoglobin reaches the age-adjusted normal range. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=see_link\">",
"     \"Iron deficiency in infants and young children: Treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=see_link&amp;anchor=H17787321#H17787321\">",
"     \"Iron deficiency in infants and young children: Treatment\", section on 'Follow-up assessment for response'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For children between two years and adolescence, we suggest slightly more evaluation before embarking on a therapeutic trial of iron. This is because IDA is somewhat less common in otherwise-healthy children than in infants. Therefore, in addition to evaluating a complete blood count (with indices for MCV and RDW), we suggest performing a reticulocyte count and reviewing a blood smear, and screening several stools for occult blood. If the results of these tests are consistent with IDA (hypochromic microcytic anemia) and there is no evidence of gastrointestinal blood loss or lead toxicity, the child is treated with iron, and further evaluation is performed only if the response is inadequate. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=see_link&amp;anchor=H17785797#H17785797\">",
"     \"Iron deficiency in infants and young children: Treatment\", section on 'Oral iron therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=see_link&amp;anchor=H18371508#H18371508\">",
"     \"Approach to the child with anemia\", section on 'Reticulocyte response'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19509677\">",
"    <span class=\"h2\">",
"     Additional laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;A more complete evaluation for IDA is indicated at presentation in children with severe anemia (eg, Hgb &lt;7) or complicated medical histories. For these patients, the evaluation should include measurements of serum iron, ferritin, total iron-binding capacity, and transferrin saturation, as well as tests of several stools for occult blood. These tests can be used to support the diagnosis of IDA (",
"    <a class=\"graphic graphic_table graphicRef82013 \" href=\"UTD.htm?1/53/1884\">",
"     table 4",
"    </a>",
"    ), but the interpretation is not straightforward because most of these measures can be affected by factors other than iron status.",
"   </p>",
"   <p>",
"    An elevated red cell distribution width (RDW) is the earliest hematologic manifestation of iron deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/57\">",
"     57",
"    </a>",
"    ], Nonetheless, iron deficiency in infants and young children usually is identified by a serum ferritin concentration of less than 12",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    and IDA is identified by a hemoglobin concentration below 11",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    combined with a low serum ferritin. However, interpretation of ferritin is complicated because it is an acute phase reactant, so that serum levels increase in liver disease, inflammation, and malignancy. As an example, the synthesis and release of ferritin by hepatic cells is directly enhanced by inflammatory cytokines such as interleukin-1 and tumor necrosis factor [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/98\">",
"     98",
"    </a>",
"    ]. Thus, a patient with iron deficiency and a concomitant inflammatory disease may have a \"falsely\" normal ferritin concentration. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=see_link\">",
"     \"Acute phase reactants\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other laboratory tests, such as erythrocyte protoporphyrin, serum transferrin receptor, and reticulocyte hemoglobin content, may prove to be more reliable measures of iron deficiency, but they are not routinely used [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With increasing availability of advanced hematology analyzers, the use of reticulocyte hemoglobin content may provide a reliable measure of early iron deficient erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/6\">",
"     6",
"    </a>",
"    ]. As an example, a prospective observational study of 202 infants (9 to 12 months of age) demonstrated that reticulocyte hemoglobin content (CHr) &le;27.5 pg was a more accurate screen for iron deficiency than a hemoglobin (Hgb) level &le;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/18/22826/abstract/101\">",
"     101",
"    </a>",
"    ]. There were six patients with iron deficiency anemia (3 percent) and 23 patients with iron deficiency (11 percent). CHr &lt;27.5 pg was more sensitive and less specific than Hgb &lt;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    in detecting iron deficiency (as confirmed by transferrin level &lt;10 percent). CHr &lt;27.5 pg detected 20 of 23 patients with iron deficiency, whereas Hgb &lt;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    detected only six (sensitivity of 83 versus 26 percent, respectively). On the other hand, CHr &lt;27.5 falsely identified 50 patients without iron deficiency, whereas Hgb &lt;11",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    falsely detected only nine (specificity of 72 versus 95 percent, respectively).",
"   </p>",
"   <p>",
"    Other conditions can produce a mild hypochromic, microcytic anemia and be confused with IDA. They include mild anemia (decline of 0.5 to 2.0",
"    <span class=\"nowrap\">",
"     g/dL)",
"    </span>",
"    following a recent infection or immunization, mild hereditary anemias (alpha or beta thalassemia traits, hemoglobin E trait), and anemia of chronic disease. Combined nutritional anemias (B12 or folate deficiency with malabsorption states) also may lead to confusion. A method to distinguish among the more common conditions is noted in the table (",
"    <a class=\"graphic graphic_table graphicRef65701 \" href=\"UTD.htm?43/41/44699\">",
"     table 5",
"    </a>",
"    ). These conditions should be considered in patients with predisposing factors, and in children who fail to respond to a therapeutic trial of iron. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=see_link&amp;anchor=H26833898#H26833898\">",
"     \"Iron deficiency in infants and young children: Treatment\", section on 'Nonresponders'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron deficiency is the most common nutritional deficiency in children. It has significant clinical consequences causing anemia, impairment of psychomotor and cognitive function, and decreasing leukocyte and lymphocyte function. (See",
"    <a class=\"local\" href=\"#H20317248\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The key to reducing the morbidity associated with iron deficiency includes prevention of iron deficiency and the identification and treatment of children who are iron deficient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prevention of iron deficiency in infants include ensuring that the daily intake of iron meets the nutritional requirements of the infant or child. The dietary recommendations are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In term infants, breastfeeding exclusively for first four to six months.",
"     </li>",
"     <li>",
"      In breastfed preterm or low birth weight infants, elemental iron supplementation (2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day; maximum 15 mg) is recommended starting at one month of age and is continued until 12 months of age.",
"     </li>",
"     <li>",
"      For infants &lt;12 months of age who are not breastfed or are partially breastfed, use only formulas fortified with at least 12",
"      <span class=\"nowrap\">",
"       mg/L",
"      </span>",
"      of iron.",
"     </li>",
"     <li>",
"      At age six months, add iron-fortified cereals (&ge;2 feeds per day) and encourage one feeding per day of foods rich in vitamin C.",
"     </li>",
"     <li>",
"      After age six months, or when developmentally ready, considering introducing pureed meats.",
"     </li>",
"     <li>",
"      Avoid feeding unmodified (nonformula) cow's milk until age 12 months.",
"     </li>",
"     <li>",
"      Children aged one to five years should consume no more than 600 mL (20 oz) of milk per day.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Requirements'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H6\">",
"     'Prevention of iron deficiency'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Screening for iron deficiency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A focused dietary history is the most important screening test and is more useful than hemoglobin levels in detecting iron deficiency. In all infants, risk assessment for iron deficiency through a brief review of dietary risk factors is recommended at 4, 18, and 24 months of age, and annually thereafter. Infants with a history of prematurity or low birth weight are also considered at risk for iron deficiency. (See",
"      <a class=\"local\" href=\"#H20316585\">",
"       'Risk assessment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In addition, laboratory screening for iron deficiency should be performed in the following patients: (see",
"      <a class=\"local\" href=\"#H20316572\">",
"       'Laboratory screening'",
"      </a>",
"      above).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Universal screening for all children: screen around 9 to 12 months of age.",
"     </li>",
"     <li>",
"      For children at high risk for iron deficiency anemia (IDA) by dietary history or because of prematurity: screen again (eg, at 15 to 18 months or when risk is identified).",
"     </li>",
"     <li>",
"      Children with special health needs (chronic infection, inflammatory disorders, chronic gastrointestinal dysfunction, restricted diets or other significant dietary risk factors for IDA) (eg, at two to five years of age).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The minimum laboratory screen for iron deficiency anemia is a hemoglobin level; levels &lt;11",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"      are abnormal. In most clinical settings, the simplest and most cost-effective measurement is a Complete Blood Count (CBC), which will include measurements of hemoglobin, hematocrit, mean corpuscular volume, and red blood cell distribution width. For children with substantial risk factors for iron deficiency, measuring serum ferritin at the time of the initial screen facilitates the diagnosis. (See",
"      <a class=\"local\" href=\"#H20316572\">",
"       'Laboratory screening'",
"      </a>",
"      above.) &nbsp;",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Diagnostic evaluation",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For infants and children presenting with a mild microcytic anemia and a presumptive diagnosis of IDA, the most cost effective strategy is a therapeutic trial of iron.",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/62/15334?source=see_link\">",
"       Ferrous sulfate",
"      </a>",
"      (3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of elemental iron, given once or twice daily between meals for four weeks) should produce a rise of greater than 1",
"      <span class=\"nowrap\">",
"       gm/dL",
"      </span>",
"      in patients with iron deficiency. We also suggest screening these children for occult blood loss and lead toxicity. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=see_link\">",
"       \"Iron deficiency in infants and young children: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A more complete evaluation for IDA is indicated at presentation in children with severe anemia (eg, Hgb &lt;7) or complicated medical histories. For these patients, the evaluation should include measurements of serum iron, ferritin, total iron-binding capacity, and transferrin saturation. These tests can be used to support the diagnosis of IDA (",
"      <a class=\"graphic graphic_table graphicRef82013 \" href=\"UTD.htm?1/53/1884\">",
"       table 4",
"      </a>",
"      ), but the interpretation is not straightforward because most of these measures can be affected by factors other than iron status. (See",
"      <a class=\"local\" href=\"#H19509677\">",
"       'Additional laboratory testing'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/1\">",
"      Stoltzfus RJ. Iron deficiency: global prevalence and consequences. Food Nutr Bull 2003; 24:S99.",
"     </a>",
"    </li>",
"    <li>",
"     DeBenoist, B, McLean, E, Egli, I, et al. Worldwide prevalence of anemia 1993-2005: WHO global database on anemia. Report, World Health Organization; Centers for Disease Control, Geneva, 2008.",
"    </li>",
"    <li>",
"     United States Department of Health and Human Services, Healthy People 2020 Nutrition and weight status objectives. Available at: file://www.healthypeople.gov/2020/topicsobjectives2020/objectiveslist.aspx?topicId=29 (Accessed on June 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/4\">",
"      Brotanek JM, Gosz J, Weitzman M, Flores G. Secular trends in the prevalence of iron deficiency among US toddlers, 1976-2002. Arch Pediatr Adolesc Med 2008; 162:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/5\">",
"      Centers for Disease Control and Prevention (CDC). Iron deficiency--United States, 1999-2000. MMWR Morb Mortal Wkly Rep 2002; 51:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/6\">",
"      Baker RD, Greer FR, Committee on Nutrition American Academy of Pediatrics. Diagnosis and prevention of iron deficiency and iron-deficiency anemia in infants and young children (0-3 years of age). Pediatrics 2010; 126:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/7\">",
"      Cusick SE, Mei Z, Cogswell ME. Continuing anemia prevention strategies are needed throughout early childhood in low-income preschool children. J Pediatr 2007; 150:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/8\">",
"      Brotanek JM, Gosz J, Weitzman M, Flores G. Iron deficiency in early childhood in the United States: risk factors and racial/ethnic disparities. Pediatrics 2007; 120:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/9\">",
"      Stellinga-Boelen AA, Storm H, Wiegersma PA, et al. Iron deficiency among children of asylum seekers in the Netherlands. J Pediatr Gastroenterol Nutr 2007; 45:591.",
"     </a>",
"    </li>",
"    <li>",
"     Andrews NC, Bridges KR. Disorders of iron metabolism and sideroblastic anemia. In: Hematology of Infancy and Childhood, 5th, Nathan DG, Orkin SH (Eds), WB Saunders, Philadelphia 1998. p.423.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/11\">",
"      Hallberg L, Brune M, Rossander L. Effect of ascorbic acid on iron absorption from different types of meals. Studies with ascorbic-acid-rich foods and synthetic ascorbic acid given in different amounts with different meals. Hum Nutr Appl Nutr 1986; 40:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/12\">",
"      Cook JD. Adaptation in iron metabolism. Am J Clin Nutr 1990; 51:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/13\">",
"      Hallberg L, Hulth&eacute;n L. Prediction of dietary iron absorption: an algorithm for calculating absorption and bioavailability of dietary iron. Am J Clin Nutr 2000; 71:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/14\">",
"      Disler PB, Lynch SR, Charlton RW, et al. The effect of tea on iron absorption. Gut 1975; 16:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/15\">",
"      Hallberg L, Rossander L, Sk&aring;nberg AB. Phytates and the inhibitory effect of bran on iron absorption in man. Am J Clin Nutr 1987; 45:988.",
"     </a>",
"    </li>",
"    <li>",
"     Ohls, RK. Evaluation and treatment of anemia in the neonate. In: Hematologic Problems of the Neonate, Christensen, RD (Ed), Philadelphia, WB Saunders, Philadelphia, 2000, p. 137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/17\">",
"      Kivivuori SM, Virtanen M, Raivio KO, et al. Oral iron is sufficient for erythropoietin treatment of very low birth-weight infants. Eur J Pediatr 1999; 158:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/18\">",
"      Kumar A, Rai AK, Basu S, et al. Cord blood and breast milk iron status in maternal anemia. Pediatrics 2008; 121:e673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/19\">",
"      Collard KJ. Iron homeostasis in the neonate. Pediatrics 2009; 123:1208.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Recommendations for preventive pediatric health care (periodicity schedule). Available at: practice.aap.org/content.aspx?aid=1599 (Accessed on August 4, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/21\">",
"      Tunnessen WW Jr, Oski FA. Consequences of starting whole cow milk at 6 months of age. J Pediatr 1987; 111:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/22\">",
"      Pizarro F, Yip R, Dallman PR, et al. Iron status with different infant feeding regimens: relevance to screening and prevention of iron deficiency. J Pediatr 1991; 118:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/23\">",
"      Ziegler EE, Fomon SJ, Nelson SE, et al. Cow milk feeding in infancy: further observations on blood loss from the gastrointestinal tract. J Pediatr 1990; 116:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/24\">",
"      Hopkins D, Emmett P, Steer C, et al. Infant feeding in the second 6 months of life related to iron status: an observational study. Arch Dis Child 2007; 92:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/25\">",
"      Male C, Persson LA, Freeman V, et al. Prevalence of iron deficiency in 12-mo-old infants from 11 European areas and influence of dietary factors on iron status (Euro-Growth study). Acta Paediatr 2001; 90:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/26\">",
"      Calvo EB, Galindo AC, Aspres NB. Iron status in exclusively breast-fed infants. Pediatrics 1992; 90:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/27\">",
"      Sutcliffe TL, Khambalia A, Westergard S, et al. Iron depletion is associated with daytime bottle-feeding in the second and third years of life. Arch Pediatr Adolesc Med 2006; 160:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/28\">",
"      Brotanek JM, Halterman JS, Auinger P, et al. Iron deficiency, prolonged bottle-feeding, and racial/ethnic disparities in young children. Arch Pediatr Adolesc Med 2005; 159:1038.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/29\">",
"      Brotanek JM, Schroer D, Valentyn L, et al. Reasons for prolonged bottle-feeding and iron deficiency among Mexican-American toddlers: an ethnographic study. Acad Pediatr 2009; 9:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/30\">",
"      Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep 1998; 47:1.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Nutrition American Academy of Pediatrics. Formula feeding of term infants. In: Pediatric Nutrition Handbook, 6, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village 2009. p.61.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/32\">",
"      de Vizia B, Poggi V, Conenna R, et al. Iron absorption and iron deficiency in infants and children with gastrointestinal diseases. J Pediatr Gastroenterol Nutr 1992; 14:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/33\">",
"      McMillan JA, Oski FA, Lourie G, et al. Iron absorption from human milk, simulated human milk, and proprietary formulas. Pediatrics 1977; 60:896.",
"     </a>",
"    </li>",
"    <li>",
"     Committee on Nutrition, American Academy of Pediatrics. Nutritional needs of the preterm infant. In: Pediatric Nutrition Handbook, 6th ed, Kleinman RE (Ed), American Academy of Pediatrics, Elk Grove Village 2009. p.79.",
"    </li>",
"    <li>",
"     Committee on Nutrition, American Academy of, Pediatrics..  Iron. In: Pediatric Nutrition Handbook, 6e, Kleinman, RE (Eds), American Academy of Pediatrics, Elk Grove Village, IL 2009. p.403-422.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/36\">",
"      Griffin IJ, Cooke RJ, Reid MM, et al. Iron nutritional status in preterm infants fed formulas fortified with iron. Arch Dis Child Fetal Neonatal Ed 1999; 81:F45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/37\">",
"      Abdelrazik N, Al-Haggar M, Al-Marsafawy H, et al. Impact of long-term oral iron supplementation in breast-fed infants. Indian J Pediatr 2007; 74:739.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/38\">",
"      Franz AR, Mihatsch WA, Sander S, et al. Prospective randomized trial of early versus late enteral iron supplementation in infants with a birth weight of less than 1301 grams. Pediatrics 2000; 106:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/39\">",
"      Steinmacher J, Pohlandt F, Bode H, et al. Randomized trial of early versus late enteral iron supplementation in infants with a birth weight of less than 1301 grams: neurocognitive development at 5.3 years' corrected age. Pediatrics 2007; 120:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/40\">",
"      Cook JD, Boy E, Flowers C, Daroca Mdel C. The influence of high-altitude living on body iron. Blood 2005; 106:1441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/41\">",
"      Walter T, Dallman PR, Pizarro F, et al. Effectiveness of iron-fortified infant cereal in prevention of iron deficiency anemia. Pediatrics 1993; 91:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/42\">",
"      American Academy of Pediatrics Committee on Nutrition: The use of whole cow's milk in infancy. Pediatrics 1992; 89:1105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/43\">",
"      Iron fortification of infant formulas. American Academy of Pediatrics. Committee on Nutrition. Pediatrics 1999; 104:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/44\">",
"      Engelmann MD, Davidsson L, Sandstr&ouml;m B, et al. The influence of meat on nonheme iron absorption in infants. Pediatr Res 1998; 43:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/45\">",
"      Fitch CW, Cannon MS, Seidel GE, Krummel DA. Dietary factors affecting iron status of children residing in rural West Virginia. W V Med J 2008; 104:19.",
"     </a>",
"    </li>",
"    <li>",
"     National Institutes of Health, Office of Dietary Supplements. Dietary supplement fact sheet: Iron. Available at: file://ods.od.nih.gov/factsheets/iron.asp (Accessed on September 23, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/47\">",
"      Rahimy MC, Fanou L, Somasse YE, et al. When to start supplementary iron to prevent iron deficiency in early childhood in sub-Saharan Africa setting. Pediatr Blood Cancer 2007; 48:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/48\">",
"      Andang'o PE, Osendarp SJ, Ayah R, et al. Efficacy of iron-fortified whole maize flour on iron status of schoolchildren in Kenya: a randomised controlled trial. Lancet 2007; 369:1799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/49\">",
"      Semba RD, Moench-Pfanner R, Sun K, et al. Iron-fortified milk and noodle consumption is associated with lower risk of anemia among children aged 6-59 mo in Indonesia. Am J Clin Nutr 2010; 92:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/50\">",
"      Rivera JA, Shamah T, Villalpando S, Monterrubio E. Effectiveness of a large-scale iron-fortified milk distribution program on anemia and iron deficiency in low-income young children in Mexico. Am J Clin Nutr 2010; 91:431.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/51\">",
"      Beinner MA, Velasquez-Mel&eacute;ndez G, Pessoa MC, Greiner T. Iron-fortified rice is as efficacious as supplemental iron drops in infants and young children. J Nutr 2010; 140:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/52\">",
"      De-Regil LM, Suchdev PS, Vist GE, et al. Home fortification of foods with multiple micronutrient powders for health and nutrition in children under two years of age. Cochrane Database Syst Rev 2011; :CD008959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/53\">",
"      De Caterina M, Grimaldi E, Di Pascale G, et al. The soluble transferrin receptor (sTfR)-ferritin index is a potential predictor of celiac disease in children with refractory iron deficiency anemia. Clin Chem Lab Med 2005; 43:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/54\">",
"      Kurekci AE, Atay AA, Sarici SU, et al. Is there a relationship between childhood Helicobacter pylori infection and iron deficiency anemia? J Trop Pediatr 2005; 51:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/55\">",
"      Wians FH Jr, Urban JE, Keffer JH, Kroft SH. Discriminating between iron deficiency anemia and anemia of chronic disease using traditional indices of iron status vs transferrin receptor concentration. Am J Clin Pathol 2001; 115:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/56\">",
"      Sandoval C, Jayabose S, Eden AN. Trends in diagnosis and management of iron deficiency during infancy and early childhood. Hematol Oncol Clin North Am 2004; 18:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/57\">",
"      Oski FA. Iron deficiency in infancy and childhood. N Engl J Med 1993; 329:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/58\">",
"      Sherriff A, Emond A, Bell JC, et al. Should infants be screened for anaemia? A prospective study investigating the relation between haemoglobin at 8, 12, and 18 months and development at 18 months. Arch Dis Child 2001; 84:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/59\">",
"      Halterman JS, Kaczorowski JM, Aligne CA, et al. Iron deficiency and cognitive achievement among school-aged children and adolescents in the United States. Pediatrics 2001; 107:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/60\">",
"      Carter RC, Jacobson JL, Burden MJ, et al. Iron deficiency anemia and cognitive function in infancy. Pediatrics 2010; 126:e427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/61\">",
"      Williams J, Wolff A, Daly A, et al. Iron supplemented formula milk related to reduction in psychomotor decline in infants from inner city areas: randomised study. BMJ 1999; 318:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/62\">",
"      Lozoff B, Clark KM, Jing Y, et al. Dose-response relationships between iron deficiency with or without anemia and infant social-emotional behavior. J Pediatr 2008; 152:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/63\">",
"      Moffatt ME, Longstaffe S, Besant J, Dureski C. Prevention of iron deficiency and psychomotor decline in high-risk infants through use of iron-fortified infant formula: a randomized clinical trial. J Pediatr 1994; 125:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/64\">",
"      Lozoff B, Wolf AW, Jimenez E. Iron-deficiency anemia and infant development: effects of extended oral iron therapy. J Pediatr 1996; 129:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/65\">",
"      Idjradinata P, Pollitt E. Reversal of developmental delays in iron-deficient anaemic infants treated with iron. Lancet 1993; 341:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/66\">",
"      Stoltzfus RJ, Kvalsvig JD, Chwaya HM, et al. Effects of iron supplementation and anthelmintic treatment on motor and language development of preschool children in Zanzibar: double blind, placebo controlled study. BMJ 2001; 323:1389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/67\">",
"      Walter T, De Andraca I, Chadud P, Perales CG. Iron deficiency anemia: adverse effects on infant psychomotor development. Pediatrics 1989; 84:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/68\">",
"      Lozoff B, Jimenez E, Smith JB. Double burden of iron deficiency in infancy and low socioeconomic status: a longitudinal analysis of cognitive test scores to age 19 years. Arch Pediatr Adolesc Med 2006; 160:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/69\">",
"      Lukowski AF, Koss M, Burden MJ, et al. Iron deficiency in infancy and neurocognitive functioning at 19 years: evidence of long-term deficits in executive function and recognition memory. Nutr Neurosci 2010; 13:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/70\">",
"      Congdon EL, Westerlund A, Algarin CR, et al. Iron deficiency in infancy is associated with altered neural correlates of recognition memory at 10 years. J Pediatr 2012; 160:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/71\">",
"      Falkingham M, Abdelhamid A, Curtis P, et al. The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis. Nutr J 2010; 9:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/72\">",
"      Algar&iacute;n C, Peirano P, Garrido M, et al. Iron deficiency anemia in infancy: long-lasting effects on auditory and visual system functioning. Pediatr Res 2003; 53:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/73\">",
"      Pisacane A, Sansone R, Impagliazzo N, et al. Iron deficiency anaemia and febrile convulsions: case-control study in children under 2 years. BMJ 1996; 313:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/74\">",
"      Daoud AS, Batieha A, Abu-Ekteish F, et al. Iron status: a possible risk factor for the first febrile seizure. Epilepsia 2002; 43:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/75\">",
"      Hartfield DS, Tan J, Yager JY, et al. The association between iron deficiency and febrile seizures in childhood. Clin Pediatr (Phila) 2009; 48:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/76\">",
"      Kobrinsky NL, Yager JY, Cheang MS, et al. Does iron deficiency raise the seizure threshold? J Child Neurol 1995; 10:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/77\">",
"      Zehetner AA, Orr N, Buckmaster A, et al. Iron supplementation for breath-holding attacks in children. Cochrane Database Syst Rev 2010; :CD008132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/78\">",
"      Lozoff B, Castillo M, Clark KM, Smith JB. Iron-fortified vs low-iron infant formula: developmental outcome at 10 years. Arch Pediatr Adolesc Med 2012; 166:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/79\">",
"      Thibault H, Galan P, Selz F, et al. The immune response in iron-deficient young children: effect of iron supplementation on cell-mediated immunity. Eur J Pediatr 1993; 152:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/80\">",
"      Galan P, Thibault H, Preziosi P, Hercberg S. Interleukin 2 production in iron-deficient children. Biol Trace Elem Res 1992; 32:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/81\">",
"      Ekiz C, Agaoglu L, Karakas Z, et al. The effect of iron deficiency anemia on the function of the immune system. Hematol J 2005; 5:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/82\">",
"      Baltimore RS, Shedd DG, Pearson HA. Effect of iron saturation on the bacteriostasis of human serum: in vivo does not correlate with in vitro saturation. J Pediatr 1982; 101:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/83\">",
"      Kumar V, Choudhry VP. Iron deficiency and infection. Indian J Pediatr 2010; 77:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/84\">",
"      Murray MJ, Murray AB, Murray MB, Murray CJ. The adverse effect of iron repletion on the course of certain infections. Br Med J 1978; 2:1113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/85\">",
"      Ojukwu JU, Okebe JU, Yahav D, Paul M. Oral iron supplementation for preventing or treating anaemia among children in malaria-endemic areas. Cochrane Database Syst Rev 2009; :CD006589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/86\">",
"      Gera T, Sachdev HP. Effect of iron supplementation on incidence of infectious illness in children: systematic review. BMJ 2002; 325:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/87\">",
"      Yadav D, Chandra J. Iron deficiency: beyond anemia. Indian J Pediatr 2011; 78:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/88\">",
"      Brown WD, Dyment PG. Pagophagia and iron deficiency anemia in adolescent girls. Pediatrics 1972; 49:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/89\">",
"      Osman YM, Wali YA, Osman OM. Craving for ice and iron-deficiency anemia: a case series from Oman. Pediatr Hematol Oncol 2005; 22:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/90\">",
"      Haoui R, Gautie L, Puisset F. [Pica: a descriptive study of patients in a speciality medical center]. Encephale 2003; 29:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/91\">",
"      Benedict SL, Bonkowsky JL, Thompson JA, et al. Cerebral sinovenous thrombosis in children: another reason to treat iron deficiency anemia. J Child Neurol 2004; 19:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/92\">",
"      Maguire JL, deVeber G, Parkin PC. Association between iron-deficiency anemia and stroke in young children. Pediatrics 2007; 120:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/93\">",
"      White KC. Anemia is a poor predictor of iron deficiency among toddlers in the United States: for heme the bell tolls. Pediatrics 2005; 115:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/94\">",
"      Boutry M, Needlman R. Use of diet history in the screening of iron deficiency. Pediatrics 1996; 98:1138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/95\">",
"      Cusick SE, Looker AC, Cogswell ME, et al. Iron-status indicators. Pediatrics 2008; 121:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/96\">",
"      Wright RO, Shannon MW, Wright RJ, Hu H. Association between iron deficiency and low-level lead poisoning in an urban primary care clinic. Am J Public Health 1999; 89:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/97\">",
"      Wright RO, Tsaih SW, Schwartz J, et al. Association between iron deficiency and blood lead level in a longitudinal analysis of children followed in an urban primary care clinic. J Pediatr 2003; 142:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/98\">",
"      Tran TN, Eubanks SK, Schaffer KJ, et al. Secretion of ferritin by rat hepatoma cells and its regulation by inflammatory cytokines and iron. Blood 1997; 90:4979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/99\">",
"      Punnonen K, Irjala K, Rajam&auml;ki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997; 89:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/100\">",
"      Brugnara C, Zurakowski D, DiCanzio J, et al. Reticulocyte hemoglobin content to diagnose iron deficiency in children. JAMA 1999; 281:2225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/18/22826/abstract/101\">",
"      Ullrich C, Wu A, Armsby C, et al. Screening healthy infants for iron deficiency using reticulocyte hemoglobin content. JAMA 2005; 294:924.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5925 Version 15.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.10.40.232-BF0A88A09A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22826=[""].join("\n");
var outline_f22_18_22826=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5261086\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IRON BALANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Perinatal risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dietary factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5260705\">",
"      Gastrointestinal disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      REQUIREMENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Prevention of iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20317248\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20317270\">",
"      Neurodevelopmental",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20317292\">",
"      Immunity and infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20317306\">",
"      Exercise capacity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20317313\">",
"      Pica and pagophagia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20317320\">",
"      Thrombosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SCREENING RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20316585\">",
"      Risk assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20316572\">",
"      Laboratory screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19509670\">",
"      Presumptive diagnosis and empiric trial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19509677\">",
"      Additional laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Screening for iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Diagnostic evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5925\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5925|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?21/45/22232\" title=\"picture 1\">",
"      Microcytic hypochromic anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5925|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/13/25822\" title=\"table 1\">",
"      Dietary sources of iron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/5/26715\" title=\"table 2\">",
"      Iron bioavailability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?25/57/26523\" title=\"table 3\">",
"      Iron deficiency evolution",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?1/53/1884\" title=\"table 4\">",
"      Influences on tests for IDA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/41/44699\" title=\"table 5\">",
"      Laboratory differential dx IDA",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/42/38569?source=related_link\">",
"      Acute phase reactants",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/20/26954?source=related_link\">",
"      Anemia in children due to decreased red blood cell production",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/19/20792?source=related_link\">",
"      Anemia of prematurity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/54/43880?source=related_link\">",
"      Approach to the child with anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/53/4954?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/41/664?source=related_link\">",
"      Clinical features of autism spectrum disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/3/37946?source=related_link\">",
"      Clinical manifestations and diagnosis of celiac disease in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/10/26793?source=related_link\">",
"      Intellectual disability (mental retardation) in children: Definition; causes; and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/2/38949?source=related_link\">",
"      Iron deficiency in infants and young children: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/14/4329?source=related_link\">",
"      Iron requirements and iron deficiency in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/37/21082?source=related_link\">",
"      Regulation of iron balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/17/35097?source=related_link\">",
"      Surveillance and screening for autism spectrum disorders in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/4/8266?source=related_link\">",
"      Vegetarian diets for children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_18_22827="Clinical interview";
var content_f22_18_22827=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70602&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Geriatric assessment performed by clinical interview: multidimensional evaluation scale for use in elderly cancer patients",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Domain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Measures",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Physical function/disability",
"       </td>",
"       <td>",
"        1) Activities of Daily Living",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2) Instrumental Activities of Daily Living",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3) World Health Organization Scale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4) Physical Performance Test",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5) Balance: FICSIT",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Socioeconomic status",
"       </td>",
"       <td>",
"        No scale listed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Comorbidity",
"       </td>",
"       <td>",
"        No scale listed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cognition",
"       </td>",
"       <td>",
"        Mini Mental Status Exam",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychological state",
"       </td>",
"       <td>",
"        Geriatric Depression Scale",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    FICSIT: Frailty and Injuries: Cooperative Studies of Intervention Techniques.",
"    <div class=\"footnotes\">",
"     * Also captures information regarding demographics, cancer characteristics, symptoms, and use of services.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22827=[""].join("\n");
var outline_f22_18_22827=null;
var title_f22_18_22828="Outcome with delayed delivery of one fetus of a multiple gestation";
var content_f22_18_22828=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68460&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=10\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Outcome with delayed delivery of one fetus of a multiple gestation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        References",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"4\">",
"        Survival rates",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        n",
"       </td>",
"       <td class=\"subtitle2\">",
"        Firstborn, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        Retained, percent",
"       </td>",
"       <td class=\"subtitle2\">",
"        <em>",
"         p",
"        </em>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Farkouh AJOG 2000*",
"         <sup>",
"          [1]",
"         </sup>",
"        </p>",
"        <p>",
"         (&gt;24 weeks)",
"        </p>",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        0.0063",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Zhang AJOG 2004",
"         <sup>",
"          [2]",
"         </sup>",
"        </p>",
"        <p>",
"         (&gt;24 weeks)",
"        </p>",
"       </td>",
"       <td>",
"        140",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Oyelese AJOG 2005",
"         <sup>",
"          [3]",
"         </sup>",
"        </p>",
"        <p>",
"         (&gt;24 weeks)",
"        </p>",
"       </td>",
"       <td>",
"        144",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        NS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Arabin AJOG 2009",
"         <sup>",
"          [4]",
"         </sup>",
"        </p>",
"        <p>",
"         (&gt;25 weeks)",
"        </p>",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        <p>",
"         0.03 (twins)",
"        </p>",
"        <p>",
"         NS (triplets)",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Plus unpublished data through 2004.",
"    </div>",
"    <div class=\"reference\">",
"     1. Farkouh, LJ, Sabin, ED, Heyborne, KD, Lindsay, LG. Delayed-interval delivery: extended series from a single maternal-fetal medicine practice. Am J Obstet Gynecol 2000; 183:1499.",
"     <br>",
"      2. Zhang, J, Hamilton, B, Martin, J, Trumble, A. Delayed interval delivery and infant survival: a population-based study. Am J Obstet Gynecol 2004; 191:470.",
"      <br>",
"       3. Oyelese, Y, Ananth, CV, Smulian, JC, Vintzileos, AM. Delayed interval delivery in twin pregnancies in the United States: Impact on perinatal mortality and morbidity. Am J Obstet Gynecol 2005; 192:439.",
"       <br>",
"        4. Arabin, B, van Eyck, J. Delayed-interval delivery in twin and triplet pregnancies: 17 years of experience in 1 perinatal center. Am J Obstet Gynecol 2009; 200:154.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22828=[""].join("\n");
var outline_f22_18_22828=null;
var title_f22_18_22829="Ibutilide sotalol duration AF";
var content_f22_18_22829=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F62459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F62459&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Reversion of AF with antiarrhythmic drugs is related to arrhythmia duration",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 379px; height: 235px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a study comparing two doses of intravenous ibutilide with intravenous sotalol for acute reversion of atrial fibrillation, the rate of successful reversion was inversely related to the duration of the arrhythmia prior to therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Vos, MA, Golitsyn, SR, Stangl, K, et al for the Ibutilide/Sotalol Comparator Study Group, Heart 1998; 79:568.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22829=[""].join("\n");
var outline_f22_18_22829=null;
var title_f22_18_22830="HDV reinfection in liver TPL";
var content_f22_18_22830=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54871&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Hepatitis D virus reinfection alone after liver transplantation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 438px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A patient who underwent transplantation for HDV cirrhosis became HBsAg negative while receiving HBIG immunoprophylaxis. Despite the absence of HBsAg from serum and liver, HDV-RNA was detected in serum and HDAg was detected in the graft for 15 months post- transplantation but not thereafter. Throughout the follow-up period, serum aminotransferases and graft histology remained normal, demonstrating the mild, benign course of isolated HDV reinfection.",
"    <div class=\"footnotes\">",
"     Arrows: liver biopsies; N: normal; ALT: alanine aminotransferase; hatched area: upper limit of normal for ALT.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Samuel, D, Zignego, AL, Reynes, M, et al, Hepatology 1995; 21:334",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22830=[""].join("\n");
var outline_f22_18_22830=null;
var title_f22_18_22831="In hospital mortality by gender";
var content_f22_18_22831=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79678%7ECARD%2F51374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79678%7ECARD%2F51374&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 554px\">",
"   <div class=\"ttl\">",
"    In-hospital mortality after a myocardial infarction is higher for women than men",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 534px; height: 278px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Data from 384,878 men and women between the ages of 30 and 89 years entered into the National Registry of Myocardial Infarction show that the in-hospital mortality after a myocardial infarction is higher for women than men (16.7 versus 11.5 percent); however, the difference in mortality rates decreases in older patients and was no longer significant over the age of 74.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Vaccarino V, Parsons L, Every NR, et al. for the National Registry of Myocardial Infarction 2 Participants. N Engl J Med 1999; 341:217.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Survival after MI is lower in women",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 316px; height: 295px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In the RESCATE study of 331 women and 1129 men, the six-month survival after a first myocardial infarction (MI) was lower in women than men (74 versus 89 percent, p &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Marrugate J, Sala J, Massia R, et al. for the RESCATE Investigators, JAMA 1998; 280:1405.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_18_22831=[""].join("\n");
var outline_f22_18_22831=null;
